

Radical Cystectomy in the Treatment of Invasive Bladder Patients

Journal of Clinical Oncology

19, 666-675

DOI: 10.1200/jco.2001.19.3.666

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bladder cancer, the limits of surgical excision—when/how much?. Urologic Oncology: Seminars and Original Investigations, 2001, 6, 221-224.	1.6	4
2	IMPACT OF SEPARATE VERSUS EN BLOC PELVIC LYMPH NODE DISSECTION ON THE NUMBER OF LYMPH NODES RETRIEVED IN CYSTECTOMY SPECIMENS. Journal of Urology, 2001, 166, 2295-2296.	0.4	232
3	Therapeutic options and treatment of muscle invasive bladder cancer. Expert Review of Anticancer Therapy, 2001, 1, 511-522.	2.4	7
4	Neoadjuvant MVAC: The Long and Winding Road Is Getting Shorter and Straighter. Journal of Clinical Oncology, 2001, 19, 4003-4004.	1.6	2
5	Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results. Journal of Clinical Oncology, 2002, 20, 3061-3071.	1.6	602
7	Neoadjuvant Chemotherapy with Cisplatin and Methotrexate in Patients with Muscle-Invasive Bladder Tumours. Acta Oncologica, 2002, 41, 447-456.	1.8	71
8	Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?. Annals of Oncology, 2002, 13, 273-279.	1.2	17
9	Bladder cancer. Current Opinion in Oncology, 2002, 14, 265-272.	2.4	31
10	Surgical Management of Bladder Carcinoma. Cancer Control, 2002, 9, 284-292.	1.8	25
11	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2002, 167, 1295-1298.	0.4	544
12	Managing locally advanced bladder cancer. Expert Review of Anticancer Therapy, 2002, 2, 656-666.	2.4	3
13	Long-Term Voiding Pattern of Patients With Ileal Orthotopic Bladder Substitutes. Journal of Urology, 2002, 167, 2052-2057.	0.4	139
14	Preservation of the Anterior Vaginal Wall During Female Radical Cystectomy With Orthotopic Urinary Diversion: Technique and Results. Journal of Urology, 2002, 168, 1442-1445.	0.4	98
15	Distressful Symptoms and Well-being After Radical Cystectomy and Orthotopic Bladder Substitution Compared With a Matched Control Population. Journal of Urology, 2002, 168, 168-175.	0.4	127
16	Prognostic-factors-based risk-stratification model for invasive urothelial carcinoma of the urinary bladder in Taiwan. Urology, 2002, 59, 232-238.	1.0	29
18	Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology, 2002, 60, 62-67.	1.0	278
19	Current perspectives in muscle invasive bladder cancer. European Journal of Cancer, 2002, 38, 460-467.	2.8	25
20	A MULTICENTER STUDY OF THE MORBIDITY OF RADICAL CYSTECTOMY IN SELECT ELDERLY PATIENTS WITH BLADDER CANCER. Journal of Urology, 2002, 167, 1325-1328.	0.4	102

#	ARTICLE	IF	CITATIONS
21	Indications and technique of the orthotopic neobladder in women. Urologic Clinics of North America, 2002, 29, 725-734.	1.8	46
23	What's new in urology. Journal of the American College of Surgeons, 2002, 195, 663-674.	0.5	4
24	After Cystectomy, Is It Justified to Perform a Bladder Replacement for Patients with Lymph Node Positive Bladder Cancer?. European Urology, 2002, 42, 344-349.	1.9	38
25	Surgery and adjunctive chemotherapy for invasive bladder cancer. Surgical Oncology, 2002, 11, 55-63.	1.6	31
26	Pathologic evaluation of radical cystectomy specimens. Cancer, 2002, 95, 668-669.	4.1	17
27	Urinary diversion after radical cystectomy. Current Treatment Options in Oncology, 2002, 3, 389-402.	3.0	12
28	Contemporary cystectomy and urinary diversion. World Journal of Urology, 2002, 20, 151-157.	2.2	37
29	Management of locally advanced bladder cancer: early vs deferred chemotherapy. World Journal of Urology, 2002, 20, 175-182.	2.2	3
31	A Study of the Morbidity, Mortality and Long-Term Survival Following Radical Cystectomy and Radical Radiotherapy in the Treatment of Invasive Bladder Cancer in Yorkshire. European Urology, 2003, 43, 246-257.	1.9	129
32	Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer, 2003, 97, 1644-1652.	4.1	146
33	Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer, 2003, 98, 955-961.	4.1	49
34	Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Critical Reviews in Oncology/Hematology, 2003, 46, 67-83.	4.4	44
35	Treatment of bladder cancer: the present and the future. Reports of Practical Oncology and Radiotherapy, 2003, 8, 25-32.	0.6	1
36	Identifying under-performing surgeons. BJU International, 2003, 91, 780-784.	2.5	14
37	Results with radical cystectomy for treating bladder cancer: a "reference standard" for high-grade, invasive bladder cancer. BJU International, 2003, 92, 12-17.	2.5	101
38	Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality). BJU International, 2003, 92, 187-187.	2.5	37
40	Disease Progression and Survival of Patients With Positive Lymph Nodes After Radical Prostatectomy. Is there a Chance of Cure?. Journal of Urology, 2003, 169, 849-854.	0.4	427
41	An Interval Longer than 12 Weeks Between the Diagnosis of Muscle Invasion and Cystectomy is Associated with Worse Outcome in Bladder Carcinoma. Journal of Urology, 2003, 169, 110-115.	0.4	228

#	ARTICLE	IF	CITATIONS
42	Follow-up strategies and management of recurrence in urologic oncology bladder cancer:. Urologic Clinics of North America, 2003, 30, 777-789.	1.8	61
43	Is There a Therapeutic Role for Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Metastatic Transitional Cell Carcinoma of the Bladder?. Journal of Urology, 2003, 169, 2113-2117.	0.4	98
44	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. Journal of Urology, 2003, 169, 177-181.	0.4	97
45	Complications of Radical Cystectomy For Nonmuscle Invasive Disease: Comparison With Muscle Invasive Disease. Journal of Urology, 2003, 169, 101-104.	0.4	119
46	Editorial: Contemporary Concepts of Radical Cystectomy And The Treatment of Bladder Cancer. Journal of Urology, 2003, 169, 116-117.	0.4	35
47	Risk Factors for Patients With Pelvic Lymph Node Metastases Following Radical Cystectomy With En Bloc Pelvic Lymphadenectomy: The Concept of Lymph Node Density. Journal of Urology, 2003, 170, 35-41.	0.4	436
48	The Prognostic Significance of Metastatic Perivesical Lymph Nodes Identified in Radical Cystectomy Specimens for Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2003, 170, 2253-2257.	0.4	23
49	Superiority of Ratio Based Lymph Node Staging for Bladder Cancer. Journal of Urology, 2003, 169, 943-945.	0.4	287
50	Organ Conservation in Invasive Bladder Cancer by Transurethral Resection, Chemotherapy and Radiation: Results of a Urodynamic and Quality of Life Study on Long-term Survivors. Journal of Urology, 2003, 170, 1772-1776.	0.4	225
51	Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology, 2003, 61, 105-108.	1.0	166
52	C: IGF-I IGFBP-3 I. Urology, 2003, 61, 359-364.	1.0	35
53	Radical cystectomy for bladder cancer after definitive prostate cancer treatment. Urology, 2003, 61, 342-347.	1.0	27
55	Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology, 2003, 61, 1053-1058.	1.0	61
56	Indications for early cystectomy. Urology, 2003, 62, 591-595.	1.0	51
57	Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy using a perioperative care plan. Urology, 2003, 62, 661-665.	1.0	106
59	Management of transitional cell carcinoma. Veterinary Clinics of North America - Small Animal Practice, 2003, 33, 597-613.	1.5	58
60	The role of pelvic lymph node dissection as a predictive and prognostic factor in bladder cancer. European Journal of Cancer, 2003, 39, 604-613.	2.8	25
61	Molecular prognostication in bladder cancer—a current perspective. European Journal of Cancer, 2003, 39, 1501-1510.	2.8	38

#	ARTICLE	IF	CITATIONS
62	Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 468-474.	1.6	28
63	Lymphadenectomy in Bladder Cancer. EAU Update Series, 2003, 1, 100-107.	0.5	6
64	Bladder Cancer Facts: Accuracy of Information on the Internet. Journal of Urology, 2003, 170, 1756-1760.	0.4	33
65	Improving and Predicting Radiosensitivity in Muscle Invasive Bladder Cancer. Journal of Urology, 2003, 169, 1983-1992.	0.4	18
66	Surgical management of bladder cancer in 2003. Expert Review of Anticancer Therapy, 2003, 3, 781-792.	2.4	3
67	Neoadjuvant chemotherapy for bladder cancer: current status. Expert Opinion on Pharmacotherapy, 2003, 4, 853-858.	1.8	1
68	Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy. Journal of Clinical Oncology, 2003, 21, 690-696.	1.6	713
69	Non-invasive Management of Invasive Bladder Cancer: Lectures by Professor William U. Shipley. Japanese Journal of Clinical Oncology, 2003, 33, 592-594.	1.3	0
70	Prognostic Values of p53 and HER-2/neu Coexpression in Invasive Bladder Cancer in Taiwan. Urologia Internationalis, 2003, 71, 262-270.	1.3	23
71	Diagnostic delay and prognosis in invasive bladder cancer. Scandinavian Journal of Urology and Nephrology, 2003, 37, 396-400.	1.4	27
73	Bladder substitution. Current Opinion in Urology, 2003, 13, 477-482.	1.8	24
74	Bladder cancer. Current Opinion in Oncology, 2003, 15, 227-233.	2.4	45
75	A Combined Technique for Radical Cystoprostatectomy and Orthotopic Ileal Neobladder. Urologia, 2003, 70, 22-28.	0.7	0
76	Perioperative Chemotherapy in Advanced Bladder Cancer — Part II: Adjuvant Treatment. Oncology Research and Treatment, 2003, 26, 484-488.	1.2	10
77	Perioperative Chemotherapy in Advanced Bladder Cancer: Part I Neoadjuvant Treatment. Oncology Research and Treatment, 2003, 26, 361-365.	1.2	2
78	Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer. Cancer Control, 2004, 11, 358-363.	1.8	4
79	An Evaluation of Quality of Life in Patients who Underwent Urinary Diversion after Radical Cistectomy: Comparison of Different Urinary Diversions, our Experience. Urologia, 2004, 71, 181-186.	0.7	0
80	Radical Cystectomy for Invasive Bladder Cancer: Results of Multi-institutional Pooled Analysis. Japanese Journal of Clinical Oncology, 2004, 34, 14-19.	1.3	50

#	ARTICLE	IF	CITATIONS
81	Urinary Bladder Cancer: Preoperative Nodal Staging with Ferumoxtran-10-enhanced MR Imaging. Radiology, 2004, 233, 449-456.	7.3	216
82	Case 3-2004. New England Journal of Medicine, 2004, 350, 394-402.	27.0	1
83	Early cystectomy for clinical stage T1 bladder cancer. Nature Reviews Urology, 2004, 1, 4-5.	1.4	6
84	Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scandinavian Journal of Urology and Nephrology, 2004, 38, 231-235.	1.4	77
85	Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial. Journal of Clinical Oncology, 2004, 22, 2540-2545.	1.6	79
86	Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report. Journal of Clinical Oncology, 2004, 22, 2781-2789.	1.6	543
87	Treatment of Invasive Bladder Cancer: Lessons from the Past and Perspective for the Future. Japanese Journal of Clinical Oncology, 2004, 34, 295-306.	1.3	26
88	Does the Who and How of Surgery in Bladder Cancer Matter?. Journal of Clinical Oncology, 2004, 22, 2762-2764.	1.6	5
89	Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder. Clinical Cancer Research, 2004, 10, 3410-3421.	7.0	110
90	Survival Rates after Radical Cystectomy according to Tumor Stage of Bladder Carcinoma at First Presentation. Urologia Internationalis, 2004, 72, 103-111.	1.3	65
91	Is Eligibility for a Chemotherapy Protocol a Good Prognostic Factor for Invasive Bladder Cancer After Radical Cystectomy?. Journal of Clinical Oncology, 2004, 22, 4103-4108.	1.6	12
92	ARTIFICIAL INTELLIGENCE FOR THE PREDICTION OF BLADDER CANCER. Biomedical Engineering - Applications, Basis and Communications, 2004, 16, 49-58.	0.6	7
93	Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncologica, 2004, 43, 749-757.	1.8	19
94	Does extended lymphadenectomy increase the morbidity of radical cystectomy?. BJU International, 2004, 93, 64-66.	2.5	106
95	Radical Cystectomy. BJU International, 2004, 94, 197-221.	2.5	78
96	Laparoscopic radical cystectomy and urinary diversion: fad or future?. BJU International, 2004, 94, 501-505.	2.5	32
97	Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients. BJU International, 2004, 94, 1021-1025.	2.5	70
98	The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU International, 2004, 94, 1258-1262.	2.5	44

#	ARTICLE	IF	CITATIONS
99	Complications of laparoscopic radical cystectomy during the initial experience. International Journal of Urology, 2004, 11, 483-488.	1.0	33
100	Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. British Journal of Cancer, 2004, 90, 578-581.	6.4	28
101	Genitourinary cancer in the elderly. Seminars in Oncology, 2004, 31, 249-263.	2.2	7
102	Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Seminars in Oncology, 2004, 31, 25-33.	2.2	31
103	Cyclooxygenase-2 Expression in Bladder Cancer: Correlation with Poor Outcome after Chemotherapy. European Urology, 2004, 45, 46-52.	1.9	26
104	Surgical Management of Infiltrating Bladder Cancer in Elderly Patients. European Urology, 2004, 45, 147-154.	1.9	42
105	Clinical Outcome of a Large-Scale Multi-Institutional Retrospective Study for Locally Advanced Bladder Cancer: A Survey Including 1131 Patients Treated during 1990â€“2000 in Japan. European Urology, 2004, 45, 176-181.	1.9	99
106	Neoadjuvant Cisplatin Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic Studies. European Urology, 2004, 45, 297-303.	1.9	220
107	Detection of Occult Tumor Cells in Lymph Nodes from Bladder Cancer Patients by MUC7 Nested RT-PCR. European Urology, 2004, 45, 314-319.	1.9	46
108	T1G3 Bladder Tumours: The Case for Conservative Treatment. European Urology, 2004, 45, 401-405.	1.9	10
109	Supra-Ampullar Cystectomy with Preservation of Sexual Function and Ileal Orthotopic Reservoir for Bladder Tumor: Twenty Years of Experience. European Urology, 2004, 46, 264-270.	1.9	50
110	Neoadjuvant Chemotherapy with Docetaxel and Cisplatin in Patients with High-Risk Resectable Bladder Carcinoma: Long Term Results. European Urology, 2004, 46, 344-351.	1.9	6
111	Lymphadenectomy with Cystectomy: Is It Necessary and What Is Its Extent?. European Urology, 2004, 46, 457-461.	1.9	44
112	T1G3 bladder cancer â€“ Indications for early cystectomy. International Urology and Nephrology, 2004, 36, 41-44.	1.4	56
114	Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives. International Journal of Clinical Oncology, 2004, 9, 484-490.	2.2	17
115	Radical cystectomy in septuagenarian patients with bladder cancer. International Urology and Nephrology, 2004, 36, 353-358.	1.4	14
116	Current Status of Radiation Therapy and Combined-Modality Treatment for Bladder Cancer. Strahlentherapie Und Onkologie, 2004, 180, 701-709.	2.0	27
120	Combined chemotherapy and external beam radiotherapy for transitional cell carcinoma of the bladder. Current Oncology Reports, 2004, 6, 230-236.	4.0	1

#	ARTICLE	IF	CITATIONS
121	Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy. <i>Cancer</i> , 2004, 101, 2540-2548.	4.1	78
122	Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 197-207.	0.8	142
123	A Meta-analysis of Randomised Trials Suggests a Survival Benefit for Combined Radiotherapy and Radical Cystectomy Compared with Radical Radiotherapy for Invasive Bladder Cancer: Are These Data Relevant to Modern Practice?. <i>Clinical Oncology</i> , 2004, 16, 166-171.	1.4	28
124	Early and late treatment-related morbidity following radical cystectomy. <i>Scandinavian Journal of Urology and Nephrology</i> , 2004, 38, 153-160.	1.4	88
125	PROGNOSIS OF SEMINAL VESICLE INVOLVEMENT BY TRANSITIONAL CELL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 2004, 172, 81-84.	0.4	25
126	Applications of laparoscopic surgery in urology. <i>Medical Clinics of North America</i> , 2004, 88, 519-538.	2.5	19
127	PARTIAL CYSTECTOMY: A CONTEMPORARY REVIEW OF THE MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERIENCE AND RECOMMENDATIONS FOR PATIENT SELECTION. <i>Journal of Urology</i> , 2004, 172, 878-881.	0.4	151
128	ORTHOTOPIC BLADDER SUBSTITUTION IN WOMEN: NONTRADITIONAL APPLICATIONS. <i>Journal of Urology</i> , 2004, 171, 1585-1588.	0.4	42
129	Microscopic and Gross Extravesical Extension in Pathological Staging of Bladder Cancer. <i>Journal of Urology</i> , 2004, 171, 640-645.	0.4	61
130	LYMPH NODE INVOLVEMENT IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A PATHO-ANATOMICAL STUDY—A SINGLE CENTER EXPERIENCE. <i>Journal of Urology</i> , 2004, 172, 1818-1821.	0.4	178
131	Correlation of Metastasis Related Gene Expression and Relapse-Free Survival in Patients With Locally Advanced Bladder Cancer Treated With Cystectomy and Chemotherapy. <i>Journal of Urology</i> , 2004, 171, 570-574.	0.4	78
132	PROSPECTIVELY PACKAGED LYMPH NODE DISSECTIONS WITH RADICAL CYSTECTOMY: EVALUATION OF NODE COUNT VARIABILITY AND NODE MAPPING. <i>Journal of Urology</i> , 2004, 172, 1286-1290.	0.4	193
133	THE MANAGEMENT OF URETHRAL TRANSITIONAL CELL CARCINOMA AFTER RADICAL CYSTECTOMY FOR INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2004, 172, 1342-1347.	0.4	86
134	Treatment and Outcome of Invasive Bladder Cancer in Patients After Renal Transplantation. <i>Journal of Urology</i> , 2004, 171, 1085-1088.	0.4	61
135	Extended Radical Lymphadenectomy in Patients With Urothelial Bladder Cancer:: Results of a Prospective Multicenter Study. <i>Journal of Urology</i> , 2004, 171, 139-144.	0.4	412
136	Stage Specific Lymph Node Metastasis Mapping in Radical Cystectomy Specimens. <i>Journal of Urology</i> , 2004, 171, 1830-1834.	0.4	226
137	THE ORTHOTOPIC T POUCH ILEAL NEOBLADDER: EXPERIENCE WITH 209 PATIENTS. <i>Journal of Urology</i> , 2004, 172, 584-587.	0.4	132
138	PRIMARY T1G3 BLADDER CANCER: ORGAN PRESERVING APPROACH OR IMMEDIATE CYSTECTOMY?. <i>Journal of Urology</i> , 2004, 172, 70-75.	0.4	123

#	ARTICLE	IF	CITATIONS
139	NODAL INVOLVEMENT IN BLADDER CANCER CASES TREATED WITH RADICAL CYSTECTOMY: INCIDENCE AND PROGNOSIS. Journal of Urology, 2004, 172, 85-89.	0.4	148
140	IMPACT OF BODY MASS INDEX ON RADICAL CYSTECTOMY. Journal of Urology, 2004, 172, 1281-1285.	0.4	152
141	Standardization of Radical Cystectomy and Pelvic Lymph Node Dissection for Bladder Cancer: A Collaborative Group Report. Journal of Urology, 2004, 171, 1823-1828.	0.4	281
142	LAPAROSCOPIC EXTENDED PELVIC LYMPHADENECTOMY FOR BLADDER CANCER: TECHNIQUE AND INITIAL OUTCOMES. Journal of Urology, 2004, 172, 1809-1812.	0.4	96
143	USEFULNESS OF CA 125 AS A PREOPERATIVE PROGNOSTIC MARKER FOR TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal of Urology, 2004, 172, 2182-2186.	0.4	18
144	Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology, 2004, 63, 73-77.	1.0	38
145	Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. Urology, 2004, 63, 619-624.	1.0	18
146	Gender differences in radical cystectomy: complications and blood loss. Urology, 2004, 63, 1095-1099.	1.0	57
147	Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology, 2004, 64, 157-161.	1.0	21
148	Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology, 2004, 64, 292-297.	1.0	149
149	Local recurrence after radical cystectomy for invasive bladder cancer: An analysis of predictive factors. Urology, 2004, 64, 744-748.	1.0	107
150	Comparison of modified Taguchi and Bricker ureteral reimplantation techniques after radical cystectomy. Urology, 2004, 64, 940-944.	1.0	12
151	The evolving role of pelvic lymphadenectomy in the treatment of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 205-211.	1.6	25
152	Critique of laparoscopic lymphadenectomy in genitourinary oncology. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 246-254.	1.6	6
153	The International Bladder Cancer Bank: Proposal for a new study concept. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 277-284.	1.6	21
154	Positron emission tomography for prostate, bladder, and renal cancer. Seminars in Nuclear Medicine, 2004, 34, 274-292.	4.6	312
155	Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiotherapy and Oncology, 2004, 72, 139-145.	0.6	63
156	Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: results of a 28-year single institution experience. Radiotherapy and Oncology, 2004, 72, 147-157.	0.6	14

#	ARTICLE	IF	CITATIONS
157	Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures. Current Opinion in Urology, 2004, 14, 271-275.	1.8	33
158	Old friends, new ways: revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes. Current Opinion in Urology, 2004, 14, 251-257.	1.8	4
159	Prognostic Implications of Extracapsular Extension of Pelvic Lymph Node Metastases in Urothelial Carcinoma of the Bladder. American Journal of Surgical Pathology, 2005, 29, 89-95.	3.7	63
160	Radical Cystectomy and Surgical Quality of Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 37-42.	4.9	9
161	The Integration of Chemotherapy and Surgery for Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 45-51.	4.9	9
162	Bladder cancer. Current Opinion in Oncology, 2005, 17, 275-280.	2.4	30
163	Current status of establishing standards for lymphadenectomy in the treatment of bladder cancer. Current Opinion in Urology, 2005, 15, 315-319.	1.8	11
164	Organ preservation in invasive bladder cancer: Brachytherapy, an alternative to cystectomy and combined modality treatment?. International Journal of Radiation Oncology Biology Physics, 2005, 61, 678-686.	0.8	39
165	Concomitant chemoradiotherapy for muscle-invasive bladder cancer: the way forward for bladder preservation?. Clinical Oncology, 2005, 17, 160-166.	1.4	12
166	Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU International, 2005, 95, 301-305.	2.5	56
167	Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU International, 2005, 95, 786-790.	2.5	135
168	Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy. International Journal of Urology, 2005, 12, 250-255.	1.0	19
169	Clinical Experience with the N-shaped Ileal Neobladder: Assessment of Complications, Voiding Patterns, and Quality of Life in Our Series of 58 Patients. European Urology, 2005, 47, 666-673.	1.9	44
170	Expression of the Endothelin Axis in Bladder Cancer: Relationship to Clinicopathologic Parameters and Long-term Survival. European Urology, 2005, 47, 593-600.	1.9	24
171	Laparoscopic Radical Cystoprostatectomy: Our Experience in A Consecutive Series of 10 Patients with a 3 Years Follow-Up. European Urology, 2005, 47, 785-792.	1.9	74
172	Upper Urinary Tract Cancer: Location is Correlated with Prognosis. European Urology, 2005, 48, 438-444.	1.9	85
173	Adjuvant and Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Literature Review. European Urology, 2005, 48, 60-68.	1.9	59
174	New HIV-Drug Inhibits In Vitro Bladder Cancer Migration and Invasion. European Urology, 2005, 48, 1025-1030.	1.9	11

#	ARTICLE	IF	CITATIONS
175	Management of muscle invasive bladder cancer?British approaches to organ conservation. Seminars in Radiation Oncology, 2005, 15, 19-27.	2.2	12
176	Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates?The Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Seminars in Radiation Oncology, 2005, 15, 36-41.	2.2	65
177	The surgical management of muscle invasive bladder cancer: A contemporary review. Seminars in Radiation Oncology, 2005, 15, 10-18.	2.2	31
178	Organ preservation by combined modality treatment in bladder cancer: The European perspective. Seminars in Radiation Oncology, 2005, 15, 28-35.	2.2	36
179	Chemotherapy for local treatment of bladder cancer. Seminars in Radiation Oncology, 2005, 15, 60-65.	2.2	9
180	CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. International Journal of Cancer, 2005, 114, 182-189.	5.1	69
181	Radical cystectomy in the elderly. Cancer, 2005, 103, 546-552.	4.1	61
182	Small cell carcinoma of the urinary bladder. Cancer, 2005, 103, 1172-1178.	4.1	252
183	Radical cystectomy in the elderly. Cancer, 2005, 104, 36-43.	4.1	193
184	Bladder carcinoma: Where are the patient advocates?. Cancer, 2005, 104, 1559-1562.	4.1	5
185	Surgical treatment of bladder carcinoma. Cancer, 2005, 104, 1563-1566.	4.1	2
186	Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer, 2005, 104, 2384-2391.	4.1	63
187	FDG-PET for preoperative staging of bladder cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1412-1417.	6.4	174
188	Organ-Sparing Treatment in Muscle-Invasive Bladder Cancer. Strahlentherapie Und Onkologie, 2005, 181, 632-637.	2.0	39
192	Adjuvant chemotherapy for transitional cell carcinoma of the bladder: Paradigms for the design of clinical trials. Current Oncology Reports, 2005, 7, 207-214.	4.0	2
193	Laparoscopic radical cystectomy. Current Urology Reports, 2005, 6, 106-108.	2.2	10
194	Laparoscopic radical cystectomy with continent urinary diversion. Current Urology Reports, 2005, 6, 109-117.	2.2	8
195	The Extent of Lymphadenectomy at the Time of Radical Cystectomy for Bladder Cancer and its Impact on Prognosis and Survival. Scientific World Journal, The, 2005, 5, 891-901.	2.1	2

#	ARTICLE	IF	CITATIONS
196	Stapleless laparoscopic assisted radical cystectomy with ileal neobladder in a male and with ileal loop in a female: initial report from Brazil. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2005, 31, 214-221.	1.5	6
197	Laparoscopic assisted radical cystoprostatectomy with Y-shaped orthotopic ileal neobladder constructed with non-absorbable titanium staples through a 5 cm Pfannensteil incision. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2005, 31, 362-369.	1.5	13
198	Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies. Nature Reviews Urology, 2005, 2, 32-37.	1.4	12
199	APE1 and XRCC1 Protein Expression Levels Predict Cancer-Specific Survival Following Radical Radiotherapy in Bladder Cancer. Clinical Cancer Research, 2005, 11, 6205-6211.	7.0	79
200	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer. Annals of Oncology, 2005, 16, i43-i44.	1.2	2
201	Recent advances in the treatment of bladder cancer. Expert Review of Anticancer Therapy, 2005, 5, 1023-1030.	2.4	2
202	Adjuvant chemotherapy for bladder cancer. Expert Review of Anticancer Therapy, 2005, 5, 987-991.	2.4	3
204	Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer. Cancer Research, 2005, 65, 11581-11587.	0.9	44
205	Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene ρ GDI2. Cancer Research, 2005, 65, 7320-7327.	0.9	105
206	Detection of Micrometastases in Pelvic Lymph Nodes in Patients Undergoing Radical Cystectomy for Focally Invasive Bladder Cancer by Real-time Reverse Transcriptase-PCR for Cytokeratin 19 and Uroplakin II. Clinical Cancer Research, 2005, 11, 3773-3777.	7.0	71
207	Dynamic MRI of Bladder Cancer: Evaluation of Staging Accuracy. American Journal of Roentgenology, 2005, 184, 121-127.	2.2	240
208	Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy. Journal of Clinical Oncology, 2005, 23, 6533-6539.	1.6	283
209	Prognostic Factors in a Recent Series of Patients Treated with Radical Cystectomy for Bladder Cancer. Urologia Internationalis, 2005, 75, 10-16.	1.3	7
210	What is the role of radiotherapy in bladder-preserving cancer therapy?. Nature Clinical Practice Oncology, 2005, 2, 4-5.	4.3	193
211	Extracapsular Extension of Pelvic Lymph Node Metastases From Urothelial Carcinoma of the Bladder Is an Independent Prognostic Factor. Journal of Clinical Oncology, 2005, 23, 2358-2365.	1.6	183
212	General Anesthesia versus Epidural and General Anesthesia in Radical Cystectomy. Urologia Internationalis, 2005, 74, 62-67.	1.3	25
213	P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncology, The, 2005, 6, 678-686.	10.7	280
214	Bladder-Sparing Treatment Modalities in the Management of Invasive Bladder Cancer. European Urology Supplements, 2005, 4, 57-60.	0.1	1

#	ARTICLE	IF	CITATIONS
215	Combined-Modality Therapy With Gemcitabine and Radiotherapy as a Bladder Preservation Strategy: Results of a Phase I Trial. Journal of Urology, 2005, 173, 1535-1535.	0.4	0
216	Bladder Cancerâ€”Resection/Ablation. Surgical Oncology Clinics of North America, 2005, 14, 321-352.	1.5	1
217	QUALITY OF CARE: PARTIAL CYSTECTOMY FOR BLADDER CANCERâ€”A CASE OF INAPPROPRIATE USE?. Journal of Urology, 2005, 174, 1050-1054.	0.4	50
218	THE TREATMENT OF PATIENTS WITH BLADDER CANCER: LETâ€™S NOT FORGET THE PAST!. Journal of Urology, 2005, 174, 814-815.	0.4	1
219	THE REGIONALIZATION OF RADICAL CYSTECTOMY TO SPECIFIC MEDICAL CENTERS. Journal of Urology, 2005, 174, 1385-1389.	0.4	85
220	IS ORTHOTOPIC BLADDER REPLACEMENT THE NEW GOLD STANDARD? EVIDENCE FROM A SYSTEMATIC REVIEW. Journal of Urology, 2005, 174, 21-28.	0.4	40
221	Clinical Indications and Outcomes with Nerve-sparing Cystectomy in Patients with Bladder Cancer. Urologic Clinics of North America, 2005, 32, 165-175.	1.8	64
222	Surgical Factors in the Treatment of Superficial and Invasive Bladder Cancer. Urologic Clinics of North America, 2005, 32, 157-164.	1.8	41
223	Neobladder with Prostatic Capsule and Seminal-sparing Cystectomy for Bladder Cancer: A Step in the Wrong Direction. Urologic Clinics of North America, 2005, 32, 177-185.	1.8	99
224	Radical Cystectomy for Bladder Cancer: The Case for Early Intervention. Urologic Clinics of North America, 2005, 32, 147-155.	1.8	29
225	URETHRAL TUMOR RECURRENCE FOLLOWING CYSTECTOMY AND URINARY DIVERSION: CLINICAL AND PATHOLOGICAL CHARACTERISTICS IN 768 MALE PATIENTS. Journal of Urology, 2005, 173, 1163-1168.	0.4	176
226	The Role of Lymphadenectomy in High-grade Invasive Bladder Cancer. Urologic Clinics of North America, 2005, 32, 187-197.	1.8	75
227	The Current and Future Application of Adjuvant Systemic Chemotherapy in Patients with Bladder Cancer Following Cystectomy. Urologic Clinics of North America, 2005, 32, 217-230.	1.8	9
228	IDENTIFYING RISK FACTORS FOR POTENTIALLY AVOIDABLE COMPLICATIONS FOLLOWING RADICAL CYSTECTOMY. Journal of Urology, 2005, 174, 1231-1237.	0.4	248
229	Neoadjuvant Chemotherapy in Patients with Invasive Bladder Cancer. Urologic Clinics of North America, 2005, 32, 231-237.	1.8	16
230	RISK GROUPS IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: STATISTICAL AND CLINICAL MODEL IMPROVING HOMOGENEITY. Journal of Urology, 2005, 174, 1226-1230.	0.4	19
231	PROGNOSTIC SIGNIFICANCE OF LYMPHOVASCULAR INVASION OF BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY. Journal of Urology, 2005, 174, 103-106.	0.4	121
232	LOCAL RECURRENCE AFTER CYSTECTOMY AND SURVIVAL OF PATIENTS WITH BLADDER CANCER: A POPULATION BASED STUDY IN GREATER AMSTERDAM. Journal of Urology, 2005, 174, 97-102.	0.4	40

#	ARTICLE	IF	CITATIONS
233	IMPACT OF MALPRACTICE CAPS ON USE AND OUTCOMES OF RADICAL CYSTECTOMY FOR BLADDER CANCER: DATA FROM THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM. Journal of Urology, 2005, 173, 2085-2089.	0.4	22
234	The management of lymph node metastasis from bladder cancer. European Journal of Surgical Oncology, 2005, 31, 348-356.	1.0	14
235	The Road to Cystectomy: Who, When and Why?. EAU Update Series, 2005, 3, 118-128.	0.5	8
236	Cystectomy â€œ Technical Considerations in Male and Female Patients. EAU Update Series, 2005, 3, 138-146.	0.5	35
237	Laparoscopic Cystectomy â€œ Evolution of A New Technique. EAU Update Series, 2005, 3, 147-155.	0.5	1
238	Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: Impact on patient outcomes and costs. Urology, 2005, 65, 488-492.	1.0	22
239	Urinary diversion in high-risk elderly patients: Modified cutaneous ureterostomy or ileal conduit?. Urology, 2005, 66, 299-304.	1.0	81
240	Non-muscle-invasive bladder cancer: The role of radical cystectomy. Urology, 2005, 66, 917-922.	1.0	24
241	Management of stage T1 tumors of the bladder: International Consensus Panel. Urology, 2005, 66, 108-125.	1.0	371
242	The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 77-81.	1.6	37
243	Extent of lymphadenectomy in radical cystectomy for bladder cancer. World Journal of Surgical Oncology, 2005, 3, 43.	1.9	5
244	LAPAROSCOPIC RADICAL CYSTECTOMY IN THE FEMALE. Journal of Urology, 2005, 173, 1912-1917.	0.4	59
245	RADICAL CYSTECTOMY FOR PRIMARY NEUROENDOCRINE TUMORS OF THE BLADDER: THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE. Journal of Urology, 2005, 174, 93-96.	0.4	142
246	UPDATE ON CHEMOTHERAPY FOR ADVANCED BLADDER CANCER. Journal of Urology, 2005, 174, 14-20.	0.4	147
247	Neoadjuvant Chemotherapy in Bladder Cancer. American Journal of Cancer, 2005, 4, 71-75.	0.4	0
248	Cystectomy for Transitional Cell Carcinoma of the Bladder: Results of a Surgery Only Series in the Neobladder Era. Journal of Urology, 2006, 176, 486-492.	0.4	322
249	Prediction of Extravesical Disease by Preoperative Serum Markers in Patients With Clinically Organ Confined Invasive Bladder Cancer. Journal of Urology, 2006, 175, 1253-1257.	0.4	15
250	The Effects of Adjusting for Case Mix on Mortality and Length of Stay Following Radical Cystectomy. Journal of Urology, 2006, 176, 1363-1368.	0.4	72

#	ARTICLE	IF	CITATIONS
251	Effect of Preoperative Delay on Survival in Patients With Bladder Cancer Undergoing Cystectomy in Quebec: A Population Based Study. <i>Journal of Urology</i> , 2006, 175, 78-83.	0.4	84
252	Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium. <i>Journal of Urology</i> , 2006, 176, 2414-2422.	0.4	613
253	The Role of Imaging in the Surveillance of Urologic Malignancies. <i>Urologic Clinics of North America</i> , 2006, 33, 377-396.	1.8	19
254	Chemotherapy practices and perspectives in invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1473-1482.	2.4	2
255	Artificial Intelligence Technique for Gene Expression Profiling of Urinary Bladder Cancer. , 2006, , .		5
256	Nuclear Medicine Studies of the Prostate, Testes, and Bladder. <i>Seminars in Nuclear Medicine</i> , 2006, 36, 51-72.	4.6	129
257	Molecular Biology of Bladder Cancer: Prognostic and Clinical Implications. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 67-77.	1.9	46
258	Open versus Laparoscopic Radical Cystectomy. <i>European Urology Supplements</i> , 2006, 5, 385-394.	0.1	9
259	Laparoscopic Radical Cystectomy and Urinary Diversion: Status in 2006. <i>European Urology Supplements</i> , 2006, 5, 950-955.	0.1	8
260	Radiotherapy in the Management of Common Genitourinary Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 321-346.	2.2	2
261	A Critical Analysis of Perioperative Mortality From Radical Cystectomy. <i>Journal of Urology</i> , 2006, 175, 886-890.	0.4	139
262	Neuro-Fuzzy Modeling: An Accurate and Interpretable Method for Predicting Bladder Cancer Progression. <i>Journal of Urology</i> , 2006, 175, 474-479.	0.4	32
263	Nomogram for Predicting Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2006, 176, 1354-1362.	0.4	185
264	Partial Cystectomy for Muscle Invasive Urothelial Carcinoma of the Bladder: A Contemporary Review of the M. D. Anderson Cancer Center Experience. <i>Journal of Urology</i> , 2006, 175, 2058-2062.	0.4	135
266	Evaluation of the Relevance of Lymph Node Density in a Contemporary Series of Patients Undergoing Radical Cystectomy. <i>Journal of Urology</i> , 2006, 176, 53-57.	0.4	94
267	Cancer Specific Outcomes in Patients With PTO Disease Following Radical Cystectomy. <i>Journal of Urology</i> , 2006, 175, 1645-1649.	0.4	48
268	Racial Disparity in Bladder Cancer: Trends in Tumor Presentation at Diagnosis. <i>Journal of Urology</i> , 2006, 176, 927-934.	0.4	62
269	Patterns of Initial Transitional Cell Recurrence in Patients After Cystectomy. <i>Journal of Urology</i> , 2006, 175, 2054-2057.	0.4	47

#	ARTICLE	IF	CITATIONS
270	Superficial (pT2a) and Deep (pT2b) Muscle Invasion in Pathological Staging of Bladder Cancer Following Radical Cystectomy. Journal of Urology, 2006, 176, 493-499.	0.4	48
271	Tumor Recurrence in the Remnant Urothelium of Females Undergoing Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: Long-Term Results From a Single Center. Journal of Urology, 2006, 175, 1268-1271.	0.4	56
272	Discharge Practice Patterns Following Cystectomy for Bladder Cancer: Evidence for the Shifting of the Burden of Care. Journal of Urology, 2006, 176, 2612-2618.	0.4	42
274	Fate of the Leftover Bladder After Supravescical Urinary Diversion for Benign Disease. Journal of Urology, 2006, 176, 620-621.	0.4	47
275	Cystectomy Delay More Than 3 Months From Initial Bladder Cancer Diagnosis Results in Decreased Disease Specific and Overall Survival. Journal of Urology, 2006, 175, 1262-1267.	0.4	168
276	Intraoperative Sentinel Node Detection Improves Nodal Staging in Invasive Bladder Cancer. Journal of Urology, 2006, 175, 84-88.	0.4	99
278	Erection- and Ejaculation-Preserving Cystectomy With Orthotopic Urinary Diversion: Is It Feasible?. Journal of Andrology, 2006, 27, 263-267.	2.0	10
280	Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments. Journal of Clinical Oncology, 2006, 24, 5519-5527.	1.6	88
281	Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application. Clinical Cancer Research, 2006, 12, 3882-3889.	7.0	121
282	Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology, 2006, 67, 105-109.	1.0	36
283	Racial disparities in resource utilization for cystectomy. Urology, 2006, 67, 288-293.	1.0	48
284	Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: Defining the risk of initial bladder preservation. Urology, 2006, 67, 737-741.	1.0	41
285	Recurrent transitional cell carcinoma in a scrotal abscess. Urology, 2006, 67, 846.e1-846.e2.	1.0	1
286	Complications after radical cystectomy: Analysis of population-based data. Urology, 2006, 68, 58-64.	1.0	216
287	Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology, 2006, 68, 538-542.	1.0	29
288	Removal of more lymph nodes may provide better outcome, as well as more accurate pathologic findings, in patients with bladder cancer—analysis of role of pelvic lymph node dissection. Urology, 2006, 68, 543-548.	1.0	37
289	Long-term results of primary adenocarcinoma of the urinary bladder: A report on 192 patients. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 13-20.	1.6	107
290	Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: Preliminary results. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 109-115.	1.6	19

#	ARTICLE	IF	CITATIONS
291	Lymphadenectomy in bladder cancer: How high is "high enough"? Urologic Oncology: Seminars and Original Investigations, 2006, 24, 349-355.	1.6	64
292	A fourteen-year review of radical cystectomy for transitional cell carcinoma demonstrating the usefulness of the concept of lymph node density. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2006, 32, 536-549.	1.5	9
293	Systemic Therapy for Bladder Cancer. , 0, , 188-211.		0
294	Robot-Assisted Radical Cystectomy in the Management of Bladder Cancer. Scientific World Journal, The, 2006, 6, 2560-2565.	2.1	8
295	Importance of Node Dissection in Relation to Neoadjuvant and Adjuvant Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 1019-1026.	4.9	1
296	Complications in laparoscopic radical cystectomy: The South American experience with 59 cases. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2006, 32, 300-305.	1.5	34
298	Comparative study of intelligent models for the prediction of bladder cancer progression. Oncology Reports, 2006, 15 Spec no., 1019-22.	2.6	3
299	CASE STUDIES IN MODELLING LARGE SCALE COMPLEX PROCESS AND BIOMEDICAL SYSTEMS. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2006, 39, 1-10.	0.4	0
300	Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney, and Prostate Cancer. Laboratory Medicine, 2006, 37, 429-435.	1.2	0
301	Bladder cancer. Current Opinion in Oncology, 2006, 18, 277-283.	2.4	13
302	Urinary bladder cancer: hard times for evidenced-based data. Current Opinion in Urology, 2006, 16, 342-343.	1.8	0
303	Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. Journal of Pathology, 2006, 209, 336-343.	4.5	73
304	Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale. BJU International, 2006, 97, 227-231.	2.5	36
305	Lymphadenectomy for invasive bladder cancer. II. technical aspects and prognostic factors. BJU International, 2006, 97, 232-237.	2.5	65
307	Radical cystectomy with ileal conduit diversion: early prospective evaluation of the impact of robotic assistance. BJU International, 2006, 98, 1059-1063.	2.5	103
308	Complications and neobladder function of the Hautmann orthotopic ileal neobladder. BJU International, 2006, 98, 1289-1294.	2.5	45
309	Minimally invasive radical cystectomy. BJU International, 2006, 98, 1064-1067.	2.5	18
310	Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU International, 2006, 98, 1172-1175.	2.5	30

#	ARTICLE	IF	CITATIONS
311	Experience and functional outcome of modified ileal neobladder in 95 patients. International Journal of Urology, 2006, 13, 1175-1179.	1.0	31
312	MANAGEMENT OF MUSCLE-INVASIVE BLADDER CANCER IN VICTORIA, 1990-1995. ANZ Journal of Surgery, 2006, 76, 113-119.	0.7	8
313	EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene, 2006, 25, 769-780.	5.9	91
314	Perioperative chemotherapy for bladder cancer. Critical Reviews in Oncology/Hematology, 2006, 57, 133-144.	4.4	21
315	Continent urinary diversion. Critical Reviews in Oncology/Hematology, 2006, 57, 255-264.	4.4	45
316	Evaluating the Effect of Reducing the High-dose Volume on the Toxicity of Radiotherapy in the Treatment of Bladder Cancer. Clinical Oncology, 2006, 18, 466-473.	1.4	23
317	Epidermal Growth Factor Receptor Status Predicts Local Response to Radical Radiotherapy in Muscle-invasive Bladder Cancer. Clinical Oncology, 2006, 18, 702-709.	1.4	14
318	Clinicopathological Features of Recurrence after Radical Cystectomy for Patients with Transitional Cell Carcinoma of the Bladder. International Urology and Nephrology, 2006, 38, 49-55.	1.4	8
319	Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer. Journal of Cancer Research and Clinical Oncology, 2006, 132, 757-764.	2.5	15
320	Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World Journal of Urology, 2006, 24, 296-304.	2.2	261
321	Improving outcomes with radical cystectomy for high-grade invasive bladder cancer. World Journal of Urology, 2006, 24, 509-516.	2.2	21
322	Treatment options for BCG failures. World Journal of Urology, 2006, 24, 481-487.	2.2	79
323	Neoadjuvant chemotherapy for bladder cancer. World Journal of Urology, 2006, 24, 531-542.	2.2	30
324	Bladder-sparing approaches to invasive disease. World Journal of Urology, 2006, 24, 517-529.	2.2	17
325	Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?. World Journal of Urology, 2006, 24, 557-564.	2.2	25
326	New imaging modalities in bladder cancer. World Journal of Urology, 2006, 24, 473-480.	2.2	32
329	Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer. Clinical and Translational Oncology, 2006, 8, 903-911.	2.4	15
330	Lymph Node Metastasis in Bladder Cancer. European Urology, 2006, 49, 13-21.	1.9	70

#	ARTICLE	IF	CITATIONS
331	Management of BCG Failures in Superficial Bladder Cancer: A Review. <i>European Urology</i> , 2006, 49, 790-797.	1.9	157
332	Supra-ampullar Cystectomy and Ileal Neobladder. <i>European Urology</i> , 2006, 50, 1223-1233.	1.9	19
334	Results of Chimney Modification Technique in Ureterointestinal Anastomosis of Hautmann Ileal Neobladder in Bladder Cancer. <i>Asian Journal of Surgery</i> , 2006, 29, 251-256.	0.4	5
335	What is the significance of pT0 at cystectomy?. <i>Surgical Oncology</i> , 2006, 15, 65-69.	1.6	6
336	The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. <i>BMC Cancer</i> , 2006, 6, 159.	2.6	61
337	Systemic Chemotherapy for Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 34-42.	1.9	1
338	Adjuvant chemotherapy in muscle-invasive bladder carcinoma. <i>Cancer</i> , 2006, 106, 783-788.	4.1	83
339	Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma. <i>Cancer</i> , 2006, 107, 60-66.	4.1	32
340	Should we screen for bladder cancer in a high-risk population?. <i>Cancer</i> , 2006, 107, 982-990.	4.1	122
341	Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. <i>Cancer</i> , 2006, 107, 1491-1495.	4.1	21
342	The prognostic and staging value of lymph node dissection in the treatment of invasive bladder cancer. <i>Nature Reviews Urology</i> , 2006, 3, 485-494.	1.4	9
343	Developing innovative strategies for advanced transitional cell carcinoma of the bladder. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 83-92.	2.4	4
344	Radical radiotherapy for urinary bladder cancer: treatment outcomes. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 269-279.	2.4	19
345	Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 281-291.	2.4	9
347	The adverse consequences of delaying radical cystectomy. <i>Nature Reviews Urology</i> , 2006, 3, 300-301.	1.4	1
348	The importance of lymphovascular invasion in patients undergoing radical cystectomy for bladder cancer. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 246-247.	4.3	1
350	Adjuvant chemotherapy of bladder cancer. <i>Annals of Oncology</i> , 2006, 17, v129-v132.	1.2	12
351	Muscle invasive and metastatic bladder cancer. <i>Annals of Oncology</i> , 2006, 17, x23-x30.	1.2	15

#	ARTICLE	IF	CITATIONS
352	Benefits of laparoscopic prostate-sparing radical cystectomy. Expert Review of Anticancer Therapy, 2006, 6, 21-26.	2.4	7
353	The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer. Oncologist, 2006, 11, 630-640.	3.7	18
354	Radiochemotherapy After Transurethral Resection for High-Risk T1 Bladder Cancer: An Alternative to Intravesical Therapy or Early Cystectomy?. Journal of Clinical Oncology, 2006, 24, 2318-2324.	1.6	105
355	Challenges in the treatment of bladder cancer. Annals of Oncology, 2006, 17, v106-v112.	1.2	63
356	Assessment of Long-Term Quality of Life Using the FACT-BL Questionnaire in Patients with an Ileal Conduit, Continent Reservoir, or Orthotopic Neobladder. Japanese Journal of Clinical Oncology, 2006, 36, 712-716.	1.3	62
357	Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer. Journal of Clinical Oncology, 2006, 24, 3967-3972.	1.6	419
358	Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. Clinical Cancer Research, 2006, 12, 6663-6676.	7.0	219
359	Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease. Clinical Cancer Research, 2006, 12, 7369-7373.	7.0	144
360	Should Prostate Cancer Status Be Determined in Patients Undergoing Radical Cystoprostatectomy?. Urologia Internationalis, 2006, 77, 307-310.	1.3	9
361	Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer. Expert Review of Anticancer Therapy, 2006, 6, 871-876.	2.4	5
362	Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2006, 6, 1301-1311.	2.4	9
363	A case of T2 muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. Nature Reviews Urology, 2006, 3, 675-679.	1.4	0
364	Are bladder cancer patients with pT0 disease following radical cystectomy cured of cancer?. Nature Reviews Urology, 2006, 3, 530-531.	1.4	1
365	Are Nomograms Better Than Currently Available Stage Groupings for Bladder Cancer?. Journal of Clinical Oncology, 2006, 24, 3819-3820.	1.6	152
366	Cost-effectiveness of bladder cancer screening. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 627-632.	1.4	2
367	Superficial bladder cancer: part 2. Management.. Expert Review of Anticancer Therapy, 2007, 7, 567-581.	2.4	32
368	Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2007, 7, 1729-1736.	2.4	7
369	Prostate-sparing cystectomy: has Pandora's box been opened?. Expert Review of Anticancer Therapy, 2007, 7, 1003-1014.	2.4	12

#	ARTICLE	IF	CITATIONS
370	Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis. PLoS Medicine, 2007, 4, e284.	8.4	79
371	Clarifying the indications for adjuvant chemotherapy in muscle-invasive bladder cancer. Nature Reviews Urology, 2007, 4, 184-185.	1.4	1
372	Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells. Cancer Biology and Therapy, 2007, 6, 1600-1605.	3.4	13
373	Surgery Insight: advantages and disadvantages of laparoscopic radical cystectomy to treat invasive bladder cancer. Nature Reviews Urology, 2007, 4, 387-394.	1.4	14
374	Emerging drugs for targeted therapy of bladder cancer. Expert Opinion on Emerging Drugs, 2007, 12, 435-448.	2.4	7
375	Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2007, 18, ii38-ii39.	1.2	1
376	Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy. Japanese Journal of Clinical Oncology, 2007, 37, 852-857.	1.3	27
377	Role of external radiation therapy in urinary cancers. Annals of Oncology, 2007, 18, vi157-vi161.	1.2	4
378	Impact of the Level of Muscle Invasion in Organ-Confined Bladder Cancer. Urologia Internationalis, 2007, 78, 145-149.	1.3	8
379	Lymphadenectomy in Bladder Cancer: A Review. Urologia Internationalis, 2007, 79, 191-199.	1.3	47
380	Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer. Clinical Cancer Research, 2007, 13, 2046-2053.	7.0	163
381	Bladder cancer. Current Opinion in Oncology, 2007, 19, 241-247.	2.4	18
382	The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery. Current Opinion in Urology, 2007, 17, 358-362.	1.8	7
383	Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Current Opinion in Urology, 2007, 17, 369-375.	1.8	93
384	Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Current Opinion in Urology, 2007, 17, 352-357.	1.8	27
385	Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: What Percentage of Patients Qualifies for Bladder Preservation Protocols?. Current Urology, 2007, 1, 24-27.	0.6	0
386	Urinary Diversion. Urology, 2007, 69, 17-49.	1.0	334
387	Urothelial Carcinoma of the Prostate. Urology, 2007, 69, 50-61.	1.0	62

#	ARTICLE	IF	CITATIONS
388	Muscle-Invasive Urothelial Carcinoma of the Bladder. <i>Urology</i> , 2007, 69, 3-16.	1.0	157
389	Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer. <i>Urology</i> , 2007, 69, 62-79.	1.0	183
390	Volume, Process of Care, and Operative Mortality for Cystectomy for Bladder Cancer. <i>Urology</i> , 2007, 69, 871-875.	1.0	137
391	Multimodal Perioperative Plan for Radical Cystectomy and Intestinal Urinary Diversion. I. Effect on Recovery of Intestinal Function and Occurrence of Complications. <i>Urology</i> , 2007, 69, 1107-1111.	1.0	63
392	Early-Stage Bladder Cancer Surveillance Does Not Improve Survival If High-Risk Patients Are Permitted to Progress to Muscle Invasion. <i>Urology</i> , 2007, 69, 1068-1072.	1.0	41
393	Effectiveness of Adjuvant Chemotherapy in Transitional Cell Carcinoma of the Urinary Bladder with Lymph Node Involvement and/or Lymphovascular Invasion Treated by Radical Cystectomy. <i>Urology</i> , 2007, 70, 257-262.	1.0	38
394	Muscle-Invasive Bladder Cancer: Predictive Factors and Prognostic Difference Between Primary and Progressive Tumors. <i>Urology</i> , 2007, 70, 477-481.	1.0	59
395	Perioperative Outcomes with Laparoscopic Radical Cystectomy: "Pure Laparoscopic" and "Open-Assisted Laparoscopic" Approaches. <i>Urology</i> , 2007, 70, 910-915.	1.0	113
396	A rationale for developing benchmarks for the treatment of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 57-65.	1.6	4
397	Surgical benchmarks for the treatment of invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 66-71.	1.6	77
398	Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: Current standards. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 72-75.	1.6	6
399	Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 76-84.	1.6	18
400	Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 303-309.	1.6	98
401	Adjuvant radiotherapy in bladder cancer: Time to take a fresh look?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 353-354.	1.6	4
402	The use and abuse of data: Nomograms and talking to patients about clinical medicine. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 333-337.	1.6	9
403	The best treatment for high-grade T1 bladder cancer is cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 523-525.	1.6	15
404	Bladder Cancer: Epidemiology, Diagnosis, and Treatment. <i>Seminars in Oncology Nursing</i> , 2007, 23, S3-S10.	1.5	3
405	Bladder carcinoma recurrence post-cystectomy simulating rectal carcinoma. <i>Clinical Radiology</i> , 2007, 62, 177-180.	1.1	3

#	ARTICLE	IF	CITATIONS
406	Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Human Pathology, 2007, 38, 741-746.	2.0	66
407	Treatment of Intermediate-Risk Nonâ€“Muscle-Invasive Bladder Cancer (NMIBC). European Urology Supplements, 2007, 6, 800-808.	0.1	7
408	Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncology, The, 2007, 8, 128-136.	10.7	198
409	Robotic Assisted Laparoscopic Radical Cystoprostatectomy: Operative and Pathological Outcomes. Journal of Urology, 2007, 178, 814-818.	0.4	137
410	Positive Surgical Margins in Soft Tissue Following Radical Cystectomy for Bladder Cancer and Cancer Specific Survival. Journal of Urology, 2007, 178, 2308-2313.	0.4	217
411	Harnblasenkarzinom. , 2007, , 301-372.		0
412	Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. Expert Review of Anticancer Therapy, 2007, 7, 1015-1026.	2.4	12
413	Lymph node density: surrogate marker for quality of resection in bladder cancer?. Expert Review of Anticancer Therapy, 2007, 7, 777-779.	2.4	5
414	Radical Cystectomy and Extended Pelvic Lymphadenectomy: Survival of Patients With Lymph Node Metastasis Above the Bifurcation of the Common Iliac Vessels Treated With Surgery Only. Journal of Urology, 2007, 178, 1218-1224.	0.4	121
415	Upper Tract Urothelial Recurrence Following Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: An Analysis of 1,069 Patients With 10-Year Followup. Journal of Urology, 2007, 177, 2088-2094.	0.4	136
417	Getting Under the Hood of the Volume-Outcome Relationship for Radical Cystectomy. Journal of Urology, 2007, 177, 2095-2099.	0.4	59
418	Comparison of Laparoscopic and Open Radical Cystoprostatectomy for Localized Bladder Cancer With 3-Year Oncological Followup: A Single Surgeon Experience. Journal of Urology, 2007, 178, 2340-2343.	0.4	86
419	Radical Cystectomy With Extended Lymphadenectomy: Evaluating Separate Package Versus en Bloc Submission for Node Positive Bladder Cancer. Journal of Urology, 2007, 177, 876-882.	0.4	136
420	Oncological and Functional Outcome of Radical Cystectomy in Patients With Bladder Cancer and Obstructive Uropathy. Journal of Urology, 2007, 178, 1206-1211.	0.4	13
421	Patterns of Recurrence and Outcomes Following Induction Bacillus Calmette-Guerin for High Risk Ta, T1 Bladder Cancer. Journal of Urology, 2007, 177, 1727-1731.	0.4	30
422	Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update. Journal of Urology, 2007, 178, 2314-2330.	0.4	730
424	Influence of Post-Cystectomy Complications on Cost and Subsequent Outcome. Journal of Urology, 2007, 177, 280-287.	0.4	61
425	Defining Optimal Therapy for Muscle Invasive Bladder Cancer. Journal of Urology, 2007, 177, 437-443.	0.4	204

#	ARTICLE	IF	CITATIONS
427	State-of-the-Art Cross-Sectional Imaging in Bladder Cancer. Current Problems in Diagnostic Radiology, 2007, 36, 83-96.	1.4	44
428	Radical Cystectomy with an Extended Pelvic Lymphadenectomy: Rationale and Results. Surgical Oncology Clinics of North America, 2007, 16, 233-245.	1.5	32
429	Urinary Diversion: Ileal Conduit to Orthotopic Neobladder Substitution. Korean Journal of Urology, 2007, 48, 565.	0.2	2
430	Five-Year, Disease-Free Survival after Repeat Palliative Multimodality Therapy in a Patient with Recurrent Metastatic Bladder Cancer. Scientific World Journal, The, 2007, 7, 1736-1742.	2.1	0
431	Combination Treatment with Ionising Radiation and Gefitinib ('Iressa', ZD1839), an Epidermal Growth Factor Receptor (EGFR) Inhibitor, Significantly Inhibits Bladder Cancer Cell Growth in vitro and in vivo. Journal of Radiation Research, 2007, 48, 351-360.	1.6	21
432	Results from three municipal hospitals regarding radical cystectomy on elderly patients. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2007, 33, 764-776.	1.5	26
433	Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2007, 33, 777-784.	1.5	14
434	The Difference in the Prognosis and Characteristics between the Progressive and Primary Muscle-invasive Bladder Cancer Treated with Radical Cystectomy. Korean Journal of Urology, 2007, 48, 1109.	0.2	7
435	Short Term Outcomes of Laparoscopic Radical Cystectomy with an Extracorporeal Ileal Conduit: Comparative Analysis with the Open Method. Korean Journal of Urology, 2007, 48, 938.	0.2	3
436	The Role of Pelvic Lymphadenectomy in the Management of Prostate and Bladder Cancer. Scientific World Journal, The, 2007, 7, 789-799.	2.1	12
438	Bladder cancers respond to intravesical instillation of (HAMLET human β -lactalbumin made lethal to) Tj ETQq0 0 0 0 BT /Overlock 10 Tf	5.1	99
439	Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer, 2007, 109, 1106-1113.	4.1	140
440	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. Cancer, 2007, 109, 1499-1505.	4.1	392
441	Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Modern Pathology, 2007, 20, 828-834.	5.5	114
442	Evaluation of findings during re-exploration for obstructive ileus after radical cystectomy and ileal-loop urinary diversion: insight into potential technical improvements. BJU International, 2007, 99, 893-897.	2.5	20
443	Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years. BJU International, 2007, 100, 137-142.	2.5	104
444	Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy. BJU International, 2007, 100, 1225-1228.	2.5	8
445	Improving the prognosis of patients after radical cystectomy. Part I: the role of lymph node dissection. BJU International, 2007, 100, 1221-1224.	2.5	23

#	ARTICLE	IF	CITATIONS
446	Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU International, 2008, 101, 89-93.	2.5	215
447	Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU International, 2007, 101, 070915222359003-???	2.5	22
448	Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma <i>in situ</i> matter? A long-term analysis of 132 patients. International Journal of Urology, 2007, 14, 995-999.	1.0	27
449	RADICAL CYSTECTOMY FOR PRIMARY BLADDER MALIGNANCY: A 10 YEAR REVIEW. ANZ Journal of Surgery, 2007, 77, 265-269.	0.7	11
450	Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. Apmis, 2007, 115, 1194-1205.	2.0	32
451	Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis after Radical Cystectomy. European Urology, 2007, 51, 137-151.	1.9	307
452	Perioperative Complications of Radical Cystectomy in a Contemporary Series. European Urology, 2007, 51, 397-402.	1.9	244
453	Major Invasive Surgery for Urologic Cancer in Octogenarians with Comorbid Medical Conditions. European Urology, 2007, 51, 1600-1605.	1.9	28
454	Advanced Age Is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy. European Urology, 2007, 51, 699-708.	1.9	154
455	Re: Should We Screen for Bladder Cancer in a High-Risk Population? A Cost Per Life-Year Saved Analysis. European Urology, 2007, 51, 1140.	1.9	1
456	P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. European Urology, 2007, 52, 769-776.	1.9	61
457	Editorial Comment on: P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. European Urology, 2007, 52, 774-775.	1.9	0
458	Perioperative Chemotherapy in Muscle-Invasive Bladder Cancer to Enhance Survival and/or as a Strategy for Bladder Preservation. Seminars in Oncology, 2007, 34, 122-128.	2.2	14
459	Radical Cystectomy and Lymphadenectomy for Invasive Bladder Cancer: Towards the Evolution of an Optimal Surgical Standard. Seminars in Oncology, 2007, 34, 110-121.	2.2	19
460	p53 and retinoblastoma pathways in bladder cancer. World Journal of Urology, 2007, 25, 563-571.	2.2	75
463	Significance of radical cystectomy for bladder cancer in patients over 80 years old. International Urology and Nephrology, 2007, 39, 209-214.	1.4	31
469	The role of lymphadenectomy in patients undergoing radical cystectomy for bladder cancer. Current Oncology Reports, 2007, 9, 213-221.	4.0	35
470	Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. International Urology and Nephrology, 2008, 40, 321-327.	1.4	55

#	ARTICLE	IF	CITATIONS
471	Survivin: a promising biomarker for detection and prognosis of bladder cancer. World Journal of Urology, 2008, 26, 59-65.	2.2	92
472	Screening for bladder cancer: a perspective. World Journal of Urology, 2008, 26, 13-18.	2.2	49
473	Clinical Results of a Concomitant Boost Radiotherapy Technique for Muscle-Invasive Bladder Cancer. Strahlentherapie Und Onkologie, 2008, 184, 313-318.	2.0	30
474	Treatment Options for High-Risk T1 Bladder Cancer. Strahlentherapie Und Onkologie, 2008, 184, 443-449.	2.0	10
477	Effective bladder preservation strategy with low-dose radiation therapy and concurrent intrarrrterial chemotherapy for muscle-invasive bladder cancer. Radiation Medicine, 2008, 26, 156-163.	0.8	13
478	The invasive T1 bladder tumor: Contemporary issues and rationale for radical cystectomy. Current Urology Reports, 2008, 9, 179-181.	2.2	4
479	Robotic urology in the United Kingdom: experience and overview of robotic-assisted cystectomy. Journal of Robotic Surgery, 2008, 1, 235-242.	1.8	2
480	First case series of robotic radical cystoprostatectomy, bilateral pelvic lymphadenectomy, and urinary diversion with the da Vinci S system. Journal of Robotic Surgery, 2008, 2, 35-40.	1.8	14
481	High-risk bladder cancer: improving outcomes with perioperative chemotherapy. Oncology Reviews, 2008, 2, 4-8.	1.8	0
482	Contemporary management of muscle-invasive bladder cancer. International Journal of Clinical Oncology, 2008, 13, 504-509.	2.2	11
483	Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer, 2008, 112, 315-325.	4.1	185
484	The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer, 2008, 112, 2401-2408.	4.1	200
485	Advanced bladder cancer: Status of firstâ€line chemotherapy and the search for active agents in the secondâ€line setting. Cancer, 2008, 113, 1284-1293.	4.1	62
486	A role for neoadjuvant gemcitabine plus cisplatin in muscleâ€invasive urothelial carcinoma of the bladder. Cancer, 2008, 113, 2471-2477.	4.1	239
487	Neoadjuvant gemcitabine and cisplatin: Another step on the path toward improving the outcomes of patients with highâ€risk, invasive bladder cancer. Cancer, 2008, 113, 2379-2381.	4.1	0
488	Similar Treatment Outcomes for Radical Cystectomy and RadicalÂRadiotherapy in Invasive Bladder Cancer Treated atÂAaÂUnited Kingdom Specialist Treatment Center. International Journal of Radiation Oncology Biology Physics, 2008, 70, 456-463.	0.8	121
489	Robotic assisted radical cystectomy: short to medium-term oncologic and functional outcomes. International Journal of Clinical Practice, 2008, 62, 1709-1714.	1.7	67
490	Conservative treatment in patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin â€ assessment of response and toxicity.. Reports of Practical Oncology and Radiotherapy, 2008, 13, 300-308.	0.6	2

#	ARTICLE	IF	CITATIONS
491	Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. <i>Oncogene</i> , 2008, 27, 55-62.	5.9	35
492	Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. <i>Oncogene</i> , 2008, 27, 6679-6689.	5.9	158
493	Survival from bladder cancer in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008, 99, S90-S92.	6.4	11
494	Clinical outcome of radical cystectomy for patients with pT4 bladder cancer. <i>International Journal of Urology</i> , 2008, 15, 58-61.	1.0	8
495	Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer. <i>International Journal of Urology</i> , 2008, 15, 314-318.	1.0	10
496	Health-related quality of life after bladder preservation therapy for muscle invasive bladder cancer. <i>International Journal of Urology</i> , 2008, 15, 403-406.	1.0	18
497	The prognostic impact of pelvic lymph node metastasis and lymphovascular invasion on bladder cancer. <i>International Journal of Urology</i> , 2008, 15, 607-611.	1.0	15
498	Clinical outcome of chemoradiotherapy for T1G3 bladder cancer. <i>International Journal of Urology</i> , 2008, 15, 747-750.	1.0	6
499	Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy. <i>International Journal of Urology</i> , 2008, 15, 971-975.	1.0	2
500	Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. <i>BJU International</i> , 2008, 101, 566-569.	2.5	60
501	Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder. <i>BJU International</i> , 2008, 101, 969-972.	2.5	28
502	Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. <i>BJU International</i> , 2008, 101, 1356-1361.	2.5	19
503	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. <i>BJU International</i> , 2008, 101, 1448-1453.	2.5	49
504	Predicting survival after radical cystectomy for bladder cancer. <i>BJU International</i> , 2008, 102, 15-22.	2.5	48
505	The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis. <i>BJU International</i> , 2008, 102, 952-957.	2.5	34
506	Invasive T1 bladder cancer: indications and rationale for radical cystectomy. <i>BJU International</i> , 2008, 102, 270-275.	2.5	46
507	Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. <i>BJU International</i> , 2008, 102, 1539-1543.	2.5	14
508	Functional and oncological outcomes after orthotopic neobladder reconstruction in women. <i>BJU International</i> , 2008, 102, 1551-1555.	2.5	66

#	ARTICLE	IF	CITATIONS
509	MUSCLE-INVASIVE BLADDER TUMOUR: CAN THE BLADDER BE PRESERVED?. BJU International, 2008, 102, 1053-1054.	2.5	0
510	Urothelial bladder cancer: biomarkers for detection and screening. BJU International, 2008, 102, 1234-1241.	2.5	20
511	The optimal management of T1G3 bladder cancer. BJU International, 2008, 102, 1265-1273.	2.5	11
512	Outcomes of radical cystectomy. BJU International, 2008, 102, 1279-1288.	2.5	21
513	Laparoscopic radical cystectomy for muscle-invasive bladder cancer: pathological and oncological outcomes. BJU International, 2008, 102, 1296-1301.	2.5	29
514	Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU International, 2008, 102, 1339-1344.	2.5	17
515	Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU International, 2008, 102, 1345-1353.	2.5	42
516	Does Schistosoma-associated bladder cancer differ from urothelial cancer? Proof from the laboratory and clinic. Cancer Genetics and Cytogenetics, 2008, 180, 160-162.	1.0	0
517	Robotic-Assisted Laparoscopic Radical Cystoprostatectomy. European Urology, 2008, 53, 310-322.	1.9	77
518	Early Versus Deferred Cystectomy for Initial High-Risk pT1G3 Urothelial Carcinoma of the Bladder: Do Risk Factors Define Feasibility of Bladder-Sparing Approach?. European Urology, 2008, 53, 146-152.	1.9	179
519	Risk Assessment of Prostatic Pathology in Patients Undergoing Radical Cystoprostatectomy. European Urology, 2008, 53, 370-375.	1.9	90
520	Intravesical Pharmacotherapy for Non-Muscle-Invasive Bladder Cancer: A Critical Analysis of Currently Available Drugs, Treatment Schedules, and Long-Term Results. European Urology, 2008, 53, 45-52.	1.9	127
521	Urinary Diversions after Cystectomy: The Association of Clinical Factors, Complications and Functional Results of Four Different Diversions. European Urology, 2008, 53, 834-844.	1.9	251
522	Re: Cystectomy for Transitional Cell Carcinoma of the Bladder: Results of a Surgery Only Series in the Neobladder Era. European Urology, 2008, 53, 208-209.	1.9	2
523	Prognostic Impact of Comorbidity in Patients with Bladder Cancer. European Urology, 2008, 53, 581-589.	1.9	48
526	More Nomograms or Better Evidence of Efficacy: What Do We Need in Urologic Oncology?. European Urology, 2008, 54, 11-12.	1.9	9
527	Robotic-assisted Laparoscopic Radical Cystectomy with Extracorporeal Urinary Diversion: Initial Experience. European Urology, 2008, 54, 570-580.	1.9	147
528	Current perioperative management of radical cystectomy with intestinal urinary reconstruction for muscle-invasive bladder cancer and reduction of the incidence of postoperative ileus. Surgical Oncology, 2008, 17, 41-48.	1.6	122

#	ARTICLE	IF	CITATIONS
529	Invasive Bladder Cancer in the Second Trimester of Pregnancy: Difficult Decisions. British Journal of Medical and Surgical Urology, 2008, 1, 43-44.	0.2	0
530	Molecular Credentialing of Rodent Bladder Carcinogenesis Models. Neoplasia, 2008, 10, 838-IN21.	5.3	52
532	Laparoscopic Radical Cystectomy and Extracorporeal Urinary Diversion: A Single Center Experience of 48 Cases with Three Years of Follow-up. Urology, 2008, 71, 41-46.	1.0	61
533	Impact of Previous Bacille Calmette-Guérin Failure Pattern on Subsequent Response to Bacille Calmette-Guérin Plus Interferon Intravesical Therapy. Urology, 2008, 71, 297-301.	1.0	88
534	Prostatic Capsule and Seminal Vesicle-Sparing Cystectomy: Improved Functional Results, Inferior Oncologic Outcome. Urology, 2008, 72, 162-166.	1.0	21
535	Distribution of Lymphatic Vessel Network in Normal Urinary Bladder. Urology, 2008, 72, 706-710.	1.0	13
536	Low-Dose Chemoradiotherapy Followed by Partial or Radical Cystectomy Against Muscle-Invasive Bladder Cancer: An Intent-to-Treat Survival Analysis. Urology, 2008, 72, 384-388.	1.0	40
537	Long-term Results of Selective Partial Cystectomy for Invasive Urothelial Bladder Carcinoma. Urology, 2008, 72, 613-616.	1.0	82
538	Is Robotic Radical Cystectomy an Appropriate Treatment for Bladder Cancer? Short-Term Oncologic and Clinical Follow-Up in 50 Consecutive Patients. Urology, 2008, 72, 617-620.	1.0	63
540	Probabilities and preferences: What economics can teach doctors and patients making difficult treatment decisions. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 669-673.	1.6	7
541	Current status of prostate-sparing cystectomy. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 486-493.	1.6	19
542	The S-shaped orthotopic ileal neobladder substitute incorporating a new seromuscular antireflux technique (split ileal end) in a series of 50 patients. European Journal of Surgical Oncology, 2008, 34, 107-114.	1.0	3
544	Comparing Lymphadenectomy During Radical Nephroureterectomy: Open Versus Laparoscopic. Urology, 2008, 71, 413-416.	1.0	36
545	Old and New Urinary Markers: Which One is the PSA for Bladder Cancer?. European Urology Supplements, 2008, 7, 422-425.	0.1	3
546	Minimally invasive radical cystectomy for bladder cancer?. Lancet Oncology, The, 2008, 9, 317-318.	10.7	5
547	Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder. Journal of Urology, 2008, 180, 2384-2388.	0.4	54
548	Oncological Evaluation of Prostate Sparing Cystectomy: The Montsouris Long-Term Results. Journal of Urology, 2008, 179, 2170-2175.	0.4	38
549	Bladder Cancer After Radiotherapy for Prostate Cancer: Detailed Analysis of Pathological Features and Outcome After Radical Cystectomy. Journal of Urology, 2008, 179, 91-95.	0.4	42

#	ARTICLE	IF	CITATIONS
551	Florida Bladder Cancer Trends 1981 to 2004: Minimal Progress in Decreasing Advanced Disease. Journal of Urology, 2008, 179, 491-495.	0.4	26
553	Outcome After Radical Cystectomy With Limited or Extended Pelvic Lymph Node Dissection. Journal of Urology, 2008, 179, 873-878.	0.4	295
554	Potency Preserving Cystectomy With Intrafascial Prostatectomy for High Risk Superficial Bladder Cancer. Journal of Urology, 2008, 179, 1727-1732.	0.4	27
555	Contemporary Open Radical Cystectomy: Analysis of Perioperative Outcomes. Journal of Urology, 2008, 179, 1313-1318.	0.4	193
556	Re: Patterns of Recurrence and Outcomes Following Induction Bacillus Calmette-Guerin for High Risk Ta, T1 Bladder Cancer. Journal of Urology, 2008, 179, 788-788.	0.4	0
558	Associations Among Age, Comorbidity and Clinical Outcomes After Radical Cystectomy: Results From the Alberta Urology Institute Radical Cystectomy Database. Journal of Urology, 2008, 180, 128-134.	0.4	84
559	Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer. Journal of Urology, 2008, 179, 743-747.	0.4	48
560	Robot-Assisted Extended Pelvic Lymphadenectomy. Journal of Endourology, 2008, 22, 1297-1302.	2.1	45
561	Laparoscopic Radical Cystectomy: Formidable Challenge to the Gold Standard. Journal of Endourology, 2008, 22, 2069-2072.	2.1	7
562	Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC. Journal of Clinical Oncology, 2008, 26, 121-126.	1.6	161
563	Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. Nature Clinical Practice Oncology, 2008, 5, 444-454.	4.3	43
564	Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial Bladder Cancer. Urologia Internationalis, 2008, 80, 74-79.	1.3	8
565	The Prognostic Significance of Pathologic Stage T0 on Organ-Confined Bladder Transitional Cell Carcinoma following Radical Cystectomy. Urologia Internationalis, 2008, 81, 394-398.	1.3	8
566	Bladder-sparing therapy for muscle-infiltrating bladder cancer. Nature Reviews Urology, 2008, 5, 368-375.	1.4	3
567	Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 1885-1893.	1.8	3
568	Urological Oncology. , 2008, , .		3
569	Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nature Reviews Urology, 2008, 5, 676-685.	1.4	33
570	T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival. Clinical Cancer Research, 2008, 14, 4800-4808.	7.0	238

#	ARTICLE	IF	CITATIONS
571	Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii47-ii48.	1.2	10
572	The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 360-364.	1.3	31
577	Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1091-1101.	2.4	13
578	Laparoscopic radical cystectomy: long-term outcomes. <i>Current Opinion in Urology</i> , 2008, 18, 167-172.	1.8	25
579	Lymphadenectomy in minimally invasive urologic oncology. <i>Current Opinion in Urology</i> , 2008, 18, 163-166.	1.8	5
580	Imaging of treated bladder cancer. , 2008, , 147-173.		0
581	Bladder cancer. <i>Current Opinion in Oncology</i> , 2008, 20, 307-314.	2.4	55
582	Bladder preserving strategies for muscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 2008, 18, 513-518.	1.8	21
583	La cistectomia ieri come oggi?. <i>Urologia</i> , 2008, 75, 124-126.	0.7	0
584	Vinflunine in the treatment of bladder cancer. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 1243-1253.	2.0	12
585	Differential Proteomic Analysis of Nuclear Matrix in Muscle-Invasive Bladder Cancer: Potential to Improve Diagnosis and Prognosis. <i>Analytical Cellular Pathology</i> , 2008, 30, 13-26.	1.4	15
586	Surgery for bladder cancer. , 2008, , 93-105.		0
587	The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder. <i>Libyan Journal of Medicine</i> , 2008, 4, 143-145.	1.6	2
588	Imaging of post-surgical complications in urinary pathologies. <i>Emergency Care Journal</i> , 2009, 5, 23.	0.3	0
589	Conservative Treatment of Invasive Bladder Cancer. <i>Current Oncology</i> , 2009, 16, 36-47.	2.2	20
590	The role of liver transplantation techniques in the surgical management of advanced renal urothelial carcinoma with or without inferior vena cava thrombus. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2009, 35, 19-23.	1.5	13
591	Bladder and Urethra. , 2009, , 1079-1120.		10
593	The Application of Endoscopic Techniques in the Management of Upper Tract Recurrence After Cystectomy and Urinary Diversion. <i>Journal of Endourology</i> , 2009, 23, 1265-1272.	2.1	6

#	ARTICLE	IF	CITATIONS
594	Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv79-iv80.	1.2	29
595	Neurofuzzy Modeling to Determine Recurrence Risk Following Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of the Bladder. <i>Clinical Cancer Research</i> , 2009, 15, 3150-3155.	7.0	24
596	Robotic Anterior Pelvic Exenteration for Bladder Cancer in the Female: Outcomes and Comparisons to Their Male Counterparts. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2009, 19, 23-27.	1.0	19
597	Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 821-830.	2.4	19
598	Prospective Study of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4314-4320.	1.6	219
599	UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. <i>British Journal of Cancer</i> , 2009, 101, 98-105.	6.4	102
600	The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder. <i>Libyan Journal of Medicine</i> , 2009, 4, 143-5.	1.6	5
601	Bladder Preservation Therapy Conducted by Intra-arterial Chemotherapy and Radiotherapy for Muscle Invasive Bladder Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 381-386.	1.3	24
602	Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 114-119.	6.3	144
603	Provider Treatment Intensity and Outcomes for Patients With Early-Stage Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 571-580.	6.3	81
604	The Risk Factor for Urethral Recurrence after Radical Cystectomy in Patients with Transitional Cell Carcinoma of the Bladder. <i>Urologia Internationalis</i> , 2009, 82, 306-311.	1.3	47
605	Transrectal Ultrasound as Diagnostic Tool for the Detection of Local Recurrence following Cystectomy and Urinary Diversion. <i>Urologia Internationalis</i> , 2009, 82, 12-16.	1.3	3
606	Organ-sparing strategies in the management of invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1765-1775.	2.4	8
607	Clinical states model for biomarkers in bladder cancer. <i>Future Oncology</i> , 2009, 5, 977-992.	2.4	10
608	Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1783-1792.	2.4	7
609	Indications, Extent, and Benefits of Pelvic Lymph Node Dissection for Patients with Bladder and Prostate Cancer. <i>Oncologist</i> , 2009, 14, 40-51.	3.7	35
610	Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009, 43, 357-364.	1.4	16
611	Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06. <i>Journal of Clinical Oncology</i> , 2009, 27, 4055-4061.	1.6	205

#	ARTICLE	IF	CITATIONS
613	Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study. <i>Clinical Cancer Research</i> , 2009, 15, 7012-7019.	7.0	69
614	How close are we to establishing standards of lymphadenectomy for invasive bladder cancer?. <i>Therapeutic Advances in Urology</i> , 2009, 1, 167-174.	2.0	3
615	Review: Use of nomograms for predictions of outcome in patients with advanced bladder cancer. <i>Therapeutic Advances in Urology</i> , 2009, 1, 13-26.	2.0	31
616	Critical review of biomarkers for the early detection and surveillance of bladder cancer. <i>Journal of Men's Health</i> , 2009, 6, 368-382.	0.3	4
617	La integración de la cirugía y el tratamiento quimioterápico en el cáncer de vejiga infiltrante. <i>Actas Urológicas Españolas</i> , 2009, 33, 1062-1068.	0.7	3
618	Recoverability of Erectile Function in Post-Radical Cystectomy Patients: Subjective and Objective Evaluations. <i>European Urology</i> , 2009, 55, 275-283.	1.9	59
619	Editorial Comment on: Recoverability of Erectile Function in Post-Radical Cystectomy Patients: Subjective and Objective Evaluations. <i>European Urology</i> , 2009, 55, 283.	1.9	0
620	External Beam Radiation Therapy Followed by Interstitial Radiotherapy with Iridium-192 for Solitary Bladder Tumours: Results of 111 Treated Patients. <i>European Urology</i> , 2009, 56, 113-122.	1.9	20
621	Editorial Comment on: External Beam Radiation Therapy Followed by Interstitial Radiotherapy with Iridium-192 for Solitary Bladder Tumours: Results of 111 Treated Patients. <i>European Urology</i> , 2009, 56, 121.	1.9	0
622	Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2009, 55, 348-358.	1.9	79
623	Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.9	117
624	Combined Ultrasmall Superparamagnetic Particles of Iron Oxide-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging Reliably Detect Pelvic Lymph Node Metastases in Normal-Sized Nodes of Bladder and Prostate Cancer Patients. <i>European Urology</i> , 2009, 55, 761-769.	1.9	217
625	The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2009, 55, 815-825.	1.9	316
626	The Impact of Lymphadenectomy and Lymph Node Metastasis on the Outcomes of Radical Cystectomy for Bladder Cancer. <i>European Urology</i> , 2009, 55, 826-835.	1.9	168
627	Complications Following Radical Cystectomy for Bladder Cancer in the Elderly. <i>European Urology</i> , 2009, 56, 443-454.	1.9	242
628	Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. <i>European Urology</i> , 2009, 56, 430-442.	1.9	584
629	EBAG9 is a tumor-promoting and prognostic factor for bladder cancer. <i>International Journal of Cancer</i> , 2009, 124, 799-805.	5.1	6
630	Lack of pathologic downstaging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. <i>Cancer</i> , 2009, 115, 792-799.	4.1	85

#	ARTICLE	IF	CITATIONS
631	Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes. <i>Cancer</i> , 2009, 115, 770-775.	4.1	27
633	Understanding bladder cancer death. <i>Cancer</i> , 2009, 115, 1011-1020.	4.1	37
634	Carbonic anhydrase IX in bladder cancer. <i>Cancer</i> , 2009, 115, 1448-1458.	4.1	86
635	Perioperative chemotherapy for urothelial cancer. <i>Cancer</i> , 2009, 115, 5139-5142.	4.1	0
636	Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. <i>Cancer</i> , 2009, 115, 5193-5201.	4.1	13
637	Cost-effectiveness analysis of immediate radical cystectomy versus intravesical <i>Bacillus Calmette-Guérin</i> therapy for high-risk, high-grade (T1G3) bladder cancer. <i>Cancer</i> , 2009, 115, 5450-5459.	4.1	56
638	Racial differences in treatment and outcomes among patients with early stage bladder cancer. <i>Cancer</i> , 2010, 116, 50-56.	4.1	52
639	Lymph node assessment and lymphadenectomy in bladder cancer. <i>Journal of Surgical Oncology</i> , 2009, 99, 225-231.	1.7	20
640	Supraphysiological Thermal Injury in Different Human Bladder Carcinoma Cell Lines. <i>Annals of Biomedical Engineering</i> , 2009, 37, 2407-2415.	2.5	7
641	Strategies for molecular expression profiling in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009, 28, 317-326.	5.9	36
642	Pathways of metastasis suppression in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009, 28, 327-333.	5.9	22
643	Quantitative risk stratification and individual comprehensive therapy for invasive bladder cancers in China. <i>International Urology and Nephrology</i> , 2009, 41, 571-577.	1.4	3
644	Laparoscopic Radical Cystectomy: Current Status, Outcomes, and Patient Selection. <i>Current Treatment Options in Oncology</i> , 2009, 10, 243-255.	3.0	24
645	The Role and Extent of Pelvic Lymphadenectomy in the Management of Patients with Invasive Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2009, 10, 267-274.	3.0	10
646	Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2009, 10, 205-215.	3.0	32
647	Radiation therapy in urinary cancer: state of the art and perspective. <i>Radiologia Medica</i> , 2009, 114, 70-82.	7.7	5
648	Pelvic lymph node dissection and outcome of robot-assisted radical cystectomy for bladder carcinoma. <i>Journal of Robotic Surgery</i> , 2009, 3, 7-12.	1.8	11
649	Robotic salvage cystectomy in the nonagenarian. <i>Journal of Robotic Surgery</i> , 2009, 3, 191-194.	1.8	0

#	ARTICLE	IF	CITATIONS
654	Does reflux in orthotopic diversion matter? A randomized prospective comparison of the Studer and T-pouch ileal neobladders. World Journal of Urology, 2009, 27, 51-55.	2.2	21
655	Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World Journal of Urology, 2009, 27, 39-44.	2.2	11
656	Outcomes of patients with clinical CIS-only disease treated with radical cystectomy. World Journal of Urology, 2009, 27, 21-25.	2.2	11
657	The impact of positive soft tissue surgical margins following radical cystectomy for high-grade, invasive bladder cancer. World Journal of Urology, 2009, 27, 33-38.	2.2	54
658	The role of lymph node density in bladder cancer prognostication. World Journal of Urology, 2009, 27, 27-32.	2.2	18
659	Oncological risk of laparoscopic surgery in urothelial carcinomas. World Journal of Urology, 2009, 27, 81-88.	2.2	72
660	Combination of BCG and interferon intravesical immunotherapy: an update. World Journal of Urology, 2009, 27, 343-346.	2.2	18
661	Chromosomal and proteome analysis of a new T24â€based cell line model for aggressive bladder cancer. Proteomics, 2009, 9, 287-298.	2.2	26
662	Human leukocyte antigen class I downâ€regulation in muscleâ€invasive bladder cancer: Its association with clinical characteristics and survival after cystectomy. Cancer Science, 2009, 100, 2331-2334.	3.9	23
663	Staging and reporting of urothelial carcinoma of the urinary bladder. Modern Pathology, 2009, 22, S70-S95.	5.5	166
664	Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: A multiâ€institutional study. International Journal of Urology, 2009, 16, 274-278.	1.0	30
666	Local recurrence of bladder cancer occurring eight years after radical cystectomy. International Journal of Urology, 2009, 16, 532-532.	1.0	1
667	Risk factors for mortality and morbidity related to radical cystectomy. BJU International, 2009, 103, 191-196.	2.5	133
668	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymphâ€node density. BJU International, 2009, 103, 302-306.	2.5	93
669	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. BJU International, 2009, 103, 1058-1063.	2.5	29
670	Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU International, 2009, 103, 1359-1362.	2.5	67
671	Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction lowâ€dose chemoâ€radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a singleâ€institutional retrospective comparative study. BJU International, 2009, 104, 189-194.	2.5	40
672	The results of concurrent chemoâ€radiotherapy for recurrence after treatment with bacillus Calmetteâ€GuÃ©rin for nonâ€muscleâ€invasive bladder cancer: is immediate cystectomy always necessary?. BJU International, 2009, 104, 179-183.	2.5	21

#	ARTICLE	IF	CITATIONS
673	Impact of body mass index on clinical and cost outcomes after radical cystectomy. BJU International, 2009, 104, 326-330.	2.5	19
674	Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density. BJU International, 2009, 104, 331-335.	2.5	67
675	A contemporary standard for morbidity and outcome after radical cystectomy. BJU International, 2009, 104, 628-632.	2.5	25
676	Prostate-sparing cystectomy: long-term oncological results. BJU International, 2009, 104, 1239-1243.	2.5	19
677	Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. BJU International, 2009, 104, 1227-1232.	2.5	64
678	Robot-assisted radical cystectomy: intermediate survival results at a mean follow-up of 25 months. BJU International, 2010, 105, 1706-1709.	2.5	45
679	Radical retropubic cystectomy. BJU International, 2009, 104, 1800-1821.	2.5	3
680	Neoadjuvant systemic therapy for urological malignancies. BJU International, 2010, 106, 6-22.	2.5	22
681	Radiochemotherapy for Bladder Cancer. Clinical Oncology, 2009, 21, 557-565.	1.4	40
682	Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial. International Journal of Radiation Oncology Biology Physics, 2009, 74, 511-517.	0.8	65
683	Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 442-448.	0.8	27
684	Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients. European Journal of Cancer, 2009, 45, 3291-3297.	2.8	151
685	Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. European Journal of Surgical Oncology, 2009, 35, 352-355.	1.0	30
686	Superficial Bladder Cancer Metastatic to the Lungs: Two Case Reports and Review of the Literature. Urology, 2009, 73, 210.e3-210.e5.	1.0	21
687	Effect of Postcystectomy Infectious Complications on Cost, Length of Stay, and Mortality. Urology, 2009, 73, 598-602.	1.0	27
688	A Thorough Pelvic Lymph Node Dissection in Presence of Positive Margins Associated With Better Clinical Outcomes in Radical Cystectomy Patients. Urology, 2009, 74, 161-165.	1.0	11
689	Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer. Urology, 2009, 74, 385-390.	1.0	22
690	Cardiac History and Risk of Post-cystectomy Cardiac Complications. Urology, 2009, 74, 1085-1089.	1.0	13

#	ARTICLE	IF	CITATIONS
691	Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 155-159.	1.6	85
692	Adjuvant chemotherapy in lymph node positive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 160-164.	1.6	17
693	Prostate-sparing cystectomy: A review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 466-472.	1.6	33
694	Preoperative hydronephrosis as an indicator of survival after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 491-495.	1.6	28
695	Bladder cancer in the elderly. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 653-667.	1.6	174
696	Harnblasenkarzinom. , 2009, , 395-476.		1
697	Extended Lymph Node Dissection. , 2009, , 134-145.		0
699	Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin. Journal of Urology, 2009, 182, 1313-1317.	0.4	109
701	Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?. Expert Review of Anticancer Therapy, 2009, 9, 747-752.	2.4	1
702	Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study. Radiotherapy and Oncology, 2009, 93, 352-357.	0.6	46
703	Cistoprostatectom�a radical con preservaci�n neurovascular para el tratamiento del c�ncer vesical. Relaci�n con la disfunci�n er�ctil: revisi�n de la literatura cient�fica. Revista Internacional De Androlog�a, 2009, 7, 121-130.	0.3	0
704	Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors. Journal of the Formosan Medical Association, 2009, 108, 872-878.	1.7	11
705	Bladder cancer. Lancet, The, 2009, 374, 239-249.	13.7	959
706	Comparison of American Joint Committee on Cancer Pathological Stage T2a Versus T2b Urothelial Carcinoma: Analysis of Patient Outcomes in Organ Confined Bladder Cancer. Journal of Urology, 2009, 181, 540-546.	0.4	20
707	Opposing Views. Journal of Urology, 2009, 181, 1994-1997.	0.4	14
708	Oncological Followup After Radical Cystectomy for Bladder Cancer��Is There Any Benefit?. Journal of Urology, 2009, 181, 1587-1593.	0.4	103
709	Is the Complication Rate of Radical Cystectomy Predictive of the Complication Rate of Other Urological Procedures?. Journal of Urology, 2009, 181, 1054-1060.	0.4	2
711	Estimating Postoperative Mortality and Morbidity Risk of Radical Cystectomy With Continent Diversion Using Predictor Equations. Journal of Urology, 2009, 182, 2619-2624.	0.4	14

#	ARTICLE	IF	CITATIONS
712	Radical Cystectomy for Bladder Cancer: Morbidity of Laparoscopic Versus Open Surgery. Journal of Urology, 2009, 181, 554-559.	0.4	84
714	Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. Journal of Urology, 2009, 182, 78-84.	0.4	93
715	p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. Journal of Urology, 2009, 182, 907-913.	0.4	54
716	A Population Based Assessment of Perioperative Mortality After Cystectomy for Bladder Cancer. Journal of Urology, 2009, 182, 70-77.	0.4	131
717	Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer. Journal of Urology, 2009, 182, 459-465.	0.4	15
718	Trends in Pelvic Lymphadenectomy at the Time of Radical Cystectomy: 1988 to 2004. Journal of Urology, 2009, 181, 2490-2495.	0.4	40
719	Clinical Outcomes and Recurrence Predictors of Lymph Node Positive Urothelial Cancer After Cystectomy. Journal of Urology, 2009, 182, 2182-2187.	0.4	70
720	Longer Wait Times Increase Overall Mortality in Patients With Bladder Cancer. Journal of Urology, 2009, 182, 1318-1324.	0.4	101
721	Associations Between Comorbidity, and Overall Survival and Bladder Cancer Specific Survival After Radical Cystectomy: Results From the Alberta Urology Institute Radical Cystectomy Database. Journal of Urology, 2009, 182, 85-93.	0.4	53
722	MULTI-INSTITUTIONAL VALIDATION OF THE PREDICTIVE VALUE OF KI-67 LABELING INDEX IN PATIENTS WITH URINARY BLADDER CANCER. Journal of Urology, 2009, 181, 69-69.	0.4	30
723	AUA Best Practice Statement for the Prevention of Deep Vein Thrombosis in Patients Undergoing Urologic Surgery. Journal of Urology, 2009, 181, 1170-1177.	0.4	126
724	Total Cystectomy Versus Bladder Preservation Therapy for Locally Invasive Bladder Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 592-606.	1.3	18
725	The oncologic results of laparoscopic radical cystectomy are not (yet) equivalent to open cystectomy. Current Opinion in Urology, 2009, 19, 522-526.	1.8	45
726	Current Trends in the Management of Bladder Cancer. Journal of Wound, Ostomy and Continence Nursing, 2009, 36, 413-421.	1.0	6
727	Does extended lymphadenectomy preclude laparoscopic or robot-assisted radical cystectomy in advanced bladder cancer?. Current Opinion in Urology, 2009, 19, 527-532.	1.8	20
728	Utility of Diagnostic and Prognostic Markers in Urothelial Carcinoma of the Bladder. Advances in Anatomic Pathology, 2009, 16, 67-78.	4.3	21
729	Intra-Arterial Chemotherapy with Gemcitabine and Cisplatin for Patients with Recurrence of Transitional Cell Carcinoma Confined to the Pelvis. Journal of Chemotherapy, 2009, 21, 91-97.	1.5	4
731	Early vs Delayed Radical Cystectomy Compared in Highgrade Superficial Bladder Tumors. Urologia, 2009, 76, 83-86.	0.7	1

#	ARTICLE	IF	CITATIONS
732	Integrating Perioperative Chemotherapy into the Treatment of Muscle-Invasive Bladder Cancer: Strategy Versus Reality. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 40-47.	4.9	30
733	Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer. <i>European Journal of Medical Research</i> , 2009, 14, 487.	2.2	27
734	Bladder cancer. <i>Current Opinion in Oncology</i> , 2009, 21, 272-277.	2.4	48
735	Radiotherapy in localized bladder cancer: what is the evidence?. <i>Current Opinion in Urology</i> , 2010, 20, 426-431.	1.8	3
736	Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. <i>Anti-Cancer Drugs</i> , 2010, 21, 101-106.	1.4	19
737	Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. <i>Current Opinion in Urology</i> , 2010, 20, 437-442.	1.8	28
738	Extended lymphadenectomy in bladder cancer. <i>Current Opinion in Urology</i> , 2010, 20, 414-420.	1.8	14
739	Novel bladder preservation therapy for locally invasive bladder cancer: Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. <i>International Journal of Oncology</i> , 2010, 37, 773-85.	3.3	19
740	Theranostic and prognostic biomarkers: genomic applications in urological malignancies. <i>Pathology</i> , 2010, 42, 384-394.	0.6	45
741	The effect of age on bladder cancer incidence, prognosis and therapy. <i>Aging Health</i> , 2010, 6, 649-659.	0.3	7
742	Association of Intravesical Tumor Location With Metastases to the Pelvic Lymph Nodes in Transitional Cell Cancer of the Bladder. <i>American Journal of the Medical Sciences</i> , 2010, 339, 341-344.	1.1	12
744	High Dickkopf-1 expression is associated with poor prognosis in patients with advanced urothelial carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 893-898.	1.8	12
745	Managing muscle-invasive bladder cancer in the elderly. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 903-915.	2.4	9
748	Bladder Cancer: Current Management and Opportunities for a Personalized Approach. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 587-596.	1.9	8
749	Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 465-72.	4.2	52
752	Treatment and outcome in muscle invasive bladder cancer: a population-based survey. <i>World Journal of Urology</i> , 2010, 28, 439-444.	2.2	15
753	A 10-Year Retrospective Review of a Nonrandomized Cohort of 458 Patients Undergoing Radical Radiotherapy or Cystectomy in Yorkshire, UK. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 119-124.	0.8	68
754	CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma. <i>Clinical and Experimental Medicine</i> , 2010, 10, 153-158.	3.6	17

#	ARTICLE	IF	CITATIONS
755	Facteurs pronostiques biologiques des cancers de la vessie. Interactions avec la radiothérapie. <i>Oncologie</i> , 2010, 12, 389-395.	0.7	0
757	The role of adjuvant chemotherapy in patients with locally advanced (pT3, pT4a) and/or lymph node-positive bladder cancer. <i>International Urology and Nephrology</i> , 2010, 42, 959-964.	1.4	2
758	Bladder Cancer in 2010: How Far have We Come?. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 244-272.	329.8	291
759	FDG-PET/CT for the Preoperative Lymph Node Staging of Invasive Bladder Cancer. <i>European Urology</i> , 2010, 57, 641-647.	1.9	149
760	A Comparison of Postoperative Complications in Open versus Robotic Cystectomy. <i>European Urology</i> , 2010, 57, 274-282.	1.9	258
761	Editorial Comment on: A Comparison of Postoperative Complications in Open versus Robotic Cystectomy. <i>European Urology</i> , 2010, 57, 281-282.	1.9	2
762	Optimizing the Approach for Lymph Node Dissection during Laparoscopic Radical Cystectomy. <i>European Urology</i> , 2010, 57, 71-78.	1.9	12
763	An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously) T1a Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 1691-1697.	1.9	169
764	A New Multimodality Technique Accurately Maps the Primary Lymphatic Landing Sites of the Bladder. <i>European Urology</i> , 2010, 57, 205-211.	1.9	150
765	Differential Complication Rates Following Radical Cystectomy in the Irradiated and Nonirradiated Pelvis. <i>European Urology</i> , 2010, 57, 1058-1063.	1.9	50
766	Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. <i>European Urology</i> , 2010, 58, 112-117.	1.9	51
767	The Learning Curve of Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , 2010, 58, 197-202.	1.9	213
768	A Critical Analysis of Orthotopic Bladder Substitutes in Adult Patients with Bladder Cancer: Is There a Perfect Solution?. <i>European Urology</i> , 2010, 58, 374-383.	1.9	52
769	Do Patients Benefit from Routine Follow-up to Detect Recurrences After Radical Cystectomy and Ileal Orthotopic Bladder Substitution?. <i>European Urology</i> , 2010, 58, 486-494.	1.9	106
770	Laparoscopic Radical Cystectomy with Orthotopic Ileal Neobladder for Bladder Cancer: Oncologic Results of 171 Cases With a Median 3-Year Follow-up. <i>European Urology</i> , 2010, 58, 442-449.	1.9	80
771	Fast Track Program in Patients Undergoing Radical Cystectomy: Results in 362 Consecutive Patients. <i>Journal of the American College of Surgeons</i> , 2010, 210, 93-99.	0.5	154
773	Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. <i>Cancer</i> , 2010, 116, 340-346.	4.1	49
774	Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer. <i>Cancer</i> , 2010, 116, 1893-1900.	4.1	144

#	ARTICLE	IF	CITATIONS
775	Patterns of care for early stage bladder cancer. <i>Cancer</i> , 2010, 116, 2604-2611.	4.1	27
776	Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer. <i>Cancer</i> , 2010, 116, 1901-1908.	4.1	63
777	Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. <i>Cancer</i> , 2010, 116, 3399-3407.	4.1	44
778	Understanding the variation in treatment intensity among patients with early stage bladder cancer. <i>Cancer</i> , 2010, 116, 3587-3594.	4.1	38
779	Examining the association between delay in diagnosis and decreased survival in bladder cancer. <i>Cancer</i> , 2010, 116, 5122-5125.	4.1	5
780	Delays in diagnosis and bladder cancer mortality. <i>Cancer</i> , 2010, 116, 5235-5242.	4.1	137
781	A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. <i>Cancer</i> , 2010, 116, 4513-4519.	4.1	35
782	Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. <i>Cancer</i> , 2010, 116, 5517-5526.	4.1	66
783	Risk factors for recurrence following radical cystectomy for pathologic node negative bladder cancer. <i>Journal of Surgical Oncology</i> , 2010, 102, 334-337.	1.7	13
784	Secretome proteomics for discovery of cancer biomarkers. <i>Journal of Proteomics</i> , 2010, 73, 2291-2305.	2.4	225
785	Prognostic value of radical cystoprostatectomy in men with bladder cancer infiltrating prostate versus co-existing prostate cancer: a research study. <i>BMC Urology</i> , 2010, 10, 16.	1.4	3
786	Robotic-assisted laparoscopic radical cystoprostatectomy and extracorporeal continent urinary diversion: highlight of surgical techniques and outcomes. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2010, 6, 315-323.	2.3	22
787	Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. <i>Cancer Science</i> , 2010, 101, 231-240.	3.9	44
788	Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. <i>BJU International</i> , 2010, 105, 468-471.	2.5	39
789	p53 expression in patients with advanced urothelial cancer of the urinary bladder. <i>BJU International</i> , 2010, 105, 489-495.	2.5	69
790	Critical analysis of complications after robotic-assisted radical cystectomy with identification of preoperative and operative risk factors. <i>BJU International</i> , 2010, 105, 520-527.	2.5	97
791	The effect of age and gender on bladder cancer: a critical review of the literature. <i>BJU International</i> , 2010, 105, 300-308.	2.5	281
792	A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. <i>BJU International</i> , 2010, 106, 349-354.	2.5	95

#	ARTICLE	IF	CITATIONS
793	Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU International, 2010, 106, 493-499.	2.5	61
794	Factors influencing the choice of urinary diversion in patients undergoing radical cystectomy. BJU International, 2010, 106, 654-657.	2.5	31
796	Evaluation of fluorodeoxyglucose positron emission tomography with computed tomography for staging of urothelial carcinoma. BJU International, 2010, 106, 658-663.	2.5	111
797	Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. BJU International, 2010, 106, 162-167.	2.5	17
798	New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification. BJU International, 2010, 106, 168-179.	2.5	8
799	Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU International, 2010, 106, 1805-1811.	2.5	17
800	Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-directed Intergroup Study (S8710). BJU International, 2011, 108, 693-699.	2.5	63
801	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU International, 2011, 108, 687-692.	2.5	28
802	Laparoscopic versus open radical cystectomy for the management of bladder cancer: Mid-term oncological outcome. International Journal of Urology, 2010, 17, 55-61.	1.0	30
803	Evidence-based clinical practice guidelines for bladder cancer (Summary "JUA 2009 Edition). International Journal of Urology, 2010, 17, 102-124.	1.0	21
804	Management of renal and bladder cancer in older adults. , 0, , 171-185.		0
805	Emerging intravesical therapies for management of nonmuscle invasive bladder cancer. Research and Reports in Urology, 2010, Volume 2, 67-84.	1.0	4
806	Efficacy of Bladder-Preserving Therapy for Patients with T3b, T4a, and T4b Transitional Cell Carcinoma of the Bladder. Korean Journal of Urology, 2010, 51, 525.	1.2	5
809	Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2010, 36, 537-547.	1.5	46
810	The value of clinical prognostic factors for survival in patients with invasive urinary bladder cancer. Medicina (Lithuania), 2010, 46, 305.	2.0	6
811	High-Grade Hydronephrosis Predicts Poor Outcomes After Radical Cystectomy in Patients with Bladder Cancer. Journal of Korean Medical Science, 2010, 25, 369.	2.5	21
812	Pattern of Failure in Bladder Cancer Patients Treated with Radical Cystectomy: Rationale for Adjuvant Radiotherapy. Journal of Korean Medical Science, 2010, 25, 835.	2.5	4
813	Initial Experiences with Robot-Assisted Laparoscopic Radical Cystectomy. Korean Journal of Urology, 2010, 51, 178.	1.2	7

#	ARTICLE	IF	CITATIONS
814	Role of Pelvic Lymphadenectomy in the Treatment of Bladder Cancer: A Mini Review. Korean Journal of Urology, 2010, 51, 371.	1.2	11
815	The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder. Clinical Cancer Research, 2010, 16, 4461-4467.	7.0	133
816	Bladder cancer. Current Opinion in Oncology, 2010, 22, 242-249.	2.4	32
817	Role of Patient-Physician Dialogue in Selecting the Type of Urinary Diversion. Urologia Internationalis, 2010, 84, 40-44.	1.3	3
818	Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract. Urologia Internationalis, 2010, 85, 47-51.	1.3	8
819	Perioperative and 5-Year Oncological Outcomes Following Open Radical Cystectomy for 200 Patients: A Single Center Experience. UroToday International Journal, 2010, 03, .	0.1	0
820	Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2010, 28, 1373-1379.	1.6	170
821	Combined-Modality Treatment for High Risk TCC of the Bladder. International Conference on Bioinformatics and Biomedical Engineering: [proceedings] International Conference on Bioinformatics and Biomedical Engineering, 2010, , .	0.0	0
822	Robot-Assisted Radical Cystectomy and Pelvic Lymph Node Dissection: A Multi-Institutional Study from Korea. Journal of Endourology, 2010, 24, 1435-1440.	2.1	29
823	Molecular screening for bladder cancer: progress and potential. Nature Reviews Urology, 2010, 7, 11-20.	3.8	70
824	Role of Pelvic Lymph Node Dissection in Lymph Node-Negative Patients with Invasive Bladder Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 247-251.	1.3	17
825	Adjuvant and neoadjuvant radiotherapy for bladder cancer: revisited. Future Oncology, 2010, 6, 1177-1191.	2.4	30
826	Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1917-1932.	2.4	16
827	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. Expert Review of Anticancer Therapy, 2010, 10, 1891-1902.	2.4	8
828	The Role of Lymphadenectomy in Minimally Invasive Urologic Oncology. Journal of Endourology, 2010, 24, 1229-1240.	2.1	3
829	Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology, 2010, 42, 356-359.	0.6	38
830	Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opinion on Investigational Drugs, 2010, 19, 875-887.	4.1	22
831	Clinical Features of Sarcomatoid Carcinoma (Carcinosarcoma) of the Urinary Bladder: Analysis of 221 Cases. Sarcoma, 2010, 2010, 1-7.	1.3	86

#	ARTICLE	IF	CITATIONS
832	Functional outcome of orthotopic bladder substitution: A comparison between the S-shaped and U-shaped neobladder. Scandinavian Journal of Urology and Nephrology, 2010, 44, 197-203.	1.4	4
833	Cathepsin L is Associated with Proliferation and Clinical Outcome of Urothelial Carcinoma of the Bladder. Journal of International Medical Research, 2010, 38, 1913-1922.	1.0	13
834	Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. Journal of Clinical Oncology, 2010, 28, 543-548.	1.6	142
835	Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer. Journal of Clinical Pathology, 2010, 63, 504-507.	2.0	21
836	Organ Preservation by the Association of Chemotherapy and Radiotherapy in Invasive Bladder Cancer. Current Drug Therapy, 2010, 5, 202-210.	0.3	0
837	Transitional research in bladder cancer: From molecular pathogenesis to useful tissue biomarkers. Cancer Biology and Therapy, 2010, 10, 407-415.	3.4	22
839	Surgical Margin Status After Robot Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium. Journal of Urology, 2010, 184, 87-91.	0.4	109
840	Early and Late Perioperative Outcomes Following Radical Cystectomy: 90-Day Readmissions, Morbidity and Mortality in a Contemporary Series. Journal of Urology, 2010, 184, 1296-1300.	0.4	226
841	How Do Commonly Performed Lymphadenectomy Templates Influence Bladder Cancer Nodal Stage?. Journal of Urology, 2010, 183, 499-504.	0.4	42
842	Characteristics and Outcomes of Patients With pT4 Urothelial Carcinoma at Radical Cystectomy: A Retrospective International Study of 583 Patients. Journal of Urology, 2010, 183, 87-93.	0.4	58
843	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. Journal of Urology, 2010, 183, 68-75.	0.4	146
844	Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients. Journal of Urology, 2010, 184, 888-894.	0.4	64
845	Oncological Outcomes After Radical Cystectomy for Bladder Cancer: Open Versus Minimally Invasive Approaches. Journal of Urology, 2010, 183, 862-870.	0.4	74
846	Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. Journal of Urology, 2010, 183, 2165-2170.	0.4	186
847	Developments in intravesical therapy for non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2010, 10, 1903-1916.	2.4	8
848	Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma. Actas Urológicas Españolas (English Edition), 2010, 34, 51-62.	0.2	5
850	Response and progression-free survival in T2 to T4 bladder tumors treated with trimodality therapy with bladder preservation. Actas Urológicas Españolas (English Edition), 2010, 34, 775-780.	0.2	2
851	pT3 Substaging is a Prognostic Indicator for Lymph Node Negative Urothelial Carcinoma of the Bladder. Journal of Urology, 2010, 184, 470-474.	0.4	29

#	ARTICLE	IF	CITATIONS
852	Cystectomy in Patients With Spinal Cord Injury: Indications and Long-Term Outcomes. Journal of Urology, 2010, 184, 92-98.	0.4	13
853	Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors. Nature Reviews Urology, 2010, 7, 84-93.	3.8	30
854	Predictors of Cancer-Specific Survival following Radical Cystectomy in Patients with Node-Positive Bladder Cancer. Current Urology, 2010, 4, 188-192.	0.6	2
855	Survival after cystectomy for invasive bladder cancer. European Journal of Surgical Oncology, 2010, 36, 292-297.	1.0	30
856	Aggregate Lymph Node Metastasis Diameter and Survival After Radical Cystectomy for Invasive Bladder Cancer. Urology, 2010, 75, 382-386.	1.0	32
857	Impact of Comorbidity on Survival of Invasive Bladder Cancer Patients, 1996-2007: A Danish Population-based Cohort Study. Urology, 2010, 75, 393-398.	1.0	31
859	Uterus-, Fallopian Tube-, Ovary-, and Vagina-sparing Cystectomy Followed by U-shaped Ileal Neobladder Construction for Female Bladder Cancer Patients: Oncological and Functional Outcomes. Urology, 2010, 75, 1499-1503.	1.0	65
860	Robot Assisted Laparoscopic Pelvic Lymphadenectomy at the Time of Radical Cystectomy Rivals That of Open Surgery: Single Institution Report. Urology, 2010, 76, 1400-1404.	1.0	60
861	Ureteroileal Anastomosis With Intraluminal Visualization: Technique and Outcomes. Urology, 2010, 76, 1496-1500.	1.0	5
862	Prostate-sparing Cystectomy for Bladder Cancer: A Step Toward a Dead-end. Urology, 2010, 76, 260-263.	1.0	8
863	Age and Body Mass Index Are Independent Risk Factors for the Development of Postoperative Paralytic Ileus After Radical Cystectomy. Urology, 2010, 76, 1419-1424.	1.0	88
864	Microscopic Invasion of Perivesical Fat by Urothelial Carcinoma: Implications for Prognosis and Pathology Practice. Urology, 2010, 76, 908-913.	1.0	19
865	Laparoendoscopic Single-site Radical Cystectomy and Pelvic Lymph Node Dissection: Initial Experience and 2-Year Follow-up. Urology, 2010, 76, 857-861.	1.0	50
866	Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial. Urology, 2010, 76, 923-926.	1.0	89
867	Editorial Comment. Urology, 2010, 76, 913-914.	1.0	1
868	Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 14-20.	1.6	53
869	Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 180-188.	1.6	34
870	The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 473-479.	1.6	100

#	ARTICLE	IF	CITATIONS
871	Role of biomarkers to predict outcomes and response to therapy. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 97-101.	1.6	7
872	Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 112-117.	1.6	36
873	T1 bladder cancer: Advocating early cystectomy to improve oncologic control. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 466-468.	1.6	6
874	Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicology Letters, 2010, 193, 131-137.	0.8	99
875	Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma. Journal of Clinical Oncology, 2010, 28, 4912-4918.	1.6	264
876	Indications and Oncologic Outcome of Radical Cystectomy for Urothelial Bladder Cancer. European Urology Supplements, 2010, 9, 10-18.	0.1	14
877	The Role of Lymphadenectomy in Radical Cystectomy. European Urology Supplements, 2010, 9, 19-24.	0.1	6
878	Current Value of Neoadjuvant Chemotherapy Prior to Cystectomy. European Urology Supplements, 2010, 9, 424-427.	0.1	3
879	Robotic Cystectomy Versus Open Cystectomy: Are We There Yet?. European Urology Supplements, 2010, 9, 433-437.	0.1	8
880	Ileal Conduit as the Standard for Urinary Diversion After Radical Cystectomy for Bladder Cancer. European Urology Supplements, 2010, 9, 736-744.	0.1	53
881	Continent Catheterizable Pouches for Urinary Diversion. European Urology Supplements, 2010, 9, 754-762.	0.1	26
883	Significance of Distal Ureteral Margin at Radical Cystectomy for Urothelial Carcinoma. Journal of Urology, 2010, 183, 81-86.	0.4	50
885	Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers. Journal of Urology, 2010, 183, 1744-1750.	0.4	91
887	Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria. Journal of Urology, 2010, 183, 929-934.	0.4	84
888	Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical Cystectomy: An International Study of 243 Patients. Journal of Urology, 2010, 183, 1757-1763.	0.4	69
889	Robot-Assisted Laparoscopic Cystoprostatectomy with Extended Pelvic Lymphadenectomy, Extracorporeal Enterocystoplasty, and Intracorporeal Enterourethral Anastomosis: Initial Montsouris Experience. Journal of Endourology, 2010, 24, 409-413.	2.1	26
890	Investigational therapies for non-muscle invasive bladder cancer. Expert Opinion on Investigational Drugs, 2010, 19, 371-383.	4.1	10
891	Cell Damage and Death by Autophagy in Human Bladder (RT4) Carcinoma Cells Resulting from Treatment with Ascorbate and Menadione. Ultrastructural Pathology, 2010, 34, 140-160.	0.9	46

#	ARTICLE	IF	CITATIONS
892	Imaging of Urothelial Cancers: What the Urologist Needs to Know. American Journal of Roentgenology, 2011, 196, 1249-1254.	2.2	19
893	Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nature Reviews Urology, 2011, 8, 631-642.	3.8	123
894	Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. Journal of Urology, 2011, 185, 456-461.	0.4	86
896	Lymphadenectomy for Bladder Cancer: Indications and Controversies. Urologic Clinics of North America, 2011, 38, 397-405.	1.8	19
897	Use of Yeast Chemigenomics and COXEN Informatics in Preclinical Evaluation of Anticancer Agents. Neoplasia, 2011, 13, 72-IN19.	5.3	27
898	Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared With Second Look Open Dissection. Journal of Urology, 2011, 185, 79-84.	0.4	55
899	Effect of Preoperative Nutritional Deficiency on Mortality After Radical Cystectomy for Bladder Cancer. Journal of Urology, 2011, 185, 90-96.	0.4	212
900	Lymphadenectomy in Urologic Oncology: Pathologic Considerations. Urologic Clinics of North America, 2011, 38, 483-495.	1.8	8
901	G3T1 Bladder Cancer: Is Early Re-Resection Necessary?. British Journal of Medical and Surgical Urology, 2011, 4, 13-17.	0.2	3
902	Management of the male urethra before and after cystectomy: From the prophylactic urethrectomy to the intraoperative frozen section biopsy of the urethral margin. Actas Urológicas Españolas (English) Tj ETQq1 1 0.7843142gBT /Over		
903	Immunohistology of the Prostate, Bladder, Kidney, and Testis. , 2011, , 593-661.		6
904	Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer, 2011, 11, 336.	2.6	69
905	The dilemma of cystectomy in old-old and oldest-old patients. Expert Review of Anticancer Therapy, 2011, 11, 1863-1870.	2.4	10
906	Prostate-sparing cystectomy: Potential functional advantages and objective oncological risks; a case series and review. Arab Journal of Urology Arab Association of Urology, 2011, 9, 107-112.	1.5	6
907	Molecular signatures that predict nodal metastasis in bladder cancer: does the primary tumor tell tales?. Expert Review of Anticancer Therapy, 2011, 11, 849-852.	2.4	5
908	Paeonia lactiflora Pall inhibits bladder cancer growth involving phosphorylation of Chk2 in vitro and in vivo. Journal of Ethnopharmacology, 2011, 135, 162-172.	4.1	42
909	Baseline Renal Function Status Limits Patient Eligibility to Receive Perioperative Chemotherapy for Invasive Bladder Cancer and Is Minimally Affected by Radical Cystectomy. Urology, 2011, 77, 160-165.	1.0	63
910	Robotic-assisted Radical Cystectomy and Orthotopic Ileal Neobladder Using a Modified Pfannenstiel Incision. Urology, 2011, 77, 491-493.	1.0	19

#	ARTICLE	IF	CITATIONS
911	Analysis of Early Complications of Robotic-assisted Radical Cystectomy Using a Standardized Reporting System. Urology, 2011, 77, 357-362.	1.0	91
912	Perioperative Mortality Is Significantly Greater in Septuagenarian and Octogenarian Patients Treated With Radical Cystectomy for Urothelial Carcinoma of the Bladder. Urology, 2011, 77, 660-666.	1.0	74
913	Oncological and Functional Outcomes of Radical Cystectomy and Orthotopic Bladder Replacement in Women. Urology, 2011, 77, 878-883.	1.0	18
914	Surgery-related Complications of Robot-assisted Radical Cystectomy With Intracorporeal Urinary Diversion. Urology, 2011, 77, 871-876.	1.0	68
915	Ethnic Differences in Bladder Cancer Survival. Urology, 2011, 78, 544-549.	1.0	94
916	Oncological and Functional Outcomes After Robot-assisted Radical Cystectomy: Critical Review of Current Status. Urology, 2011, 78, 977-984.	1.0	26
917	Second opinion pathology in tertiary care of patients with urologic malignancies. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 194-198.	1.6	28
918	Comparison of 2002 TNM nodal status with lymph node density in node-positive patients after radical cystectomy for bladder cancer: Analysis by the number of lymph nodes removed. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 199-204.	1.6	14
919	Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 309-313.	1.6	9
920	Postoperative nomogram for invasive bladder cancer: Does it really work? A multicenter cohort study. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 698-702.	1.6	5
921	A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncology, The, 2011, 12, 137-143.	10.7	138
922	Genetic susceptibility to bladder cancer risk and outcome. Personalized Medicine, 2011, 8, 365-374.	1.5	46
923	Outcomes of Single Lymph Node Positive Urothelial Carcinoma After Radical Cystectomy. Journal of Urology, 2011, 185, 2085-2090.	0.4	20
924	Comparison of ¹¹ C-Choline With ¹⁸ F-FDG in Positron Emission Tomography/Computerized Tomography for Staging Urothelial Carcinoma: A Prospective Study. Journal of Urology, 2011, 186, 436-441.	0.4	31
925	Hospital and Surgical Caseload are Predictors of Comprehensive Surgical Treatment for Bladder Cancer: A Population Based Study. Journal of Urology, 2011, 186, 824-828.	0.4	9
926	Presacral and Retroperitoneal Lymph Node Involvement in Urothelial Bladder Cancer: Results of a Prospective Mapping Study. Journal of Urology, 2011, 186, 1269-1273.	0.4	25
927	Detection of Asymptomatic Recurrence During Routine Oncological Followup After Radical Cystectomy is Associated With Improved Patient Survival. Journal of Urology, 2011, 186, 1796-1802.	0.4	46
928	Management of pT1G3 Bladder Cancer. European Urology Supplements, 2011, 10, e1-e4.	0.1	3

#	ARTICLE	IF	CITATIONS
930	Predictors of Outcome of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer. Scientific World Journal, The, 2011, 11, 369-381.	2.1	72
931	Evidence for PTEN-independent Akt activation and Akt-independent p27Kip1 expression in advanced bladder cancer. Oncology Letters, 2011, 2, 1089-1093.	1.8	8
932	Recognition and Treatment of BCG Failure in Bladder Cancer. Scientific World Journal, The, 2011, 11, 602-613.	2.1	24
933	Current therapeutic strategies for invasive and metastatic bladder cancer. OncoTargets and Therapy, 2011, 4, 97.	2.0	33
934	Lymphadenectomy in Management of Invasive Bladder Cancer. International Journal of Surgical Oncology, 2011, 2011, 1-9.	0.6	19
935	Update on Chemotherapy in the Treatment of Urothelial Carcinoma. Scientific World Journal, The, 2011, 11, 1981-1994.	2.1	22
936	Radical Cystectomy and Orthotopic Bladder Substitution Using Ileum. Korean Journal of Urology, 2011, 52, 233.	1.2	17
937	S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer. PLoS ONE, 2011, 6, e27509.	2.5	81
938	Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?. Current Opinion in Urology, 2011, 21, 434-439.	1.8	7
939	The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Current Opinion in Urology, 2011, 21, 428-433.	1.8	40
940	Urinary Bladder Masses. Journal of Computer Assisted Tomography, 2011, 35, 411-424.	0.9	23
941	Bladder cancer. Current Opinion in Oncology, 2011, 23, 275-282.	2.4	40
942	Recent advances in robot-assisted radical cystectomy. Current Opinion in Urology, 2011, 21, 65-70.	1.8	16
943	Latest advances in cone-beam CT for bladder radiotherapy. Imaging in Medicine, 2011, 3, 321-332.	0.0	3
944	Management of elderly patients with advanced infiltrating and metastatic bladder cancer: an oncogeriatric approach. Aging Health, 2011, 7, 491-502.	0.3	0
945	Improvements in clinical staging of muscle-invasive bladder cancer. Nature Reviews Urology, 2011, 8, 360-361.	3.8	1
946	Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Current Urology, 2011, 5, 57-61.	0.6	1
947	Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU International, 2011, 107, 58-62.	2.5	46

#	ARTICLE	IF	CITATIONS
948	Comparison of the new American Joint Committee on Cancer substratification in node-negative pT2 urothelial carcinoma of the bladder: analysis of patient outcomes in a contemporary series. BJU International, 2011, 107, 919-923.	2.5	15
949	Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU International, 2011, 107, 1668-1675.	2.5	89
950	Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU International, 2011, 107, 540-546.	2.5	37
951	Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy. BJU International, 2011, 107, 628-635.	2.5	52
952	Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study. BJU International, 2011, 107, 905-911.	2.5	36
953	Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU International, 2011, 107, 1069-1073.	2.5	28
954	Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU International, 2011, 107, 898-904.	2.5	184
955	Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU International, 2011, 107, 46-52.	2.5	41
956	Laparoscopic extended pelvic lymph node dissection during radical cystectomy: technique and clinical outcomes. BJU International, 2011, 108, 124-128.	2.5	15
957	Robotic extended pelvic lymphadenectomy for bladder cancer with increased nodal yield. BJU International, 2011, 107, 1802-1805.	2.5	39
958	Extranodal extension in node-positive bladder cancer: the continuing controversy. BJU International, 2011, 108, 38-43.	2.5	18
959	The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU International, 2011, 108, E84-90.	2.5	29
960	Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer?. BJU International, 2011, 108, 1292-1296.	2.5	10
961	Is patient outcome compromised during the initial experience with robot-assisted radical cystectomy? Results of 164 consecutive cases. BJU International, 2011, 108, 882-887.	2.5	60
962	Improved cancer specific survival in patients with carcinoma invading bladder muscle expressing cyclooxygenase-2. BJU International, 2011, 108, 531-537.	2.5	8
963	Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU International, 2011, 108, 539-545.	2.5	156
964	Mid-term oncological control after laparoscopic radical cystectomy in men: a single-centre experience. BJU International, 2011, 108, 1180-1184.	2.5	16
965	IMPROVED CANCER SPECIFIC SURVIVAL IN PATIENTS WITH CARCINOMA INVADING BLADDER MUSCLE EXPRESSING CYCLOOXYGENASE-2. BJU International, 2011, 108, 537-538.	2.5	0

#	ARTICLE	IF	CITATIONS
966	Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder. <i>BJU International</i> , 2011, 108, E278-E283.	2.5	16
967	Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNRC score. <i>BJU International</i> , 2011, 108, 1800-1805.	2.5	83
968	Prognostic implications of lymph node involvement in bladder cancer: are we understaging using current methods?. <i>BJU International</i> , 2011, 108, 484-492.	2.5	16
969	Peri- and postoperative outcomes of robot-assisted radical cystectomy (RARC). <i>BJU International</i> , 2011, 108, 969-975.	2.5	20
970	Robotic cystectomy: surgical technique. <i>BJU International</i> , 2011, 108, 962-968.	2.5	31
971	Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens. <i>International Journal of Urology</i> , 2011, 18, 350-357.	1.0	11
972	Older patients suffer from adverse histopathological features after radical cystectomy. <i>International Journal of Urology</i> , 2011, 18, 576-584.	1.0	15
973	Immunohistochemical biomarkers for bladder cancer prognosis. <i>International Journal of Urology</i> , 2011, 18, 616-629.	1.0	51
974	Extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer. <i>Histopathology</i> , 2011, 58, 571-578.	2.9	20
975	Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. <i>British Journal of Cancer</i> , 2011, 104, 75-82.	6.4	157
976	Defining Morbidity of Robot-Assisted Radical Cystectomy Using a Standardized Reporting Methodology. <i>European Urology</i> , 2011, 59, 213-218.	1.9	80
977	Long-term Follow-up of Bladder Cancer Patients with Disseminated Tumour Cells in Bone Marrow. <i>European Urology</i> , 2011, 60, 231-238.	1.9	13
978	Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. <i>European Urology</i> , 2011, 59, 1009-1018.	1.9	570
979	The Role of Laparoscopic and Robotic Cystectomy in the Management of Muscle-Invasive Bladder Cancer With Special Emphasis on Cancer Control and Complications. <i>European Urology</i> , 2011, 60, 767-775.	1.9	145
980	Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours. <i>European Urology</i> , 2011, 60, 350-357.	1.9	138
981	Does the Extent of Lymphadenectomy in Radical Cystectomy for Bladder Cancer Influence Disease-Free Survival? A Prospective Single-Center Study. <i>European Urology</i> , 2011, 60, 572-577.	1.9	104
982	Lymph Node Dissection Technique Is More Important Than Lymph Node Count in Identifying Nodal Metastases in Radical Cystectomy Patients: A Comparative Mapping Study. <i>European Urology</i> , 2011, 60, 946-952.	1.9	121
983	Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion in Patients with Transitional Cell Carcinoma of the Bladder. <i>European Urology</i> , 2011, 60, 1066-1073.	1.9	183

#	ARTICLE	IF	CITATIONS
984	VEGF-C as a Decision-making Biomarker for Selected Patients with Invasive Bladder Cancer Who Underwent Bladder-preserving Radical Surgery. Archives of Medical Research, 2011, 42, 405-411.	3.3	9
985	Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. European Radiology, 2011, 21, 2178-2186.	4.5	157
986	Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Annals of Surgical Oncology, 2011, 18, 2018-2025.	1.5	112
987	Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study. Annals of Surgical Oncology, 2011, 18, 3833-3838.	1.5	11
988	The History and Anatomy of Urologic Lymphadenectomy. Urologic Clinics of North America, 2011, 38, 375-386.	1.8	4
990	Prediction of prognosis after radical cystectomy for pathologic node-negative bladder cancer. International Urology and Nephrology, 2011, 43, 1059-1065.	1.4	4
991	T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy. International Urology and Nephrology, 2011, 43, 1047-1057.	1.4	31
992	Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1151-1173.	2.5	160
993	The role of lymph node dissection in the management of urothelial carcinoma of the upper urinary tract. International Journal of Clinical Oncology, 2011, 16, 170-178.	2.2	24
994	Role of lymph node dissection in management of bladder cancer. International Journal of Clinical Oncology, 2011, 16, 179-185.	2.2	16
995	Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World Journal of Urology, 2011, 29, 415-422.	2.2	19
996	Impact of gender on bladder cancer incidence, staging, and prognosis. World Journal of Urology, 2011, 29, 457-463.	2.2	194
998	Therapeutic interventions targeting organ preservation in muscle-invasive bladder cancer: a review. Clinical and Translational Oncology, 2011, 13, 315-321.	2.4	1
999	SEOM clinical guidelines for the treatment of invasive bladder cancer. Clinical and Translational Oncology, 2011, 13, 552-559.	2.4	6
1000	Current management of muscle-invasive bladder cancer. Clinical and Translational Oncology, 2011, 13, 855-861.	2.4	2
1001	Can Bcl-XL expression predict the radio sensitivity of Bilharzial-related squamous bladder carcinoma? a prospective comparative study. BMC Cancer, 2011, 11, 16.	2.6	6
1002	Intensity modulated radiotherapy for elderly bladder cancer patients. Radiation Oncology, 2011, 6, 75.	2.7	27
1003	Somatic mutation of fibroblast growth factor receptor–3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. Journal of Pathology, 2011, 224, 270-279.	4.5	73

#	ARTICLE	IF	CITATIONS
1004	Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. <i>Proteomics - Clinical Applications</i> , 2011, 5, 493-503.	1.6	29
1005	A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study. <i>Prostate</i> , 2011, 71, 1587-1594.	2.3	21
1006	Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. <i>Molecular Carcinogenesis</i> , 2011, 50, 931-944.	2.7	206
1007	A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. <i>Cancer</i> , 2011, 117, 103-109.	4.1	89
1008	Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. <i>Cancer</i> , 2011, 117, 1190-1196.	4.1	29
1009	Diagnosis and Management of Urothelial Carcinoma of the Bladder. <i>Postgraduate Medicine</i> , 2011, 123, 43-55.	2.0	33
1010	Are provider volumes a suitable measure of quality of care?. <i>Nature Reviews Urology</i> , 2011, 8, 361-363.	3.8	1
1012	CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 733-742.	4.4	36
1013	Curcumin Modulates MicroRNA-203-Mediated Regulation of the Src-Akt Axis in Bladder Cancer. <i>Cancer Prevention Research</i> , 2011, 4, 1698-1709.	1.5	181
1014	Are we undertreating invasive bladder cancer? Optimizing outcomes in a high-risk disease. <i>Current Opinion in Supportive and Palliative Care</i> , 2011, 5, 192-198.	1.3	0
1015	A Framework to Select Clinically Relevant Cancer Cell Lines for Investigation by Establishing Their Molecular Similarity with Primary Human Cancers. <i>Cancer Research</i> , 2011, 71, 7398-7409.	0.9	22
1016	Cyclin-Dependent Kinase-Associated Protein Cks2 is Associated with Bladder Cancer Progression. <i>Journal of International Medical Research</i> , 2011, 39, 533-540.	1.0	55
1017	Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. <i>Therapeutic Advances in Urology</i> , 2011, 3, 107-117.	2.0	20
1018	Src and Caveolin-1 Reciprocally Regulate Metastasis via a Common Downstream Signaling Pathway in Bladder Cancer. <i>Cancer Research</i> , 2011, 71, 832-841.	0.9	88
1019	Pelvic Lymphadenectomy in the Treatment of Invasive Bladder Cancer: Literature Review. <i>Advances in Urology</i> , 2011, 2011, 1-8.	1.3	2
1020	Current and Emerging Strategies for the Management of Bladder Cancer. <i>Clinical Medicine Reviews in Oncology</i> , 2011, 3, 1-12.	0.0	0
1021	Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 733-738.	1.6	155
1022	Kuhn's Paradigms: Are Those Closest to Treating Bladder Cancer the Last to Appreciate the Paradigm Shift?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2135-2137.	1.6	27

#	ARTICLE	IF	CITATIONS
1023	Preoperative Hydronephrosis Predicts Advanced Bladder Cancer but Is Not an Independent Factor for Cancer-Specific Survival after Radical Cystectomy. <i>Urologia Internationalis</i> , 2011, 86, 25-30.	1.3	13
1024	Detection of Nuclear Matrix Protein 22 and Survivin Baseline Level in Patients after Radical Cystectomy. <i>Urologia Internationalis</i> , 2011, 87, 445-449.	1.3	5
1025	Excision Repair Cross-Complementing Group 1 May Predict the Efficacy of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2561-2569.	7.0	53
1026	Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 3443-3449.	1.6	222
1027	Vinflunine in the treatment of advanced bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 13-20.	2.4	11
1028	Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 853-858.	2.4	6
1029	Improving selection of appropriate urinary diversion following radical cystectomy for bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 941-948.	2.4	40
1030	Global epigenetic profiling in bladder cancer. <i>Epigenomics</i> , 2011, 3, 35-45.	2.1	39
1031	Management of Bladder Cancer following Solid Organ Transplantation. <i>Advances in Urology</i> , 2011, 2011, 1-7.	1.3	24
1032	Incidence of occult lymph-node metastasis missed by standard pathological examination in patients with bladder cancer undergoing radical cystectomy. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 419-424.	1.4	12
1033	BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. <i>Annals of Oncology</i> , 2011, 22, 139-144.	1.2	123
1034	Preoperative lymph-node staging of invasive urothelial bladder cancer with ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: Correlation with histopathology. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 122-128.	1.4	68
1035	Clinical Outcomes of Patients with pT0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 115-120.	1.3	5
1036	Does extended lymph node dissection affect the lymph node density and survival after radical cystectomy?. <i>Indian Journal of Cancer</i> , 2011, 48, 230.	0.2	4
1037	Hand-Assisted Laparoscopic Radical Cystectomy and Orthotopic S-Shaped Ileal Neobladder: Functional and Oncologic Outcomes. <i>UroToday International Journal</i> , 2011, 04, .	0.1	0
1038	Urodynamic evaluation of patients with studer orthotopic urinary diversion and the impact of body mass index on micturition parameters. <i>Turk Uroloji Dergisi</i> , 2011, 37, 20-24.	0.4	0
1039	Analysis of the Distribution and Temporal Trends of Grade and Stage in Urothelial Bladder Cancer in Northern New England from 1994 to 2004. <i>ISRN Pathology</i> , 2012, 2012, 1-7.	0.4	4
1040	Impact of a Bladder Cancer Diagnosis on Smoking Behavior. <i>Journal of Clinical Oncology</i> , 2012, 30, 1871-1878.	1.6	90

#	ARTICLE	IF	CITATIONS
1041	Solitary Skin Metastasis Adjacent to Ureterocutaneostomy 4 Years After Radical Cystectomy for Bladder Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 331-334.	1.3	5
1042	Inflammatory Pathways as Promising Targets to Increase Chemotherapy Response in Bladder Cancer. Mediators of Inflammation, 2012, 2012, 1-11.	3.0	53
1043	Muscle Invasive Bladder Cancer: From Diagnosis to Survivorship. Advances in Urology, 2012, 2012, 1-10.	1.3	34
1044	Analysis of the perioperative and five-year oncological outcome of two hundred cases of open radical cystectomy: A single center experience. Indian Journal of Cancer, 2012, 49, 96.	0.2	5
1045	Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back. Advances in Urology, 2012, 2012, 1-2.	1.3	0
1046	Current Strategies to Enhance Recovery following Radical Cystectomy: Single Centre Initial Experience. ISRN Urology, 2012, 2012, 1-6.	1.5	4
1047	Urothelial cancers: using biology to improve outcomes. Expert Review of Anticancer Therapy, 2012, 12, 87-98.	2.4	8
1048	Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Annals of Oncology, 2012, 23, 695-700.	1.2	182
1049	Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. Current Opinion in Oncology, 2012, 24, 278-283.	2.4	7
1050	Current and Emerging Strategies in Bladder Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 589-603.	1.7	15
1052	Characteristics of Lymph Node Metastases Defining the Outcome After Radical Cystectomy of Urothelial Bladder Carcinoma. Japanese Journal of Clinical Oncology, 2012, 42, 1066-1072.	1.3	8
1053	Radiotherapy plus Chemotherapy in Muscle-Invasive Bladder Cancer. New England Journal of Medicine, 2012, 367, 379-381.	27.0	7
1054	Bladder conservation for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2012, 12, 1015-1020.	2.4	5
1055	Robotic-assisted radical cystectomy: current technique and outcomes. Expert Review of Anticancer Therapy, 2012, 12, 913-917.	2.4	2
1056	Contemporary management of muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2012, 12, 941-950.	2.4	17
1057	Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary Pathology. Archives of Pathology and Laboratory Medicine, 2012, 136, 372-390.	2.5	42
1058	Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. New England Journal of Medicine, 2012, 366, 1477-1488.	27.0	788
1059	The Urinary Tract. , 2012, , .		3

#	ARTICLE	IF	CITATIONS
1060	A Comparison of Early Complications Between Open and Robot-Assisted Radical Cystectomy. Journal of Endourology, 2012, 26, 670-675.	2.1	49
1061	Perioperative chemotherapy for upper tract urothelial cancer. Nature Reviews Urology, 2012, 9, 266-273.	3.8	18
1062	Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. British Journal of Cancer, 2012, 107, 1826-1832.	6.4	34
1063	Current status of robot-assisted radical cystectomy for bladder cancer. Nature Reviews Urology, 2012, 9, 573-582.	3.8	4
1064	The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. British Journal of Cancer, 2012, 106, 1187-1195.	6.4	17
1065	The History and Future of the Urologic Oncology Study Group (UOSG) of the Japan Clinical Oncology Group (JCOG). Japanese Journal of Clinical Oncology, 2012, 42, 363-367.	1.3	0
1066	Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein. Journal of Clinical Oncology, 2012, 30, 340-341.	1.6	12
1067	Hedgehog Signaling Regulates Bladder Cancer Growth and Tumorigenicity. Cancer Research, 2012, 72, 4449-4458.	0.9	43
1068	Robotic Versus Open Radical Cystectomy: Prospective Comparison of Perioperative and Pathologic Outcomes in Japan. Japanese Journal of Clinical Oncology, 2012, 42, 625-631.	1.3	48
1069	Schistosomiasis and bladder cancer: similarities and differences from urothelial cancer. Expert Review of Anticancer Therapy, 2012, 12, 753-763.	2.4	22
1070	Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. Acta Radiologica, 2012, 53, 943-949.	1.1	20
1071	Is Robot-Assisted Radical Cystectomy Justified in the Elderly? A Comparison of Robotic Versus Open Radical Cystectomy for Bladder Cancer in Elderly ≥75 Years Old. Journal of Endourology, 2012, 26, 1301-1306.	2.1	53
1072	Reply to O. Dizdar et al. Journal of Clinical Oncology, 2012, 30, 339-340.	1.6	0
1073	Value of Current Chemotherapy and Surgery in Advanced and Metastatic Bladder Cancer. Urologia Internationalis, 2012, 88, 249-258.	1.3	80
1074	Oncolytic Viruses in the Treatment of Bladder Cancer. Advances in Urology, 2012, 2012, 1-11.	1.3	19
1075	Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA. Advances in Urology, 2012, 2012, 1-8.	1.3	31
1076	A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy. Advances in Urology, 2012, 2012, 1-6.	1.3	13
1077	Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder. Libyan Journal of Medicine, 2012, 7, 14694.	1.6	11

#	ARTICLE	IF	CITATIONS
1078	Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 825-830.	1.3	17
1079	Pathological possibilities and pitfalls in detecting aggressive bladder cancer. Current Opinion in Urology, 2012, 22, 397-404.	1.8	9
1080	Simultaneous Cystectomy and Nephroureterectomy due to Synchronous Upper Urinary Tract Tumors and Invasive Bladder Cancer: Open and Laparoscopic Approaches. Current Urology, 2012, 6, 76-81.	0.6	10
1081	CD24 Is an Effector of HIF-1 α -Driven Primary Tumor Growth and Metastasis. Cancer Research, 2012, 72, 5600-5612.	0.9	115
1082	Bladder Cancer and Stem Cells. Current Signal Transduction Therapy, 2012, 7, 209-219.	0.5	0
1083	Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. Pathology, 2012, 44, 448-452.	0.6	11
1084	Purification, characterization and anticancer activity of a polysaccharide from Panax ginseng. International Journal of Biological Macromolecules, 2012, 51, 968-973.	7.5	70
1085	Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential. Expert Review of Anticancer Therapy, 2012, 12, 743-752.	2.4	9
1088	Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long-term oncological, functional, and quality of life results. World Journal of Urology, 2012, 30, 725-732.	2.2	23
1089	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World Journal of Urology, 2012, 30, 753-759.	2.2	33
1090	Radical cystectomy in patients over 70 years of age: impact of comorbidity on perioperative morbidity and mortality. World Journal of Urology, 2012, 30, 769-776.	2.2	36
1091	Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease. World Journal of Urology, 2012, 30, 795-799.	2.2	17
1092	Laparoscopic radical cystectomy: initial experience using the single-incision triangulated umbilical surgery (SITUS) technique. World Journal of Urology, 2012, 30, 619-624.	2.2	19
1093	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World Journal of Urology, 2012, 30, 807-814.	2.2	16
1094	Patterns of local recurrence after radical cystectomy in a contemporary series of patients with muscle-invasive bladder cancer. World Journal of Urology, 2012, 30, 821-826.	2.2	21
1095	Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 467-474.	2.8	12
1096	Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 149-156.	2.8	9
1097	Risk stratification of survival by lymphovascular invasion, pathological stage, and surgical margin in patients with bladder cancer treated with radical cystectomy. International Journal of Clinical Oncology, 2012, 17, 456-461.	2.2	19

#	ARTICLE	IF	CITATIONS
1098	A comparative dosimetric study of 3-dimensional conformal radical radiotherapy for bladder cancer patients versus conventional 2-dimensional radical radiotherapy in NCI-Cairo, Egypt. Chinese-German Journal of Clinical Oncology, 2012, 11, 632-634.	0.1	0
1099	The incidence and relevance of prostate cancer in radical cystoprostatectomy specimens. International Urology and Nephrology, 2012, 44, 1705-1710.	1.4	13
1100	Development of a nomogram to predict non-organ-confined bladder urothelial cancer before radical cystectomy. International Urology and Nephrology, 2012, 44, 1711-1719.	1.4	28
1101	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. European Urology, 2012, 62, 677-684.	1.9	93
1102	Comorbidity and Performance Indices as Predictors of Cancer-Independent Mortality But Not of Cancer-Specific Mortality After Radical Cystectomy for Urothelial Carcinoma of the Bladder. European Urology, 2012, 62, 662-670.	1.9	86
1103	Critical Evaluation of the American Joint Committee on Cancer TNM Nodal Staging System in Patients with Lymph Node-Positive Disease after Radical Cystectomy. European Urology, 2012, 62, 671-676.	1.9	30
1104	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2012, 62, 523-533.	1.9	214
1105	Standardized Analysis of Frequency and Severity of Complications After Robot-assisted Radical Cystectomy. European Urology, 2012, 62, 806-813.	1.9	125
1106	Technical Advances in Bladder Cancer Patient Care: Progress or Promise?. European Urology, 2012, 62, 814-815.	1.9	3
1107	Robotic Intracorporeal Orthotopic Ileal Neobladder: Replicating Open Surgical Principles. European Urology, 2012, 62, 891-901.	1.9	170
1108	Whole-Pelvis or Bladder-Only Chemoradiation for Lymph Node-Negative Invasive Bladder Cancer: Single-Institution Experience. International Journal of Radiation Oncology Biology Physics, 2012, 82, e457-e462.	0.8	122
1109	Bladder Preservation for Localized Muscle-Invasive Bladder Cancer: The Survival Impact of Local Utilization Rates of Definitive Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, e197-e204.	0.8	21
1110	Comparative Outcomes of Pure Squamous Cell Carcinoma and Urothelial Carcinoma With Squamous Differentiation in Patients Treated With Radical Cystectomy. Journal of Urology, 2012, 187, 74-79.	0.4	60
1111	Complications and Long-Term Results of Salvage Cystectomy After Failed Bladder Sparing Therapy for Muscle Invasive Bladder Cancer. Journal of Urology, 2012, 187, 463-468.	0.4	95
1112	Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. Journal of Urology, 2012, 187, 457-462.	0.4	43
1113	Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial. Journal of Urology, 2012, 187, 862-867.	0.4	78
1114	External Validation of a Biomarker Based Pre-Cystectomy Algorithm to Predict Nonorgan Confined Urothelial Cancers. Journal of Urology, 2012, 187, 840-844.	0.4	7
1115	Preoperative Staging of Invasive Bladder Cancer With Dynamic Gadolinium-enhanced Magnetic Resonance Imaging: Results From a Prospective Study. Urology, 2012, 80, 1313-1318.	1.0	75

#	ARTICLE	IF	CITATIONS
1116	Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: Results from the Canadian Bladder Cancer Network Database. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 825-832.	1.6	25
1117	Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 772-780.	1.6	33
1118	Innovations in Radical Cystectomy and Pelvic Lymph Node Dissection. Seminars in Oncology, 2012, 39, 573-582.	2.2	18
1119	Management of Cancer in the Older Adult. Clinics in Geriatric Medicine, 2012, 28, 33-49.	2.6	12
1121	Minimum incision endoscopic radical cystectomy in patients with malignant tumors of the urinary bladder: Clinical and oncological outcomes at a single institution. European Journal of Surgical Oncology, 2012, 38, 1101-1105.	1.0	25
1122	1905 ADHERENCE TO SURVEILLANCE GUIDELINES AFTER RADICAL CYSTECTOMY: A POPULATION-BASED ANALYSIS. Journal of Urology, 2012, 187, .	0.4	0
1123	Robotic assisted laparoscopic radical cystectomy for bladder carcinoma: early experience and oncologic outcomes. Formosan Journal of Surgery, 2012, 45, 178-182.	0.2	3
1124	Volume Outcomes of Cystectomy—Is it the Surgeon or the Setting?. Journal of Urology, 2012, 188, 2139-2144.	0.4	57
1125	Best practice in the treatment of nonmuscle invasive bladder cancer. Therapeutic Advances in Urology, 2012, 4, 13-32.	2.0	125
1126	Robotic Urologic Surgery. , 2012, , .		4
1127	Outcomes of Laparoscopic and Robotic Radical Cystectomy in the Elderly Patients. Urology, 2012, 79, 585-590.	1.0	45
1128	Sunitinib Malate Provides Activity Against Murine Bladder Tumor Growth and Invasion in a Preclinical Orthotopic Model. Urology, 2012, 80, 736.e1-736.e5.	1.0	10
1129	The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 44-48.	1.6	50
1130	Disparities in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 81-88.	1.6	62
1132	Mechanism of cisplatin resistance in human urothelial carcinoma cells. Food and Chemical Toxicology, 2012, 50, 1226-1237.	3.6	13
1133	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. European Journal of Cancer, 2012, 48, 1503-1511.	2.8	50
1134	Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagnostic Pathology, 2012, 7, 159.	2.0	40
1135	Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience. Canadian Urological Association Journal, 2012, 6, E116-E120.	0.6	2

#	ARTICLE	IF	CITATIONS
1136	Intravesical therapies for bladder cancer – indications and limitations. BJU International, 2012, 110, 12-21.	2.5	33
1137	Prognostic Value of Cell-Cycle Regulation Biomarkers in Bladder Cancer. Seminars in Oncology, 2012, 39, 524-533.	2.2	61
1138	Neoadjuvant and Adjuvant Chemotherapy Approaches for Invasive Bladder Cancer. Seminars in Oncology, 2012, 39, 588-597.	2.2	13
1139	Radical cystectomy for the treatment of bladder cancer: What have we learnt from Surgical Outcomes Monitoring and Improvement Program reports?. Surgical Practice, 2012, 16, 164-167.	0.2	1
1141	Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?. Nature Reviews Urology, 2012, 9, 41-51.	3.8	113
1142	Diagnosis and treatment of urethral recurrence after radical cystectomy in the male. Actas Urológicas Españolas (English Edition), 2012, 36, 42-47.	0.2	4
1143	High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Human Pathology, 2012, 43, 1590-1595.	2.0	66
1144	Bladder cancer and schistosomiasis. Journal of the Egyptian National Cancer Institute, 2012, 24, 151-159.	1.5	73
1145	Is Adjunctive Systemic Chemotherapy After Cystectomy for T2N+ Disease of Therapeutic Benefit?. Journal of Urology, 2012, 188, 358-360.	0.4	3
1146	Surgical and Chemotherapeutic Management of Regional Lymph Nodes in Bladder Cancer. Journal of Urology, 2012, 188, 1081-1088.	0.4	19
1147	Does Partial Cystectomy Compromise Oncologic Outcomes for Patients with Bladder Cancer Compared to Radical Cystectomy? A Matched Case-Control Analysis. Journal of Urology, 2012, 188, 1115-1119.	0.4	93
1148	Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Review of Anticancer Therapy, 2012, 12, 271-281.	2.4	92
1149	Minimally invasive cystectomy approaches in the treatment of bladder cancer. Expert Review of Anticancer Therapy, 2012, 12, 733-741.	2.4	4
1150	HAMLET: functional properties and therapeutic potential. Future Oncology, 2012, 8, 1301-1313.	2.4	22
1151	Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1537-1543.	2.4	6
1152	1064 A NOVEL SIMULATION MODEL OF NON-MUSCLE INVASIVE BLADDER CANCER A PLATFORM FOR A VIRTUAL RANDOMIZED TRIAL OF CONSERVATIVE THERAPY VS CYSTECTOMY IN BCG REFRACTORY PATIENTS. Journal of Urology, 2012, 187, .	0.4	1
1156	Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Actas Urológicas Españolas (English Edition), 2012, 36, 449-460.	0.2	9
1158	Molecular Pathology of Bladder Cancer. Surgical Pathology Clinics, 2012, 5, 843-858.	1.7	3

#	ARTICLE	IF	CITATIONS
1159	The role of radiotherapy in urinary bladder cancer: current status. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2012, 38, 144-156.	1.5	34
1160	Bladder Cancer and Schistosomiasis: Is There a Difference for the Association?. , 0, , .		1
1161	Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. Canadian Urological Association Journal, 2012, 6, 217.	0.6	18
1162	Schistosomiasis and Bladder Cancer. , 0, , .		1
1163	Tumors of the Kidney, Bladder, Ureters, and Renal Pelvis. , 2012, , 1303-1309.		2
1164	Update on the management of invasive bladder cancer 2012. Cancer Management and Research, 2012, 4, 177.	1.9	3
1165	Prognostic factors in radical cystectomy affecting survival. Archives of Medical Science, 2012, 4, 650-654.	0.9	8
1166	Our Experiences with Robot-Assisted Laparoscopic Radical Cystectomy: Orthotopic Neobladder by the Suprapubic Incision Method. Korean Journal of Urology, 2012, 53, 766.	1.2	5
1167	Extended Pelvic Lymph Node Dissection: Before or after Radical Cystectomy? A Multicenter Study of the Turkish Society of Urooncology. Korean Journal of Urology, 2012, 53, 451.	1.2	3
1168	Development and Validation of a Reference Table for Prediction of Postoperative Mortality Rate in Patients Treated with Radical Cystectomy: A Population-based Study. Annals of Surgical Oncology, 2012, 19, 309-317.	1.5	36
1169	Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. International Journal of Cancer, 2012, 130, 2922-2929.	5.1	40
1170	CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Medicine, 2012, 1, 76-81.	2.8	23
1171	Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer, 2012, 118, 3920-3927.	4.1	40
1172	The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer. Cancer, 2012, 118, 5525-5534.	4.1	38
1173	Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 591-600.	1.3	62
1174	Status of Robot-Assisted Radical Cystectomy (RARC) in 2012. Indian Journal of Surgical Oncology, 2012, 3, 85-90.	0.7	0
1178	Decreasing operative time and incontinence rates in patients treated with radical cystectomy and urethral diversion: a prospective randomized trial using a new suturing device (CAPIO). International Urology and Nephrology, 2012, 44, 769-774.	1.4	5
1179	Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer. Molecular Imaging and Biology, 2012, 14, 245-251.	2.6	51

#	ARTICLE	IF	CITATIONS
1180	Role and Extent of Lymphadenectomy During Radical Cystectomy for Invasive Bladder Cancer. Current Urology Reports, 2012, 13, 115-121.	2.2	16
1181	Neoadjuvant Chemotherapy for Invasive Bladder Cancer. Current Urology Reports, 2012, 13, 136-146.	2.2	23
1183	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. BJU International, 2012, 109, 70-76.	2.5	22
1184	Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: Development of novel bladder preservation approach, Osaka Medical College regimen. International Journal of Urology, 2012, 19, 26-38.	1.0	6
1185	Selective bladder preservation with curative intent for muscle-invasive bladder cancer: A contemporary review. International Journal of Urology, 2012, 19, 388-401.	1.0	58
1186	External Validation of Postoperative Nomograms for Prediction of All-Cause Mortality, Cancer-Specific Mortality, and Recurrence in Patients With Urothelial Carcinoma of the Bladder. European Urology, 2012, 61, 58-64.	1.9	69
1187	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. European Urology, 2012, 61, 237-242.	1.9	69
1188	Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience. European Urology, 2012, 61, 705-711.	1.9	354
1189	Diagnostic Efficacy of [11C]Choline Positron Emission Tomography/Computed Tomography Compared With Conventional Computed Tomography in Lymph Node Staging of Patients With Bladder Cancer Prior to Radical Cystectomy. European Urology, 2012, 61, 1031-1038.	1.9	75
1190	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. European Urology, 2012, 61, 810-817.	1.9	163
1191	Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients. European Urology, 2012, 61, 1039-1047.	1.9	334
1192	Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 18-30.	1.8	18
1193	Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract. International Journal of Urology, 2012, 19, 710-721.	1.0	50
1194	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. BJU International, 2012, 109, 685-690.	2.5	30
1195	Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing risks analysis. BJU International, 2012, 109, 564-569.	2.5	44
1196	Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU International, 2012, 109, 860-866.	2.5	55
1197	Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases. BJU International, 2012, 109, 1031-1036.	2.5	45
1198	Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU International, 2012, 109, 846-854.	2.5	101

#	ARTICLE	IF	CITATIONS
1199	Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU International, 2012, 109, 1147-1154.	2.5	64
1200	Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches. BJU International, 2012, 110, E203-8.	2.5	12
1201	Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU International, 2012, 110, E222-7.	2.5	74
1202	Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU International, 2012, 110, 1163-1168.	2.5	59
1203	Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. BJU International, 2012, 110, 1463-1470.	2.5	45
1204	Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU International, 2012, 110, 1317-1323.	2.5	50
1205	A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors. BJU International, 2012, 110, E533-40.	2.5	48
1206	Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU International, 2012, 110, E590-5.	2.5	21
1207	Towards bloodless cystectomy: a 10-year experience of intraoperative cell salvage during radical cystectomy. BJU International, 2012, 110, E608-13.	2.5	22
1208	Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer, 2012, 118, 72-81.	4.1	45
1209	A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aNO-M0 bladder cancer. Cancer, 2012, 118, 358-364.	4.1	34
1212	Lymph node metastasis mapping in extended lymphadenectomy to the level of the inferior mesenteric artery for bladder cancer. International Journal of Clinical Oncology, 2012, 17, 63-68.	2.2	3
1213	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU International, 2013, 111, 74-84.	2.5	26
1214	Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU International, 2013, 111, 404-411.	2.5	48
1215	Outcomes of Minimally Invasive Urologic Surgery in the Elderly Patient Population. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 84-90.	0.7	2
1216	Perioperative Complications and Mortality After Radical Cystectomy When Using a Standardized Reporting Methodology. Clinical Genitourinary Cancer, 2013, 11, 189-197.	1.9	75
1217	Fast-track rehabilitation after robot-assisted laparoscopic cystectomy accelerates postoperative recovery. BJU International, 2013, 112, E99-106.	2.5	69
1218	Improvements in Safety and Recovery Following Cystectomy: Reassessing the Role of Pre-Operative Bowel Preparation and Interventions to Speed Return of Post-Operative Bowel Function. Current Urology Reports, 2013, 14, 78-83.	2.2	8

#	ARTICLE	IF	CITATIONS
1219	The natural history of secondary muscle-invasive bladder cancer. BMC Urology, 2013, 13, 23.	1.4	17
1220	MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urology, 2013, 13, 5.	1.4	16
1221	Advances in bladder cancer imaging. BMC Medicine, 2013, 11, 104.	5.5	68
1222	Reducing Morbidity of Pelvic and Retroperitoneal Lymphadenectomy. Current Urology Reports, 2013, 14, 488-495.	2.2	3
1223	Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer. Current Urology Reports, 2013, 14, 109-115.	2.2	14
1224	Cost Analysis of Open Radical Cystectomy Versus Robot-assisted Radical Cystectomy. Current Urology Reports, 2013, 14, 26-31.	2.2	34
1228	Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clinical and Translational Oncology, 2013, 15, 849-854.	2.4	49
1229	Hybrid procedure using perineal and abdominal approaches for radical prostatocystectomy: initial experience with 16 select cases. SpringerPlus, 2013, 2, 348.	1.2	1
1230	Surveillance of patients with bladder cancer following cystectomy: yield of CT urography. Abdominal Imaging, 2013, 38, 1415-1421.	2.0	12
1231	The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?. World Journal of Urology, 2013, 31, 1369-1376.	2.2	8
1232	Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. World Journal of Urology, 2013, 31, 1023-1028.	2.2	26
1233	Do pure squamous cell carcinomas and urothelial carcinomas have similar prognosis after radical cystectomy?. World Journal of Urology, 2013, 31, 1177-1182.	2.2	8
1234	Robotic-assisted laparoscopic radical cystectomy: history, techniques and outcomes. World Journal of Urology, 2013, 31, 489-497.	2.2	18
1235	Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. International Urology and Nephrology, 2013, 45, 1561-1567.	1.4	13
1236	Comparison of microscopic (pT3a) and gross extravesical extension (pT3b) in pathological staging of bladder cancer: analysis of patient outcomes. International Urology and Nephrology, 2013, 45, 387-393.	1.4	11
1237	Robot-assisted laparoscopic vs open radical cystectomy: comparison of complications and perioperative oncological outcomes in 200 patients. BJU International, 2013, 112, E290-4.	2.5	91
1238	In-hospital mortality and failure-to-rescue rates after radical cystectomy. BJU International, 2013, 112, E20-7.	2.5	28
1239	Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU International, 2013, 112, E51-8.	2.5	82

#	ARTICLE	IF	CITATIONS
1240	Editorial Comment to ¹⁸<sc>F</sc>-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study. International Journal of Urology, 2013, 20, 796-797.	1.0	0
1241	Management of sexual problems in cancer patients and survivors. Current Problems in Cancer, 2013, 37, 319-352.	2.0	34
1242	Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 480-486.	1.6	32
1243	Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Human Pathology, 2013, 44, 612-622.	2.0	15
1244	Molecular genetics and genomics progress in urothelial bladder cancer. Seminars in Diagnostic Pathology, 2013, 30, 313-320.	1.5	18
1245	Oncologic Outcomes Achieved by Radical Cystectomy. European Urology, 2013, 64, 225-226.	1.9	2
1246	Immediate cystectomy or conservative management for T1G3 bladder cancer: A meta-analysis of general survival rate. Chinese-German Journal of Clinical Oncology, 2013, 12, 243-245.	0.1	0
1247	The SPARC Score: A Multifactorial Outcome Prediction Model for Patients Undergoing Radical Cystectomy for Bladder Cancer. Journal of Urology, 2013, 190, 2005-2010.	0.4	65
1248	Comprehensive handbook for developing a bladder cancer cystectomy database. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 812-826.	1.6	7
1249	396 CANCER-SPECIFIC MORTALITY FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER WITH LYMPH NODE INVOLVEMENT: IMPACT OF DISEASE FEATURES AND ADJUVANT CHEMOTHERAPY. Journal of Urology, 2013, 189, .	0.4	1
1250	Re: Does Partial Cystectomy Compromise Oncologic Outcomes for Patients with Bladder Cancer Compared to Radical Cystectomy? A Matched Case-Control Analysis. Journal of Urology, 2013, 189, 1600-1601.	0.4	1
1251	Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1709-1715.	1.6	31
1252	Bladder Cancer Patterns of Pelvic Failure: Implications for Adjuvant Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 363-369.	0.8	52
1253	A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 359-365.	1.6	31
1255	Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 303-311.	1.6	55
1257	Improving bladder cancer patient care: a pharmacoeconomic perspective. Expert Review of Anticancer Therapy, 2013, 13, 661-668.	2.4	13
1258	Trimodality treatment in the conservative management of infiltrating bladder cancer: A critical review of the literature. Critical Reviews in Oncology/Hematology, 2013, 86, 176-190.	4.4	15
1259	EAU Guidelines on Robotic and Single-site Surgery in Urology. European Urology, 2013, 64, 277-291.	1.9	141

#	ARTICLE	IF	CITATIONS
1260	Spatially controlled photothermal heating of bladder tissue through single-walled carbon nanohorns delivered with a fiberoptic microneedle device. <i>Lasers in Medical Science</i> , 2013, 28, 1143-1150.	2.1	20
1261	PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway. <i>Molecular Cancer</i> , 2013, 12, 148.	19.2	28
1262	Clinicopathological risk factors for recurrence after neoadjuvant chemotherapy and radical hysterectomy in cervical cancer. <i>World Journal of Surgical Oncology</i> , 2013, 11, 301.	1.9	19
1263	Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. <i>Medical Oncology</i> , 2013, 30, 705.	2.5	29
1264	CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 673-679.	2.8	39
1265	Impact of Smoking intensity on Outcomes of Patients with Non Muscle Invasive Bladder Cancer Treated by BCG Immunotherapy. <i>Ultrastructural Pathology</i> , 2013, 37, 273-277.	0.9	9
1266	PMN and anti-tumor immunityâ€”The case of bladder cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2013, 23, 183-189.	9.6	38
1267	Eerste resultaten van de robotcystectomie met aanleg van de urinedeviatie volgens Bricker intracorporeel. <i>Tijdschrift Voor Urologie</i> , 2013, 3, 118-124.	0.1	0
1268	Do we use the right criteria for determining the clinical significance of incidental prostate cancer at radical cystoprostatectomy?. <i>Scandinavian Journal of Urology</i> , 2013, 47, 358-362.	1.0	9
1269	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. <i>European Urology</i> , 2013, 63, 371-378.	1.9	47
1270	ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2013, 63, 45-57.	1.9	361
1271	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinomaâ€”Neoadjuvant and Adjuvant Settings. <i>European Urology</i> , 2013, 63, 58-66.	1.9	151
1272	A Novel Risk Stratification to Predict Local-Regional Failures in Urothelial Carcinoma of the Bladder After Radical Cystectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 81-88.	0.8	50
1273	Kidney and Bladder Cancer. , 2013, , 537-555.		0
1274	A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage <scp>T</scp>2 bladder cancer. <i>BJU International</i> , 2013, 111, 240-248.	2.5	45
1275	A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer. <i>BJU International</i> , 2013, 111, 186-187.	2.5	3
1276	Predictors of cancerâ€”specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , 2013, 111, E30-6.	2.5	77
1277	Longâ€”term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy. <i>BJU International</i> , 2013, 111, E37-42.	2.5	17

#	ARTICLE	IF	CITATIONS
1278	Comparison of Surveillance Strategies for Low-Risk Bladder Cancer Patients. Medical Decision Making, 2013, 33, 198-214.	2.4	11
1279	Anatomic basis of radical cystectomy and orthotopic urinary diversion in female patients. Clinical Anatomy, 2013, 26, 105-109.	2.7	8
1280	Robotic-assisted Radical Cystectomy With Extracorporeal Urinary Diversion for Urothelial Carcinoma of the Bladder: Analysis of Complications and Oncologic Outcomes in 175 Patients With a Median Follow-up of 3 Years. Urology, 2013, 82, 1323-1329.	1.0	38
1281	“Never Events” Centers for Medicare and Medicaid Services Complications After Radical Cystectomy. Urology, 2013, 81, 527-532.	1.0	19
1282	Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1270-1275.	1.6	10
1283	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. Journal of Urology, 2013, 189, 1214-1221.	0.4	291
1284	Survival Impact of Followup Care after Radical Cystectomy for Bladder Cancer. Journal of Urology, 2013, 190, 1698-1703.	0.4	13
1285	Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1663-1669.	1.6	38
1286	Long-term Outcomes of Robot-assisted Radical Cystectomy for Bladder Cancer. European Urology, 2013, 64, 219-224.	1.9	73
1287	Anatomic Basis for Lymph Node Counts as Measure of Lymph Node Dissection Extent: A Cadaveric Study. Urology, 2013, 81, 358-363.	1.0	43
1288	Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma. Urologic Clinics of North America, 2013, 40, 233-247.	1.8	15
1289	Plasmacytoid Urothelial Carcinoma, a Chemosensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis. Journal of Urology, 2013, 189, 1656-1661.	0.4	138
1290	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1716-1724.	1.6	15
1291	Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. European Urology, 2013, 64, 52-57.	1.9	189
1292	Neobladder long term follow-up. Journal of the Egyptian National Cancer Institute, 2013, 25, 43-49.	1.5	0
1293	Lymph node-positive bladder cancer: surgical, pathologic, molecular and prognostic aspects. Expert Review of Anticancer Therapy, 2013, 13, 1281-1295.	2.4	13
1294	Combined Ultrasmall Superparamagnetic Particles of Iron Oxide—Enhanced and Diffusion-weighted Magnetic Resonance Imaging Facilitates Detection of Metastases in Normal-sized Pelvic Lymph Nodes of Patients with Bladder and Prostate Cancer. European Urology, 2013, 64, 953-960.	1.9	146
1295	A prospective randomized multicenter study of Turkish Society of Urooncology comparing two different mechanical bowel preparation methods for radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 664-670.	1.6	16

#	ARTICLE	IF	CITATIONS
1296	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , 2013, 49, 1889-1897.	2.8	154
1297	Response to induction chemotherapy and surgery in non-organ confined bladder cancer: A single institution experience. <i>European Journal of Surgical Oncology</i> , 2013, 39, 365-371.	1.0	29
1298	Nomograms Predicting Response to Therapy and Outcomes After Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 311-316.	0.8	32
1299	Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy. <i>European Urology</i> , 2013, 64, 266-276.	1.9	62
1300	Prognostic Risk Stratification of Patients with Urothelial Carcinoma of the Bladder with Recurrence After Radical Cystectomy. <i>Journal of Urology</i> , 2013, 189, 1275-1281.	0.4	51
1301	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2013, 64, 456-464.	1.9	101
1302	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. <i>European Urology</i> , 2013, 64, 837-845.	1.9	61
1303	Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 894-898.	1.6	46
1304	Editorial Comment. <i>Journal of Urology</i> , 2013, 190, 927-927.	0.4	0
1305	Advanced bladder cancer: New agents and new approaches. A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 9-16.	1.6	12
1306	Neoadjuvant chemotherapy in muscle-invasive bladder cancer: Ready for prime time?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 288-294.	4.4	4
1307	Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. <i>European Journal of Surgical Oncology</i> , 2013, 39, 372-379.	1.0	20
1308	Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1150-1156.	1.0	29
1309	Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1737-1743.	1.6	57
1310	Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004). <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 261-269.	0.8	115
1311	Building a Medical Neighborhood in the Safety Net: An Innovative Technology Improves Hematuria Workups. <i>Urology</i> , 2013, 82, 1277-1282.	1.0	18
1312	Using Preoperative Albumin Levels As a Surrogate Marker for Outcomes After Radical Cystectomy for Bladder Cancer. <i>Urology</i> , 2013, 81, 587-592.	1.0	86
1313	Urinary Bladder Cancer: The Current and Potential Role of MR Imaging in Non-Distant Metastatic Lesions. <i>Journal of Cancer Therapy</i> , 2013, 04, 504-512.	0.4	1

#	ARTICLE	IF	CITATIONS
1314	Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scandinavian Journal of Urology, 2013, 47, 483-490.	1.0	15
1315	IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer. PLoS ONE, 2013, 8, e61901.	2.5	94
1316	A Phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder. Urology, 2013, 82, 111-117.	1.0	30
1317	Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. European Urology, 2013, 64, 465-471.	1.9	68
1318	Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer. Urologic Clinics of North America, 2013, 40, 295-304.	1.8	5
1320	Multidisciplinary Management of Patients with Localized Bladder Cancer. Surgical Oncology Clinics of North America, 2013, 22, 357-373.	1.5	2
1321	Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen). International Journal of Oncology, 2013, 43, 79-87.	3.3	10
1322	Bladder preservation in the treatment of muscle-invasive bladder cancer (<scp>MIBC</scp>): a review of the literature and a practical approach to therapy. BJU International, 2013, 112, 13-25.	2.5	67
1323	Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncology, The, 2013, 14, 863-872.	10.7	129
1324	Hospitalization Trends After Prostate and Bladder Surgery: Implications of Potential Payment Reforms. Journal of Urology, 2013, 189, 59-65.	0.4	64
1325	Validation of New AJCC Exclusion Criteria for Subepithelial Prostatic Stromal Invasion from pT4a Bladder Urothelial Carcinoma. Journal of Urology, 2013, 189, 53-58.	0.4	27
1326	Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. Annals of Surgical Oncology, 2013, 20, 1027-1034.	1.5	25
1327	External Validation of Extranodal Extension and Lymph Node Density as Predictors of Survival in Node-positive Bladder Cancer after Radical Cystectomy. Annals of Surgical Oncology, 2013, 20, 1389-1394.	1.5	31
1328	Oncologic outcomes for lymph node-positive urothelial carcinoma patients treated with robot assisted radical cystectomy: With mean follow-up of 3.5 years. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1621-1627.	1.6	25
1329	Emerging drugs for urothelial carcinoma. Expert Opinion on Emerging Drugs, 2013, 18, 477-494.	2.4	8
1334	High Expression of H3K27me3 Is an Independent Predictor of Worse Outcome in Patients with Urothelial Carcinoma of Bladder Treated with Radical Cystectomy. BioMed Research International, 2013, 2013, 1-8.	1.9	17
1335	Suppressions of Migration and Invasion by Cantharidin in TSGH-8301 Human Bladder Carcinoma Cells through the Inhibitions of Matrix Metalloproteinase-2/-9 Signaling. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-8.	1.2	17
1336	Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer. Current Opinion in Urology, 2013, 23, 423-428.	1.8	6

#	ARTICLE	IF	CITATIONS
1337	Optimal use and outcomes of orthotopic neobladder reconstruction in men and women. Current Opinion in Urology, 2013, 23, 479-486.	1.8	16
1338	Clinical Applications of Recent Molecular Advances in Urologic Malignancies. Advances in Anatomic Pathology, 2013, 20, 175-203.	4.3	26
1339	Management of superficial and muscle-invasive urothelial cancers of the bladder. Current Opinion in Oncology, 2013, 25, 281-288.	2.4	36
1340	Robotic Surgery. Cancer Journal (Sudbury, Mass), 2013, 19, 133-139.	2.0	32
1341	Orthotopic Bladder Substitution (Neobladder). Journal of Wound, Ostomy and Continence Nursing, 2013, 40, 73-82.	1.0	16
1342	Perioperative outcomes in radical cystectomy. Current Opinion in Urology, 2013, 23, 456-465.	1.8	30
1343	Â-H2AX level in peripheral blood lymphocytes as a risk predictor for bladder cancer. Carcinogenesis, 2013, 34, 2543-2547.	2.8	22
1344	Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-Â€œInduced Angiogenesis. Cancer Research, 2013, 73, 1097-1106.	0.9	150
1345	Principal component analysis based preÂ€cystectomy model to predict pathological stage in patients with clinical organÂ€œconfined bladder cancer. BJU International, 2013, 111, E167-72.	2.5	18
1346	Evaluation of Open and Laparoscopic Radical Cystoprostatectomy Combined with Orthotopic Neobladder: A Single-Surgeon Experience. Urologia Internationalis, 2013, 90, 348-353.	1.3	8
1347	Laparoscopic versus Open Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Single Institute Comparative Analysis. Urologia Internationalis, 2013, 91, 109-112.	1.3	14
1348	Multimodality Therapy Including Surgical Resection and Intraoperative Electron Radiotherapy for Recurrent or Advanced Primary Carcinoma of the Urinary Bladder or Ureter. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 596-600.	1.3	7
1349	Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery?. Current Opinion in Urology, 2013, 23, 449-455.	1.8	6
1350	Impact of surgeon and volume on extended lymphadenectomy at the time of robotÂ€œassisted radical cystectomy: results from the International Robotic Cystectomy Consortium (<scp>IRCC</scp>). BJU International, 2013, 111, 1075-1080.	2.5	49
1351	Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder Â€œ A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Canadian Urological Association Journal, 2013, 7, 312.	0.6	18
1352	Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology, 2013, 2013, 1-6.	1.3	34
1353	Carcinosarcoma of the Bladder: A Case Report and Review of the Literature. Case Reports in Urology, 2013, 2013, 1-3.	0.3	3
1354	Short-term Change in Renal Function in Patients Undergoing Continent vs Noncontinent Urinary Diversions. UroToday International Journal, 2013, 06, .	0.1	2

#	ARTICLE	IF	CITATIONS
1355	Higher surgeon and hospital volume improves long-term survival after radical cystectomy. <i>Cancer</i> , 2013, 119, 3546-3554.	4.1	87
1356	Therapeutic enhancement of Sâ€¹1 with CPT â€¹1 through downâ€¹regulation of thymidylate synthase in bladder cancer. <i>Cancer Medicine</i> , 2013, 2, 488-495.	2.8	5
1357	Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscleâ€¹invasive bladder cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 310-317.	1.1	17
1358	Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches. <i>International Journal of Cancer</i> , 2013, 133, 2145-2156.	5.1	28
1359	Systematic Assessment of Complications and Outcome of Radical Cystectomy Undertaken with Curative Intent in Patients with Comorbidity and over 75 Years of Age. <i>Urologia Internationalis</i> , 2013, 90, 195-201.	1.3	20
1360	Neoadjuvant Gemcitabine Plus Carboplatin for Locally Advanced Bladder Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 193-199.	1.3	13
1361	Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1257-1268.	2.4	4
1362	Preoperative Neutrophil/Lymphocyte Ratio Predicts Overall Survival and Extravesical Disease in Patients Undergoing Radical Cystectomy. <i>Journal of Endourology</i> , 2013, 27, 1046-1050.	2.1	81
1363	Current status of minimally invasive radical cystectomy: an outcome-based comparison. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 681-695.	2.4	9
1364	A realâ€¹life snapshot of the current trends of urinary diversion. <i>BJU International</i> , 2013, 112, 428-429.	2.5	0
1365	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage <scp>T</scp>1 disease and negative lymph nodes after radical cystectomy. <i>BJU International</i> , 2013, 111, 1215-1221.	2.5	55
1366	The treatment of muscle-invasive bladder cancer in elderly patients. <i>Aging Health</i> , 2013, 9, 529-538.	0.3	0
1367	Neoadjuvant chemotherapy in bladder cancer. <i>Clinical Investigation</i> , 2013, 3, 991-1002.	0.0	2
1368	Primary Bladder Preservation Treatment for Urothelial Bladder Cancer. <i>Cancer Control</i> , 2013, 20, 188-199.	1.8	26
1369	Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis. <i>BMC Urology</i> , 2013, 13, 73.	1.4	12
1370	Role of Systemic Chemotherapy in Urothelial Urinary Bladder Cancer. <i>Cancer Control</i> , 2013, 20, 200-210.	1.8	22
1371	Estrogen receptor-â€¹2 expression and pharmacological targeting in bladder cancer. <i>Oncology Reports</i> , 2013, 30, 131-138.	2.6	32
1372	Increased expression of â€¹-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer. <i>Oncology Reports</i> , 2013, 30, 1073-1080.	2.6	23

#	ARTICLE	IF	CITATIONS
1373	Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer. <i>Oncology Letters</i> , 2013, 5, 229-235.	1.8	21
1374	Cistectomía radical laparoscópica: técnica y resultados en 100 pacientes consecutivos. <i>Revista Chilena De Cirugía</i> , 2013, 65, 150-156.	0.1	1
1375	Radical cystectomy is the treatment of choice for invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2013, 3, 409.	0.6	10
1376	In favour of bladder preservation using combined modality treatment. <i>Canadian Urological Association Journal</i> , 2013, 3, 412.	0.6	2
1377	HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3). <i>Archivio Italiano Di Urologia Andrologia</i> , 2013, 85, 73.	0.8	10
1378	Pure Laparoscopic Radical Cystectomy with Ileal Conduit: A Single Surgeon's Mid-Term Outcomes. <i>Yonsei Medical Journal</i> , 2013, 54, 912.	2.2	8
1379	Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohort. <i>Canadian Urological Association Journal</i> , 2013, 7, 552.	0.6	34
1380	Update on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2013, 4, 56.	0.6	84
1381	A case of isolated rectal recurrence of muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2013, 7, 376.	0.6	1
1382	Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy + concomitant boost, with or without concurrent cisplatin, for patients with invasive bladder cancer – clinical outcome. <i>Wspolczesna Onkologia</i> , 2013, 3, 302-306.	1.4	3
1383	Can Neutrophil-Lymphocyte Ratio and Lymph Node Density Be Used as Prognostic Factors in Patients Undergoing Radical Cystectomy?. <i>Scientific World Journal</i> , The, 2013, 2013, 1-5.	2.1	30
1384	Surveillance strategies after definitive therapy of invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2013, 3, 237.	0.6	32
1385	Role of lymphadenectomy for invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2013, 3, 206.	0.6	3
1386	Autologous Immunotherapy as a Novel Treatment for Bladder Cancer. , 2013, , .		0
1387	Metastasis After Primary Treatment – Peri-Operative and Bladder-Preservation Therapy in Muscle Invasive Diseases. , 2013, , .		0
1388	Identification of lymphatic pathway involved in the spread of bladder cancer: Evidence obtained from fluorescence navigation with intraoperatively injected indocyanine green. <i>Canadian Urological Association Journal</i> , 2013, 7, 322.	0.6	16
1389	Determining when to recommend continent urinary diversion. <i>Canadian Urological Association Journal</i> , 2013, 2, 407.	0.6	3
1390	Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat. <i>Canadian Urological Association Journal</i> , 2013, 3, 232.	0.6	8

#	ARTICLE	IF	CITATIONS
1391	Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder. Canadian Urological Association Journal, 2013, 6, E116-E120.	0.6	0
1392	Laparoscopic versus Open Radical Cystectomy in Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Studies. PLoS ONE, 2014, 9, e95667.	2.5	88
1393	Peri-Operative Morbidity Associated with Radical Cystectomy in a Multicenter Database of Community and Academic Hospitals. PLoS ONE, 2014, 9, e111281.	2.5	84
1394	Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients. Cancer Management and Research, 2014, 6, 459.	1.9	19
1395	CISTECTOMIA RADICAL POR CÂNCER VESICAL EN UN HOSPITAL DOCENTE-ASISTENCIAL: ANÁLISIS DE RESULTADOS PERIOPERATORIOS. Revista Chilena De Cirugía, 2014, 66, 351-358.	0.1	0
1396	Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. Canadian Urological Association Journal, 2014, 8, 287.	0.6	11
1397	Factors affecting recurrence and progression in intravesical BCG treated high grade non muscle invasive bladder cancer. Pakistan Journal of Medical Sciences, 2014, 30, 326-30.	0.6	10
1398	Current Evidence for the Treatment of Bladder Cancer. The Ewha Medical Journal, 2014, 37, 1.	0.2	1
1400	Long-Term Oncologic Outcomes after Radical Cystectomy for Bladder Cancer at a Single Institution. Journal of Korean Medical Science, 2014, 29, 669.	2.5	6
1401	Systemic therapy for bladder cancer â€“ a medical oncologistâ€™s perspective. Journal of Solid Tumors, 2014, 4, 25-35.	0.1	14
1402	Loss of expression of the tumour suppressor gene <i>AIMP3</i> predicts survival following radiotherapy in muscle-invasive bladder cancer. International Journal of Cancer, 2015, 136, 709-720.	5.1	24
1403	Cistectomia radical / experi�ncia de um centro oncol�gico. Acta Urol�gica Portuguesa, 2014, 31, 63-68.	0.1	0
1404	Muscle-invasive bladder cancer: evaluating treatment and survival in the <sc>National </sc> <sc>Cancer </sc> <sc>Data </sc> <sc>Base </sc>. BJU International, 2014, 114, 719-726.	2.5	132
1405	Impact of <i>ERBB2</i> mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biology and Therapy, 2014, 15, 1239-1247.	3.4	30
1406	Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder. Journal of Translational Medicine, 2014, 12, 199.	4.4	14
1407	Incidental Sonographic Detection of Non-Muscle-Invasive Papillary Urothelial Carcinoma in a Low-Risk Patient. Journal of Diagnostic Medical Sonography, 2014, 30, 34-38.	0.3	0
1408	Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer. Journal of Radiotherapy in Practice, 2014, 13, 428-437.	0.5	8
1409	Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer. Tumor Biology, 2014, 35, 10249-10257.	1.8	91

#	ARTICLE	IF	CITATIONS
1410	A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2014, 53, 1321-1328.	1.8	31
1411	What About Conventional Laparoscopic Radical Cystectomy? Cost-Analysis of Open Versus Laparoscopic Radical Cystectomy. <i>Journal of Endourology</i> , 2014, 28, 410-415.	2.1	9
1413	Strategies to improve quality of life in bladder cancer patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 537-544.	1.4	3
1414	The effects of a physical exercise programme after radical cystectomy for urinary bladder cancer. A pilot randomized controlled trial. <i>Clinical Rehabilitation</i> , 2014, 28, 451-459.	2.2	38
1415	Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. <i>Cancers</i> , 2014, 6, 2313-2329.	3.7	14
1416	S292: Risk factors associated with postoperative complications following radical cystectomy. <i>European Urology Supplements</i> , 2014, 13, e1600.	0.1	0
1417	Knowledge of the harms of tobacco use among patients with bladder cancer. <i>Cancer</i> , 2014, 120, 3914-3922.	4.1	37
1418	Scoring system development for prediction of extravesical bladder cancer. <i>Vojnosanitetski Pregled</i> , 2014, 71, 851-857.	0.2	5
1419	Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-6.	0.9	12
1420	Characterization of Uptake and Internalization of Exosomes by Bladder Cancer Cells. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	172
1421	Conditional survival after radical cystectomy. <i>Nature Reviews Urology</i> , 2014, 11, 8-9.	3.8	4
1423	Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1429-1443.	2.4	1
1424	Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy. <i>BJU International</i> , 2014, 113, 554-560.	2.5	43
1425	Bladder Carcinoma. <i>Medical Radiology</i> , 2014, , 377-386.	0.1	1
1426	Radical Cystectomy in the Elderly: National Trends and Disparities in Perioperative Outcomes and Quality of Care. <i>Urologia Internationalis</i> , 2014, 92, 27-34.	1.3	35
1427	Giant neobladder stone. <i>ANZ Journal of Surgery</i> , 2014, 84, 390-391.	0.7	4
1428	Outcomes After Urothelial Recurrence in Bladder Cancer Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2014, 84, 1420-1426.	1.0	38
1429	Racial variation in the quality of surgical care for bladder cancer. <i>Cancer</i> , 2014, 120, 1018-1025.	4.1	46

#	ARTICLE	IF	CITATIONS
1430	ULTRASONOGRAPHIC FINDINGS RELATED TO PROGNOSIS IN CANINE TRANSITIONAL CELL CARCINOMA. Veterinary Radiology and Ultrasound, 2014, 55, 79-84.	0.9	20
1431	Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233. Journal of Clinical Oncology, 2014, 32, 3801-3809.	1.6	353
1432	Disparity in bladder cancer outcomes: What's sex got to do with it?. Cancer, 2014, 120, 461-463.	4.1	2
1433	Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1108-1115.	1.6	24
1434	S117: Patterns, risks and outcomes of urethral recurrence after radical cystectomy for urothelial cancer; over 20 year single center experience. European Urology Supplements, 2014, 13, e1482.	0.1	0
1435	Contemporary 90-day mortality rates after radical cystectomy in the elderly. European Journal of Surgical Oncology, 2014, 40, 1738-1745.	1.0	80
1436	Pseudoaneurysm of the anterior tibial artery after ankle arthroscopy. ANZ Journal of Surgery, 2014, 84, 391-393.	0.7	7
1437	Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. BJU International, 2014, 114, 221-228.	2.5	75
1438	Downregulation of <sc>DAB</sc>2<sc>IP</sc> results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. Cancer Science, 2014, 105, 704-712.	3.9	52
1439	Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer, 2014, 120, 1272-1280.	4.1	60
1440	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU International, 2014, 113, 11-23.	2.5	274
1441	Extended vs nonâ€extended pelvic lymph node dissection and their influence on recurrenceâ€free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and metaâ€analysis of comparative studies. BJU International, 2014, 113, E39-48.	2.5	62
1443	Role of fluorodeoxyglucose positron emission tomography (<sc>FDG PET</sc>)â€computed tomography (<sc>CT</sc>) in the staging of bladder cancer. BJU International, 2014, 114, 389-395.	2.5	102
1444	Radical cystectomy and the implications of comorbidity. Expert Review of Anticancer Therapy, 2014, 14, 289-295.	2.4	15
1445	Pure intracorporeal laparoscopic radical cystectomy with orthotopic â€Uâ€shaped ileal neobladder. BMC Urology, 2014, 14, 89.	1.4	8
1446	Influence of Histologic Criteria and Confounding Factors in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (pT3a). American Journal of Surgical Pathology, 2014, 38, 167-175.	3.7	16
1447	Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer. Clinical Nuclear Medicine, 2014, 39, e308-e312.	1.3	39
1448	Tumor Regression Grade of Urothelial Bladder Cancer After Neoadjuvant Chemotherapy. American Journal of Surgical Pathology, 2014, 38, 325-332.	3.7	34

#	ARTICLE	IF	CITATIONS
1449	Neobladders and continent catheterizable stomas for the bladder cancer survivor. <i>Current Opinion in Urology</i> , 2014, 24, 407-414.	1.8	6
1450	Everything Old Is New Again! Neoadjuvant Chemotherapy in the Treatment of Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1868-1870.	1.6	16
1451	Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario. <i>Canadian Urological Association Journal</i> , 2014, 8, 297.	0.6	3
1452	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014, 8, 309.	0.6	12
1453	Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 206.	2.8	17
1454	Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin. <i>Urologia Internationalis</i> , 2014, 92, 180-185.	1.3	7
1455	Computed tomography imaging-guided percutaneous argon-helium cryoablation of muscle-invasive bladder cancer: Initial experience in 32 patients. <i>Cryobiology</i> , 2014, 69, 318-322.	0.7	12
1456	Patterns of Practice in the Radiation Therapy for Bladder Cancer: Survey of the Japanese Radiation Oncology Study Group (JROSG). <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1109-1115.	1.3	9
1457	The Charlson Comorbidity Index Predicts Survival after Disease Recurrence in Patients following Radical Cystectomy for Urothelial Carcinoma of the Bladder. <i>Urologia Internationalis</i> , 2014, 93, 303-310.	1.3	27
1458	Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review. <i>Journal of Contemporary Brachytherapy</i> , 2014, 2, 191-199.	0.9	13
1459	Status of Her2 over expression in muscle invasive urothelial bladder carcinoma: Report of 21 cases. <i>Urology Annals</i> , 2014, 6, 63.	0.6	10
1460	Importance of the Neutrophil-to-Lymphocyte Ratio in Muscle-Invasive and Non-Muscle Invasive Bladder Tumors. <i>Urologia</i> , 2014, 81, 120-124.	0.7	22
1461	Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	46
1462	Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. <i>Radiation Oncology</i> , 2014, 9, 213.	2.7	15
1463	Oncologic Outcome after Laparoscopic Radical Cystectomy without Neoadjuvant or Adjuvant Therapy with a Median Follow-Up of 32 Months. <i>Urologia Internationalis</i> , 2014, 92, 55-63.	1.3	2
1464	Her2/neu expression in urothelial dysplasia, carcinoma in situ, and superficial urothelial carcinoma and its value in assessing the response to BCG therapy. <i>Egyptian Journal of Pathology</i> , 2014, 34, 25-31.	0.0	1
1465	Adjuvant chemotherapy for bladder cancer—why does level 1 evidence not support it?. <i>Annals of Oncology</i> , 2014, 25, 1930-1934.	1.2	20
1466	Decreased expression of c-Src in human transitional cell carcinoma. <i>Biomarkers and Genomic Medicine</i> , 2014, 6, 37-42.	0.2	1

#	ARTICLE	IF	CITATIONS
1467	Follow-up after cystectomy: Regularly scheduled, risk adjusted, or symptom guided?. European Journal of Surgical Oncology, 2014, 40, 1677-1685.	1.0	22
1468	Impact of robotics on the outcome of elderly patients with endometrial cancer. Gynecologic Oncology, 2014, 133, 556-562.	1.4	70
1469	Local and systemic recurrence patterns of urothelial cancer after radical cystectomy. Kaohsiung Journal of Medical Sciences, 2014, 30, 504-509.	1.9	8
1470	18F-fluorodeoxyglucoseâ€“Positron Emission Tomography/Computed Tomography Aids Staging and Predicts Mortality in Patients With Muscle-invasive Bladder Cancer. Urology, 2014, 83, 393-399.	1.0	41
1471	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 433-440.	1.6	31
1472	Oncologic Outcomes Following Robot-assisted Radical Cystectomy with Minimum 5-year Follow-up: The Roswell Park Cancer Institute Experience. European Urology, 2014, 66, 920-928.	1.9	44
1473	Preservaci3n vesical electiva en tumor vesical m3sculo invasivo. Actas Urol3gicas Espa3olas, 2014, 38, 7-13.	0.7	2
1474	The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. World Journal of Urology, 2014, 32, 453-459.	2.2	24
1475	Standardized assessment of complications in a contemporary series of <scp>E</scp>uropean patients undergoing radical cystectomy. International Journal of Urology, 2014, 21, 143-149.	1.0	106
1476	Robotic Surgery of the Bladder. , 2014, , .		2
1477	Muscle Invasive Bladder Cancer: Examining Survivor Burden and Unmet Needs. Journal of Urology, 2014, 191, 48-53.	0.4	99
1478	Long-term changes in renal function outcomes following radical cystectomy and urinary diversion. International Journal of Clinical Oncology, 2014, 19, 1105-1111.	2.2	35
1479	Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer. World Journal of Urology, 2014, 32, 1463-1468.	2.2	6
1480	Gender-specific survival following radical cystectomy for pT4 bladder cancer. World Journal of Urology, 2014, 32, 1433-1439.	2.2	21
1481	Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World Journal of Urology, 2014, 32, 1295-1301.	2.2	13
1482	Comparison of early postoperative morbidity after robotâ€“assisted and open radical cystectomy: results of a prospective observational study. BJU International, 2014, 113, 458-467.	2.5	61
1483	Î±4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients. European Journal of Cancer, 2014, 50, 840-851.	2.8	11
1484	Human urinary bladder regeneration through tissue engineering â€“ An analysis of 131 clinical cases. Experimental Biology and Medicine, 2014, 239, 264-271.	2.4	58

#	ARTICLE	IF	CITATIONS
1485	Metastatic Behavior of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: Association with Primary Tumor Location. <i>Annals of Surgical Oncology</i> , 2014, 21, 1038-1045.	1.5	45
1486	Increasing Utilization of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer in the United States. <i>Current Urology Reports</i> , 2014, 15, 394.	2.2	24
1487	Accurate Determination of the Pathological Stage with Gross Dissection Protocol for Radical Cystectomy. <i>Pathology and Oncology Research</i> , 2014, 20, 677-685.	1.9	5
1488	Clinicopathological Characteristics of Incidental Prostate Cancer Discovered from Radical Cystoprostatectomy Specimen: A Multicenter French Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 684-690.	1.5	22
1489	Oncologic outcomes between open and robotic-assisted radical cystectomy: a propensity score matched analysis. <i>World Journal of Urology</i> , 2014, 32, 1441-1446.	2.2	12
1490	Urinary functional outcomes in female neobladder patients. <i>World Journal of Urology</i> , 2014, 32, 221-228.	2.2	41
1491	Elective bladder-sparing treatment for muscle invasive bladder cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 7-13.	0.2	1
1492	Impact of Bladder Cancer on Health Related Quality of Life in 1,476 Older Americans: A Cross-Sectional Study. <i>Journal of Urology</i> , 2014, 192, 690-695.	0.4	42
1493	In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 53.e9-53.e14.	1.6	15
1494	Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC). <i>World Journal of Urology</i> , 2014, 32, 1281-1285.	2.2	24
1495	Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. <i>BJU International</i> , 2014, 114, 67-74.	2.5	46
1496	CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. <i>Modern Pathology</i> , 2014, 27, 87-95.	5.5	74
1497	A prospective randomised controlled trial of laparoscopic vs open radical cystectomy for bladder cancer: perioperative and oncologic outcomes with 5-year follow-upT Lin et al. <i>British Journal of Cancer</i> , 2014, 110, 842-849.	6.4	60
1498	Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2014, 21, 3-4.	1.0	12
1499	Efficacy of robot-assisted radical cystectomy (<sc>RARC</sc>) in advanced bladder cancer: results from the <sc>International <sc>Radical <sc>Cystectomy <sc>Consortium (<sc>IRCC</sc>). <i>BJU International</i> , 2014, 114, 98-103.	2.5	14
1500	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. <i>Cancer Research</i> , 2014, 74, 5808-5818.	0.9	24
1501	Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 966-974.	1.6	33
1502	Critical analysis of the 2010 TNM classification in patients with lymph node-positive bladder cancer: Influence of lymph node disease burden. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1003-1009.	1.6	9

#	ARTICLE	IF	CITATIONS
1503	Relationship of the Number of Removed Lymph Nodes to Bladder Cancer and Competing Mortality After Radical Cystectomy. <i>European Urology</i> , 2014, 66, 987-990.	1.9	34
1504	Neoadjuvante chemotherapie voor het spierinvasief urotheelcelcarcinoom van de blaas: een landelijke inventarisatie. <i>Tijdschrift Voor Urologie</i> , 2014, 4, 50-56.	0.1	0
1505	Sexual dysfunction after cystectomy and urinary diversion. <i>Nature Reviews Urology</i> , 2014, 11, 445-453.	3.8	70
1506	Intermediate-Term Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Urothelial Carcinoma. <i>Journal of Endourology</i> , 2014, 28, 939-945.	2.1	29
1507	Long-term Outcomes in Treatment of Invasive Bladder Cancer With Concomitant Boost and Accelerated Hyperfractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 562-569.	0.8	3
1508	Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. <i>European Journal of Radiology</i> , 2014, 83, 2013-2018.	2.6	48
1509	The Health Economics of Bladder Cancer: An Updated Review of the Published Literature. <i>Pharmacoeconomics</i> , 2014, 32, 1093-1104.	3.3	166
1510	Curative Therapy for Bladder Cancer in Routine Clinical Practice: A Population-based Outcomes Study. <i>Clinical Oncology</i> , 2014, 26, 506-514.	1.4	54
1511	Risk Prediction Models of Locoregional Failure After Radical Cystectomy for Urothelial Carcinoma: External Validation in a Cohort of Korean Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1032-1037.	0.8	23
1512	Adherence to surveillance guidelines after radical cystectomy: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 779-784.	1.6	12
1513	Multimodal management of muscle-invasive bladder cancer. <i>Current Problems in Cancer</i> , 2014, 38, 80-108.	2.0	76
1514	Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1078-1087.	1.6	42
1515	The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells. <i>BMC Cancer</i> , 2014, 14, 412.	2.6	33
1517	Outcomes of a bladder preservation technique in female patients undergoing pelvic exenteration surgery for advanced gynaecological tumours. <i>International Urogynecology Journal</i> , 2014, 25, 953-960.	1.4	2
1518	Seeking a standard for adequate pathologic lymph node staging in primary bladder carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 595-602.	2.8	5
1519	Significance of ERBB2 Overexpression in Therapeutic Resistance and Cancer-Specific Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Selective Bladder-Sparing Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 303-311.	0.8	34
1520	Synchronous bladder and prostate cancers in the specimens of radical cystoprostatectomy: A multicenter retrospective analysis. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 371-375.	1.9	2
1521	The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 317-326.	1.6	25

#	ARTICLE	IF	CITATIONS
1522	Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 117-127.	1.6	87
1523	MP5-11 THE IMPACT OF LENGTH OF URETERAL RESECTION ON BENIGN URETERO-INTESTINAL STRICTURE RATE IN ILEAL CONDUIT OR ILEAL NEOBLADDER URINARY DIVERSION FOLLOWING CYSTECTOMY. Journal of Urology, 2014, 191, .	0.4	0
1524	Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Human Pathology, 2014, 45, 674-682.	2.0	49
1525	Seminal-sparing Cystectomy: Technical Evolution and Results Over a 20-Year Period. Urology, 2014, 83, 856-862.	1.0	10
1526	Robotic vs. open radical cystectomy in bladder cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2014, 40, 1399-1411.	1.0	66
1527	Treating octogenarians with muscle-invasive bladder cancer: Preoperative opportunities for increasing the benefits of surgical intervention. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 37.e13-37.e16.	1.6	5
1528	Detubularised isolated ureterosigmoidostomy (Atta pouch): Manometric and radiological studies in a sample of patients. Arab Journal of Urology Arab Association of Urology, 2014, 12, 197-203.	1.5	3
1529	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. European Urology, 2014, 66, 361-370.	1.9	125
1530	Late Recurrence after Radical Cystectomy: Patterns, Risk Factors and Outcomes. Journal of Urology, 2014, 191, 1256-1261.	0.4	18
1531	Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Journal of Urology, 2014, 191, 40-47.	0.4	153
1532	Trends in the Utilization of Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Results From the National Cancer Database. Urology, 2014, 83, 75-80.	1.0	126
1533	Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: Prognostic value in invasive urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 648-656.	1.6	19
1534	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 52.e1-52.e9.	1.6	55
1535	Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination Chemotherapy. Journal of Urology, 2014, 191, 35-39.	0.4	6
1536	Robotic and Laparoscopic Radical Cystectomy for Bladder Cancer: Long-term Oncologic Outcomes. European Urology, 2014, 65, 193-200.	1.9	103
1537	Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 326-331.	0.8	72
1538	Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. European Journal of Surgical Oncology, 2014, 40, 121-127.	1.0	132
1539	Radical Cystectomy in a Dutch University Hospital: Long-Term Outcomes and Prognostic Factors in a Homogeneous Surgery-Only Series. Clinical Genitourinary Cancer, 2014, 12, 190-195.	1.9	14

#	ARTICLE	IF	CITATIONS
1540	Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. <i>European Urology</i> , 2014, 66, 1157-1164.	1.9	163
1541	The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy. <i>Journal of Urology</i> , 2014, 192, 714-720.	0.4	22
1542	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841.	0.4	19
1543	T2 Muscle-Invasive Bladder Cancer. <i>Seminars in Oncology</i> , 2014, 41, e11-e18.	2.2	0
1544	Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy. <i>International Journal of Urology</i> , 2014, 21, 52-57.	1.0	29
1545	Outcome in patients with exclusive carcinoma <i>in situ</i> (<scp>CIS</scp>) after radical cystectomy. <i>BJU International</i> , 2014, 113, 65-69.	2.5	13
1546	Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients. <i>Clinical and Translational Oncology</i> , 2014, 16, 91-95.	2.4	5
1547	Screening candidate genes associated with bladder cancer using DNA microarray. <i>Molecular Medicine Reports</i> , 2014, 10, 3087-3091.	2.4	1
1548	The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): A new treatment option for invasive bladder cancer patients with lymph node metastasis. <i>International Journal of Oncology</i> , 2014, 44, 1895-1903.	3.3	13
1549	Predictors of Outcome in Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1549-1554.	4.9	4
1550	Role of osteopontin in the regulation of human bladder cancer proliferation and migration in T24 cells. <i>Molecular Medicine Reports</i> , 2015, 11, 3701-3707.	2.4	15
1551	Pelvic Irradiation and Its Effects on the Lower Urinary Tract: a Literature Review. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 295-302.	0.5	1
1552	Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population-based study. <i>BJU International</i> , 2015, 116, 18-25.	2.5	29
1553	Effect of quantum dots on the biological behavior of the EJ human bladder urothelial carcinoma cell line. <i>Molecular Medicine Reports</i> , 2015, 12, 6157-6163.	2.4	3
1555	Histological variant as the significant predictor of survival in patients with lymph node positive urothelial carcinoma of the bladder. <i>Scientific Reports</i> , 2015, 5, 9626.	3.3	11
1556	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. <i>European Urology Focus</i> , 2015, 1, 75-81.	3.1	6
1560	Prognostic effect of preoperative anemia in patients who have undergone radical cystectomy for bladder cancer. <i>Cancer Treatment Communications</i> , 2015, 4, 196-199.	0.4	4
1561	Enteroplastias de sustitución en el varón: fundamentos y realización. <i>EMC - Urología</i> , 2015, 47, 1-26.	0.0	0

#	ARTICLE	IF	CITATIONS
1564	Commentaar. Is er een plaats voor de laparoscopische radicale cystectomie bij de behandeling van spierinvasief blaascarcinoom?. Tijdschrift Voor Urologie, 2015, 5, 104-105.	0.1	1
1565	Current status of robotic assisted radical cystectomy with intracorporeal ileal neobladder for bladder cancer. Journal of Surgical Oncology, 2015, 112, 427-429.	1.7	11
1566	Pelvic recurrence after radical cystectomy: a call to arms. BJU International, 2015, 116, 172-173.	2.5	10
1568	Robot-assisted radical cystectomy. Journal of Surgical Oncology, 2015, 112, 728-735.	1.7	3
1569	Comparative impact of continent and incontinent urinary diversion on long-term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a. International Journal of Urology, 2015, 22, 651-656.	1.0	33
1570	Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years. Bladder Cancer, 2015, 1, 3-13.	0.4	9
1571	Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma. Current Opinion in Urology, 2015, 25, 468-475.	1.8	2
1572	Orthotopic urinary diversion. Current Opinion in Urology, 2015, 25, 545-549.	1.8	18
1573	Bladder reconstruction: The past, present and future. Oncology Letters, 2015, 10, 3-10.	1.8	41
1574	Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy. International Journal of Urology, 2015, 22, 742-746.	1.0	22
1575	Functional and Clinicopathologic Outcomes Using a Modified Vescica Ileale Padovana Technique. Bladder Cancer, 2015, 1, 73-79.	0.4	4
1576	The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer. Bladder Cancer, 2015, 1, 45-63.	0.4	7
1577	Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time. Canadian Urological Association Journal, 2015, 9, 236.	0.6	8
1578	The prognostic significance of preoperative leukocytosis and neutrophil-to-lymphocyte ratio in patients who underwent radical cystectomy for bladder cancer. Canadian Urological Association Journal, 2015, 9, 789.	0.6	25
1579	Impact of lymphovascular invasion on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection. OncoTargets and Therapy, 2015, 8, 3401.	2.0	4
1580	Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease. Bladder Cancer, 2015, 1, 105-116.	0.4	13
1581	Optimal management of muscle-invasive bladder cancer – a review. Research and Reports in Urology, 2015, 7, 143.	1.0	19
1582	Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging?. Bladder Cancer, 2015, 1, 91-96.	0.4	12

#	ARTICLE	IF	CITATIONS
1583	The Role of Population-Based Observational Research in Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 123-131.	0.4	1
1584	New and Promising Strategies in the Management of Bladder Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 105-112.	3.8	20
1585	Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 65-72.	0.4	69
1586	External Validation of Models for Prediction of Lymph Node Metastasis in Urothelial Carcinoma of the Bladder. <i>PLoS ONE</i> , 2015, 10, e0120552.	2.5	5
1587	Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0131245.	2.5	42
1588	MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. <i>PLoS ONE</i> , 2015, 10, e0143441.	2.5	44
1590	Adjuvant Chemotherapy Correlates with Improved Survival after Radical Cystectomy in Patients with pT3b (Macroscopic Perivesical Tissue Invasion) Bladder Cancer. <i>Journal of Cancer</i> , 2015, 6, 750-758.	2.5	14
1591	Outcomes of Trimodality Approach in the Management of T2N0M0 Bladder Cancer. <i>Tumori</i> , 2015, 101, 232-237.	1.1	1
1592	Immediate Radical Cystectomy for Massive Bleeding of Bladder Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-4.	1.9	5
1593	The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer. <i>Advances in Urology</i> , 2015, 2015, 1-6.	1.3	10
1594	Complications of Radical Cystectomy and Orthotopic Reconstruction. <i>Advances in Urology</i> , 2015, 2015, 1-7.	1.3	41
1595	Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients. <i>Bladder Cancer</i> , 2015, 1, 143-150.	0.4	3
1596	Estimation of mortality and morbidity risk of radical cystectomy using POSSUM and the Portsmouth predictor equation. <i>Central European Journal of Urology</i> , 2015, 68, 270-6.	0.3	7
1597	Long-term Disease-free Survival after Hepatic Metastasectomy for Urothelial Carcinoma of the Bladder: A Case Report and Review of the Literature. <i>Clinical Medicine Insights Urology</i> , 2015, 8, CMU.S29263.	0.4	1
1598	Continuous chemoradiation following complete response to neo-adjuvant chemotherapy provides improved outcomes in muscle invasive urothelial carcinoma. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	0
1602	Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: A new paradigm to be explored?. <i>International Urology and Nephrology</i> , 2015, 47, 1129-1134.	1.4	10
1603	Is Frozen Section Analysis of Ureteral Margins at Time of Radical Cystectomy Useful?. <i>Current Urology Reports</i> , 2015, 16, 38.	2.2	10
1604	Long-term Oncologic Outcomes Following Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>European Urology</i> , 2015, 68, 721-728.	1.9	143

#	ARTICLE	IF	CITATIONS
1605	Outcomes of Radical Cystectomy in Potential Candidates for Bladder Preservation Therapy. <i>Urology</i> , 2015, 85, 869-875.	1.0	18
1606	Electrochemical immunosensor for detecting typical bladder cancer biomarker based on reduced graphene oxide-tetraethylene pentamine and trimetallic AuPdPt nanoparticles. <i>Talanta</i> , 2015, 143, 77-82.	5.5	41
1607	Does skip metastasis or other lymph node parameters have additional effects on survival of patients undergoing radical cystectomy for bladder cancer?. <i>Korean Journal of Urology</i> , 2015, 56, 357.	1.2	8
1608	Diagnosis of Bladder Carcinoma. <i>Surgical Pathology Clinics</i> , 2015, 8, 677-685.	1.7	17
1609	Patterns of care for readmission after radical cystectomy in New York State and the effect of care fragmentation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 426.e13-426.e19.	1.6	21
1610	Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. <i>Oncology Reports</i> , 2015, 34, 2738-2744.	2.6	17
1611	Concomitant Gleason Score ≥ 7 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy. <i>International Urology and Nephrology</i> , 2015, 47, 1789-1796.	1.4	7
1612	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 76-86.	10.7	323
1613	Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent. <i>World Journal of Urology</i> , 2015, 33, 813-819.	2.2	6
1614	Bladder Preservation Strategies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 289-300.	2.2	10
1615	The prognostic value of pretreatment of systemic inflammatory responses in patients with urothelial carcinoma undergoing radical cystectomy. <i>British Journal of Cancer</i> , 2015, 112, 461-467.	6.4	55
1617	The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. <i>BJU International</i> , 2015, 115, 198-205.	2.5	73
1618	Radical Cystectomy and Adjuvant Chemotherapy for Bladder Cancer in the Elderly: A Population-based Study. <i>Urology</i> , 2015, 85, 791-798.	1.0	46
1619	Forkhead box protein P3 (Foxp3) expression serves as an early chronic inflammation marker of squamous cell differentiation and aggressive pathology of urothelial carcinomas in neurological patients. <i>BJU International</i> , 2015, 115, 28-32.	2.5	10
1620	The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect. <i>International Journal of Radiation Biology</i> , 2015, 91, 368-378.	1.8	48
1621	Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 731-742.	3.3	14
1622	Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review. <i>European Urology</i> , 2015, 67, 876-888.	1.9	72
1623	Novel Bladder Preservation Therapy with Osaka Medical College Regimen. <i>Journal of Urology</i> , 2015, 193, 443-450.	0.4	13

#	ARTICLE	IF	CITATIONS
1624	Systematic Review and Cumulative Analysis of Oncologic and Functional Outcomes After Robot-assisted Radical Cystectomy. <i>European Urology</i> , 2015, 67, 402-422.	1.9	199
1625	Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 387.e17-387.e27.	1.6	39
1626	Three-tiered nodal classification system for bladder cancer: a new proposal. <i>Future Oncology</i> , 2015, 11, 399-408.	2.4	4
1627	Differences in the recurrence pattern after neoadjuvant chemotherapy compared to surgery alone in patients with muscle-invasive bladder cancer. <i>Medical Oncology</i> , 2015, 32, 421.	2.5	9
1628	Subcutaneous Injections of the Mannose-Sensitive Hemagglutination Pilus Strain of <i>Pseudomonas aeruginosa</i> Stimulate Host Immunity, Reduce Bladder Cancer Size and Improve Tumor Survival in Mice. <i>Cell Biochemistry and Biophysics</i> , 2015, 73, 245-252.	1.8	4
1629	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015, 68, 238-253.	1.9	211
1630	Extracapsular Extension of Pelvic Lymph Node Metastasis is an Independent Prognostic Factor in Bladder Cancer: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 3745-3750.	1.5	27
1631	Surgical landscape of radical cystectomy for bladder cancer in France over the last 10 years. <i>World Journal of Urology</i> , 2015, 33, 889-890.	2.2	1
1632	Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. <i>World Journal of Urology</i> , 2015, 33, 1429-1437.	2.2	31
1633	Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis. <i>Biomarkers in Medicine</i> , 2015, 9, 187-197.	1.4	10
1634	Standardized analysis of complications after robot-assisted radical cystectomy: Korea University Hospital experience. <i>Korean Journal of Urology</i> , 2015, 56, 48.	1.2	7
1635	Efficacy of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 717-724.	1.8	25
1636	Robot-Assisted Radical Cystectomy Using a Side-Docking Technique. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2015, 25, 207-211.	1.0	5
1637	An improved technique for bladder cancer: Pure laparoscopic radical cystectomy with orthotopic U-shape ileal neobladder using titanium staples. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1522-1528.	1.0	2
1638	Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 339.e1-339.e8.	1.6	21
1639	Controversies in Robotics: Open Versus Robotic Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 421-427.	1.9	17
1640	High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e243-e251.	1.9	22
1641	Urethral recurrence in women with orthotopic bladder substitutes: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 204.e17-204.e23.	1.6	24

#	ARTICLE	IF	CITATIONS
1642	Sources of variation in follow-up expenditure after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 267.e31-267.e37.	1.6	2
1643	Prediction of mortality after radical cystectomy for bladder cancer by machine learning techniques. Computers in Biology and Medicine, 2015, 63, 124-132.	7.0	71
1644	Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. Journal of Urology, 2015, 194, 1220-1225.	0.4	9
1645	Pitfalls and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Urinary Bladder Cancer. Translational Oncology, 2015, 8, 217-230.	3.7	47
1646	Resolution of hypercalcemia of malignancy following radical cystectomy in a patient with paraneoplastic syndrome associated with urothelial carcinoma of the bladder. Urology Annals, 2015, 7, 86.	0.6	6
1647	Randomized Trial of Studer Pouch versus T-Pouch Orthotopic Ileal Neobladder in Patients with Bladder Cancer. Journal of Urology, 2015, 194, 433-440.	0.4	41
1648	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 386.e7-386.e13.	1.6	31
1649	Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer. Urologic Clinics of North America, 2015, 42, 217-224.	1.8	9
1650	Editorial Comment. Urology, 2015, 85, 888-889.	1.0	0
1651	Videourodynamic Evaluation of Intracorporeally Reconstructed Orthotopic U-shaped Ileal Neobladders. Urology, 2015, 85, 883-889.	1.0	16
1652	The effect of length of ureteral resection on benign ureterointestinal stricture rate in ileal conduit or ileal neobladder urinary diversion following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 65.e1-65.e8.	1.6	46
1653	New Trends in the Surgical Management of Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 253-269.	2.2	9
1654	Radical Transurethral Resection Alone, Robotic or Partial Cystectomy, or Extended Lymphadenectomy. Urologic Clinics of North America, 2015, 42, 189-199.	1.8	7
1655	Lessons Learned from Routine Intraoperative Ureteral Margin Frozen Sections during Radical Cystectomy. Urology Practice, 2015, 2, 90-95.	0.5	0
1656	Neoadjuvant Chemotherapy in the Management of Muscle-Invasive Bladder Cancer. Urologic Clinics of North America, 2015, 42, 181-187.	1.8	7
1659	Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting. Journal of Cancer Research and Clinical Oncology, 2015, 141, 169-176.	2.5	16
1660	Case report. Patiënt met poortmetastasen na een robotgeassisteerde radicale cystectomie. Tijdschrift Voor Urologie, 2015, 5, 62-64.	0.1	0
1661	Prospective validation of DACH2 as a novel biomarker for prediction of metastasis and prognosis in muscle-invasive urothelial carcinoma of the bladder. Biochemical and Biophysical Research Communications, 2015, 459, 416-423.	2.1	3

#	ARTICLE	IF	CITATIONS
1662	Evaluation of the response chemotherapy for penile metastasis of bladder cancer using 18F-fluorodeoxyglucose-PET/CT. International Journal of Surgery Case Reports, 2015, 11, 33-36.	0.6	6
1663	Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. BMC Urology, 2015, 15, 15.	1.4	1
1664	FDG PET-CT for Lymph Node Staging of Bladder Cancer: A Prospective Study of Patients with Extended Pelvic Lymphadenectomy. Annals of Surgical Oncology, 2015, 22, 3150-3156.	1.5	52
1665	Perioperative Strategies to Reduce Postoperative Complications After Radical Cystectomy. Current Urology Reports, 2015, 16, 26.	2.2	3
1666	A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC). Critical Reviews in Oncology/Hematology, 2015, 94, 105-115.	4.4	65
1667	Validation of a Coding Algorithm to Identify Bladder Cancer and Distinguish Stage in an Electronic Medical Records Database. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 303-307.	2.5	15
1668	Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. Clinical Genitourinary Cancer, 2015, 13, e153-e158.	1.9	10
1670	Orthotopic Bladder Substitution. , 2015, , 165-173.		0
1671	Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. Journal of Urology, 2015, 194, 790-798.	0.4	85
1672	Nutritional predictors of complications following radical cystectomy. World Journal of Urology, 2015, 33, 1129-1137.	2.2	48
1673	Immunohistochemical assessment of lymphatic and blood vessel invasion in T1 urothelial carcinoma of the bladder. Scandinavian Journal of Urology, 2015, 49, 382-387.	1.0	11
1674	Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Critical Reviews in Oncology/Hematology, 2015, 95, 387-396.	4.4	100
1675	Female reproductive organ-sparing radical cystectomy. Current Opinion in Urology, 2015, 25, 105-110.	1.8	21
1676	11C-Choline PET/CT and Bladder Cancer. Clinical Nuclear Medicine, 2015, 40, e124-e128.	1.3	30
1677	Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2015, 13, e229-e233.	1.9	42
1678	Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treatment Reviews, 2015, 41, 341-353.	7.7	43
1679	Perioperative Therapy for Muscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 301-318.	2.2	5
1680	Quality of Life and Overall Survival in High Risk Patients After Radical Cystectomy With a Simple Urinary Derivation. Cirug�a Espa�ola (English Edition), 2015, 93, 368-374.	0.1	0

#	ARTICLE	IF	CITATIONS
1681	Utility of SAM68 in the progression and prognosis for bladder cancer. BMC Cancer, 2015, 15, 364.	2.6	16
1682	An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer. BMC Urology, 2015, 15, 59.	1.4	14
1683	Adjuvant Chemotherapy Is Possibly Beneficial for Locally Advanced or Node-Positive Bladder Cancer. Clinical Genitourinary Cancer, 2015, 13, e107-e112.	1.9	7
1684	Sentinel lymph node: established and new areas of use. Clinical and Translational Imaging, 2015, 3, 225-236.	2.1	8
1685	Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. Journal of Urology, 2015, 194, 1567-1574.	0.4	69
1686	Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy. Japanese Journal of Clinical Oncology, 2015, 45, 963-967.	1.3	1
1688	Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer, 2015, 15, 447.	2.6	53
1689	Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway. Journal of Urology, 2015, 194, 1209-1213.	0.4	90
1690	Gasless Single-Port RoboSurgeon Surgery in Urology. , 2015, , .		5
1691	Treatment and Outcomes of Urethral Recurrence of Urinary Bladder Cancer in Women after Radical Cystectomy and Orthotopic Neobladder: A Series of 12 Cases. Urologia Internationalis, 2015, 94, 45-49.	1.3	13
1692	Pelvic local recurrence in a patient with muscle-invasive bladder cancer treated with interstitial thermal therapy and interstitial brachytherapy. Practical Radiation Oncology, 2015, 5, e483-e487.	2.1	0
1693	Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy. BMC Urology, 2015, 15, 53.	1.4	19
1694	Patterns, risks and outcomes of urethral recurrence after radical cystectomy for urothelial cancer; over 20 year single center experience. International Journal of Surgery, 2015, 13, 148-151.	2.7	22
1695	Modelling bladder cancer in mice: opportunities and challenges. Nature Reviews Cancer, 2015, 15, 42-54.	28.4	114
1696	Radical cystectomy vs. chemoradiation in T2-4aNOMO bladder cancer: A case-control study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 19.e1-19.e5.	1.6	40
1698	Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. European Journal of Surgical Oncology, 2015, 41, 368-377.	1.0	52
1699	Prostate Capsule Sparing versus Nerve Sparing Radical Cystectomy for Bladder Cancer: Results of a Randomized, Controlled Trial. Journal of Urology, 2015, 193, 64-70.	0.4	28
1702	Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: A systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). Critical Reviews in Oncology/Hematology, 2015, 93, 36-49.	4.4	18

#	ARTICLE	IF	CITATIONS
1703	Long-term analysis of oncological outcomes after laparoscopic radical cystectomy in Europe: results from a multicentre study by the European Association of Urology (EAU) section of Urologic Technology. BJU International, 2015, 115, 937-945.	2.5	48
1704	Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy. World Journal of Urology, 2015, 33, 373-379.	2.2	10
1705	The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. Bladder Cancer, 2016, 2, 319-327.	0.4	21
1706	Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience. Ecancermedicalscience, 2016, 10, 657.	1.1	4
1707	Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma. Yonsei Medical Journal, 2016, 57, 831.	2.2	12
1708	Pelvic Lymph Node Dissection may be Limited on the Contralateral Side in Strictly Unilateral Bladder Cancer without Compromising Oncological Radicality. Bladder Cancer, 2016, 2, 53-59.	0.4	6
1709	Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer, 2016, 2, 215-224.	0.4	32
1710	Is there a measurable association of epidural use at cystectomy and postoperative outcomes? A population-based study. Canadian Urological Association Journal, 2016, 10, 321.	0.6	19
1711	Laparoscopic Radical Cystectomy in the Elderly – Results of a Single Center LRC only Series. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 1099-1108.	1.5	6
1712	Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy. Bladder Cancer, 2016, 2, 101-109.	0.4	31
1713	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. Bladder Cancer, 2016, 2, 263-272.	0.4	7
1714	Treatment of Muscle-Invasive Bladder Cancer in Older Patients. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e228-e233.	3.8	4
1715	Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Translational Andrology and Urology, 2016, 5, 735-744.	1.4	43
1716	Radical cystectomy with pelvic lymphadenectomy: pathologic, operative and morbidity outcomes in a Brazilian cohort. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 431-437.	1.5	5
1717	Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?. Translational Andrology and Urology, 2016, 5, 702-710.	1.4	13
1718	Unusual presentation of bladder cancer resurgence and efficacy of radiotherapy. BMJ Case Reports, 2016, 2016, bcr2015213538.	0.5	1
1719	Low Grade Lymphoma Mimicking Metastatic Urothelial Carcinoma: When Do We Need Further Histologic Staging?. Case Reports in Oncological Medicine, 2016, 2016, 1-6.	0.3	1
1720	Functional Assessment of the Hautmann Ileal Neobladder with Chimney Modification Using Uroflowmetry and a Questionnaire. BioMed Research International, 2016, 2016, 1-6.	1.9	6

#	ARTICLE	IF	CITATIONS
1721	Past, present and future of urological robotic surgery. Investigative and Clinical Urology, 2016, 57, 75.	2.0	25
1722	Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 234-241.	1.5	20
1723	Benefits of Minimal Access Surgery in Elderly Patients with Pelvic Cancer. Cancers, 2016, 8, 12.	3.7	12
1724	The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma. Bladder Cancer, 2016, 2, 425-432.	0.4	23
1725	Robotic Assisted Radical Cystectomy with Extracorporeal Urinary Diversion Does Not Show a Benefit over Open Radical Cystectomy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 2016, 11, e0166221.	2.5	68
1726	Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer. OncoTargets and Therapy, 2016, Volume 9, 4917-4922.	2.0	19
1727	Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon β Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Annals of Surgical Oncology, 2016, 23, 4110-4114.	1.5	22
1728	Incidence and risk factors for acute kidney injury after radical cystectomy. International Journal of Urology, 2016, 23, 558-563.	1.0	16
1729	Clinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery. International Journal of Urology, 2016, 23, 132-137.	1.0	5
1730	The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Scientific Reports, 2016, 6, 19740.	3.3	157
1731	Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Scientific Reports, 2016, 6, 20894.	3.3	15
1733	C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy. Oncology Letters, 2016, 12, 3995-4000.	1.8	15
1734	miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death and Disease, 2016, 7, e2503-e2503.	6.3	93
1735	Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor. Medicine (United States), 2016, 95, e5372.	1.0	44
1736	Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers. Current Treatment Options in Oncology, 2016, 17, 15.	3.0	10
1737	CCR7 as a predictive biomarker associated with computed tomography for the diagnosis of lymph node metastasis in bladder carcinoma. Oncology Letters, 2016, 11, 735-740.	1.8	7
1738	Biased Expression of the FOXP3 ³ Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. Clinical Cancer Research, 2016, 22, 5349-5361.	7.0	21
1739	Venous thromboembolism after radical cystectomy: Experience with screening ultrasonography. Arab Journal of Urology Arab Association of Urology, 2016, 14, 37-43.	1.5	6

#	ARTICLE	IF	CITATIONS
1740	Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e393-e399.	1.9	2
1741	Thermal dosimetry for bladder hyperthermia treatment. An overview. <i>International Journal of Hyperthermia</i> , 2016, 32, 417-433.	2.5	25
1742	CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 337.e11-337.e18.	1.6	18
1743	c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelialâ€mesenchymal transition in bladder cancer by regulating Akt/GSK-3Î²/Snail signaling. <i>Cell Death and Disease</i> , 2016, 7, e2088-e2088.	6.3	94
1744	Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy. <i>World Journal of Urology</i> , 2016, 34, 41-48.	2.2	18
1745	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. <i>European Urology</i> , 2016, 70, 611-620.	1.9	120
1746	Oncological Outcomes in Patients Treated with Radical Cystectomy for Bladder Cancer: Comparison Between Open, Laparoscopic, and Robot-Assisted Approaches. <i>Journal of Endourology</i> , 2016, 30, 783-791.	2.1	32
1747	Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , 2016, 27, 1311-1316.	1.2	49
1748	Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. <i>World Journal of Urology</i> , 2016, 34, 1567-1573.	2.2	19
1749	Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 271-278.	1.6	8
1750	Hyperthermia and radiotherapy in bladder cancer. <i>International Journal of Hyperthermia</i> , 2016, 32, 398-406.	2.5	15
1751	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. <i>Journal of Urology</i> , 2016, 196, 1036-1041.	0.4	33
1752	Perioperative change in neutrophilâ€lymphocyte ratio predicts the overall survival of patients with bladder cancer undergoing radical cystectomy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1162-1167.	1.3	13
1753	Malignant ureteroenteric anastomotic stricture following radical cystectomy with urinary diversion: Patterns, risk factors, and outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 485.e1-485.e6.	1.6	13
1754	Ulceration in bladder cancer associates with extravesical disease, independent of cell cycle, or hypoxia pathways status. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e9-484.e17.	1.6	1
1755	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 533.e1-533.e10.	1.6	17
1756	Robot-assisted laparoscopic radical cystectomy with complete intracorporeal urinary diversion. <i>Asian Journal of Urology</i> , 2016, 3, 156-166.	1.2	12
1757	Unmet informational and supportive care needs of patients following cystectomy for bladder cancer based on age, sex, and treatment choices. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 531.e7-531.e14.	1.6	58

#	ARTICLE	IF	CITATIONS
1758	The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy. Journal of Health Communication, 2016, 21, 99-104.	2.4	55
1759	Development and Validation of a Quality Assurance Score for Robot-assisted Radical Cystectomy: A 10-year Analysis. Urology, 2016, 97, 124-129.	1.0	30
1760	Concurrent chemoradiotherapy in elderly patients with muscle-invasive bladder cancer: A single-center experience. Journal of Cancer Research and Practice, 2016, 3, 73-76.	0.2	3
1761	High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG—Shortage. Current Urology Reports, 2016, 17, 68.	2.2	64
1762	Contemporary evidence for robot-assisted radical cystectomy for treating bladder cancer. Nature Reviews Urology, 2016, 13, 533-539.	3.8	12
1763	Bladder Preservation for Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 151-163.	0.4	25
1764	A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surgical Oncology, 2016, 25, 281-297.	1.6	87
1765	Radio-Guided Lymph Node Mapping in Bladder Cancer Using SPECT/CT and Intraoperative ^{131}I -Probe Methods. Clinical Nuclear Medicine, 2016, 41, e362-e367.	1.3	9
1766	Systemic therapy for bladder cancer finally comes into a new age. Future Oncology, 2016, 12, 2227-2242.	2.4	6
1767	Enteroplastiche di sostituzione nell'uomo: principio e realizzazione. EMC - Tecniche Chirurgiche - Chirurgia Generale, 2016, 16, 1-25.	0.0	0
1768	Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPAR γ signalling pathway. Scientific Reports, 2016, 6, 35783.	3.3	90
1769	Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—Results of a nationwide population-based study. European Journal of Cancer, 2016, 69, 1-8.	2.8	39
1770	Trends in cancer of the urinary bladder and urinary tract in elderly in Denmark, 2008–2012. Acta Oncologica, 2016, 55, 85-90.	1.8	8
1772	A study of the prognostic and predictive role of HER-2 expression in bladder urothelial carcinoma. Egyptian Journal of Pathology, 2016, 36, 241-250.	0.0	0
1773	Long-term results of a prospective randomized trial assessing the impact of re-adaptation of the dorsolateral peritoneal layer after extended pelvic lymph node dissection and cystectomy. BJU International, 2016, 117, 618-628.	2.5	10
1774	Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 99.	8.6	70
1775	Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. Journal of Urology, 2016, 196, 1030-1035.	0.4	23
1776	Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients. Radiation Oncology, 2016, 11, 45.	2.7	29

#	ARTICLE	IF	CITATIONS
1777	Bladder Preservation Therapy: A Review of the Literature and Future Directions. <i>Urology</i> , 2016, 96, 54-61.	1.0	16
1778	Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. <i>Future Oncology</i> , 2016, 12, 1795-1804.	2.4	11
1779	The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e1-484.e8.	1.6	66
1780	Effects of an autologous fibrin sealant on lymphatic leakage after radical cystectomy: <scp>A</scp> matched case-control study. <i>Surgical Practice</i> , 2016, 20, 119-123.	0.2	1
1781	Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy. <i>Urologia Internationalis</i> , 2016, 96, 51-56.	1.3	45
1782	Critical Analysis of Early Recurrence after Laparoscopic Radical Cystectomy in a Large Cohort by the ESUT. <i>Journal of Urology</i> , 2016, 195, 1710-1717.	0.4	38
1783	Prognostic value of Ki67 and p63 expressions in bladder cancer patients who underwent radical cystectomy. <i>International Urology and Nephrology</i> , 2016, 48, 495-501.	1.4	19
1784	Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. <i>Journal of Urology</i> , 2016, 195, 1911-1919.	0.4	35
1786	Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e59-e65.	1.9	50
1787	The interplay of extracellular matrix and microbiome in urothelial bladder cancer. <i>Nature Reviews Urology</i> , 2016, 13, 77-90.	3.8	89
1788	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. <i>British Journal of Cancer</i> , 2016, 114, 207-212.	6.4	53
1789	Novel therapeutic targets in advanced urothelial carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 106-115.	4.4	45
1790	Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. <i>European Journal of Surgical Oncology</i> , 2016, 42, 735-743.	1.0	49
1791	Oncologic Equivalence between Laparoscopic/Robotic and Open Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 1646-1647.	0.4	5
1792	Radical cystectomy in the treatment of bladder cancer in Iceland: A population-based study. <i>Scandinavian Journal of Urology</i> , 2016, 50, 65-70.	1.0	4
1793	Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e1-256.e6.	1.6	86
1794	The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. <i>World Journal of Urology</i> , 2016, 34, 1229-1237.	2.2	69
1795	PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes. <i>Urology</i> , 2016, 91, 241.e1-241.e7.	1.0	125

#	ARTICLE	IF	CITATIONS
1796	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 4.e11-4.e17.	1.6	14
1797	A Review of Neoadjuvant and Adjuvant Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer. <i>Urology Practice</i> , 2016, 3, 41-49.	0.5	0
1798	Perioperative management and oncological outcomes following radical cystectomy for bladder cancer: a matched retrospective cohort study. <i>Canadian Journal of Anaesthesia</i> , 2016, 63, 584-595.	1.6	24
1799	Analysis of open and intracorporeal robotic assisted radical cystectomy shows no significant difference in recurrence patterns and oncological outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 257.e1-257.e9.	1.6	32
1800	The Role of Surgery in Local Recurrences after Radical Cystectomy for Bladder Cancer. <i>Urologia Internationalis</i> , 2016, 96, 132-135.	1.3	3
1801	Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor. <i>Toxicology and Applied Pharmacology</i> , 2016, 290, 98-106.	2.8	11
1802	Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?. <i>European Journal of Cancer</i> , 2016, 54, 69-74.	2.8	12
1803	Open radical cystectomy: still the gold standard for muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 33-39.	2.2	28
1804	Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan. <i>Tumor Biology</i> , 2016, 37, 6971-6977.	1.8	12
1805	Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 262-270.	1.6	8
1806	A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2016, 195, 880-885.	0.4	22
1807	Preconcentration-enhanced immunosensing for whole human cancer cell lysate based on a nanofluidic preconcentrator. <i>Biochip Journal</i> , 2016, 10, 159-166.	4.9	5
1808	Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1031-1039.	0.8	33
1809	Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival. <i>World Journal of Urology</i> , 2016, 34, 569-576.	2.2	21
1810	Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis. <i>Clinical Cancer Research</i> , 2016, 22, 1086-1094.	7.0	27
1812	Comparing RECIST with EORTC criteria in metastatic bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 187-194.	2.5	12
1813	Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 59.e1-59.e8.	1.6	51
1814	An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e67-e74.	1.9	2

#	ARTICLE	IF	CITATIONS
1815	Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2016, 34, 695-701.	2.2	3
1816	Comparison of Perioperative Morbidity of Radical Cystectomy With Neobladder Versus Ileal Conduit: A Matched Pair Analysis of 170 Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 244-248.	1.9	11
1817	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. <i>Oncogene</i> , 2016, 35, 1541-1553.	5.9	108
1818	The morbidity of laparoscopic radical cystectomy: analysis of postoperative complications in a multicenter cohort by the European Association of Urology (EAU)-Section of Uro-Technology. <i>World Journal of Urology</i> , 2016, 34, 149-156.	2.2	29
1819	A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 53-59.	0.4	95
1820	A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium. <i>Urologia Internationalis</i> , 2016, 96, 5-13.	1.3	27
1821	The Prognostic Significance of the Early Postoperative Neutrophil-to-Lymphocyte Ratio in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2016, 23, 335-342.	1.5	50
1822	Lymph node dissection in bladder cancer: Where do we stand?. <i>World Journal of Urology</i> , 2017, 35, 527-533.	2.2	9
1823	Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 145-151.e2.	1.9	40
1824	Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2017, 35, 229-235.	2.2	25
1825	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017, 71, 462-475.	1.9	1,241
1826	Feasibility of photoacoustic evaluations on dual-wavelength thermal treatment of <i>ex vivo</i> bladder tumors. <i>Journal of Biophotonics</i> , 2017, 10, 577-588.	2.3	13
1827	Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. <i>Journal of Surgical Oncology</i> , 2017, 115, 455-461.	1.7	46
1828	Three-dimensional texture features from intensity and high-order derivative maps for the discrimination between bladder tumors and wall tissues via MRI. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2017, 12, 645-656.	2.8	58
1829	Patterns of Referral to Radiation Oncology among Patients with Bladder Cancer: a Population-based Study. <i>Clinical Oncology</i> , 2017, 29, 171-179.	1.4	17
1830	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. <i>European Urology</i> , 2017, 71, 961-969.	1.9	154
1831	Revisión sistemática de resultados perioperatorios y complicaciones después de cistectomía radical abierta, laparoscópica y asistida por robot. <i>Actas Urológicas Españolas</i> , 2017, 41, 416-425.	0.7	16
1832	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>European Urology</i> , 2017, 71, 952-960.	1.9	253

#	ARTICLE	IF	CITATIONS
1833	Bacillus Calmette-Guerin improves local and systemic response to radiotherapy in invasive bladder cancer. Nitric Oxide - Biology and Chemistry, 2017, 64, 22-30.	2.7	5
1834	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treatment Reviews, 2017, 54, 1-9.	7.7	44
1835	Radical cystectomy: do we need standardization?. Expert Review of Anticancer Therapy, 2017, 17, 101-107.	2.4	1
1836	Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. Urology, 2017, 102, 148-158.	1.0	12
1837	Current Concepts in the Management of Muscle Invasive Bladder Cancer. Indian Journal of Surgical Oncology, 2017, 8, 74-81.	0.7	9
1838	Systematic review of the oncological and functional outcomes of pelvic organâ€preserving radical cystectomy (<scp>RC</scp>) compared with standard <scp>RC</scp> in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU International, 2017, 120, 12-24.	2.5	63
1839	An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program. Urology, 2017, 103, 91-98.	1.0	27
1840	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Scientific Reports, 2017, 7, 42713.	3.3	85
1841	Peri-operative allogeneic blood transfusion and outcomes after radical cystectomy: a population-based study. World Journal of Urology, 2017, 35, 1435-1442.	2.2	23
1842	Induction of mitochondrial-dependent apoptosis in T24 cells by a selenium (Se)-containing polysaccharide from Ginkgo biloba L. leaves. International Journal of Biological Macromolecules, 2017, 101, 126-130.	7.5	48
1843	Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 458.e1-458.e7.	1.6	7
1844	Preoperative prediction of muscular invasiveness of bladder cancer with radiomic features on conventional MRI and its high-order derivative maps. Abdominal Radiology, 2017, 42, 1896-1905.	2.1	47
1845	Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 457.e15-457.e21.	1.6	18
1847	Lymph node density vs. the American Joint Committee on Cancer TNM nodal staging system in node-positive bladder cancer in patients undergoing extended or super-extended pelvic lymphadenectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 151.e1-151.e7.	1.6	15
1848	Fluorescence-Based Molecular Imaging of Porcine Urinary Bladder Sentinel Lymph Nodes. Journal of Nuclear Medicine, 2017, 58, 547-553.	5.0	24
1849	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. ESMO Open, 2017, 2, e000123.	4.5	5
1850	Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer. Medical Oncology, 2017, 34, 90.	2.5	16
1851	Bladder cancer. Nature Reviews Disease Primers, 2017, 3, 17022.	30.5	590

#	ARTICLE	IF	CITATIONS
1852	Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. <i>Advances in Anatomic Pathology</i> , 2017, 24, 113-127.	4.3	47
1853	Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumor staging in patients undergoing radical cystectomy for bladder cancer. <i>Asian Journal of Urology</i> , 2017, 4, 239-246.	1.2	14
1854	Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer. <i>Cancer Causes and Control</i> , 2017, 28, 755-766.	1.8	23
1855	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <i>Journal of Urology</i> , 2017, 198, 817-823.	0.4	31
1856	Deep Surgical Site Infections after Open Radical Cystectomy and Urinary Diversion Significantly Increase Hospitalisation Time and Total Treatment Costs. <i>Urologia Internationalis</i> , 2017, 98, 268-273.	1.3	9
1857	Preoperative determinant of early postoperative renal function following radical cystectomy and intestinal urinary diversion. <i>International Urology and Nephrology</i> , 2017, 49, 233-238.	1.4	10
1858	Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2201-2214.	4.1	59
1859	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. <i>Urology</i> , 2017, 106, 119-124.	1.0	8
1860	Advances in medical imaging for the diagnosis and management of common genitourinary cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 473-491.	1.6	44
1862	The Role of Robotics in the Invasive Management of Bladder Cancer. <i>Current Urology Reports</i> , 2017, 18, 57.	2.2	4
1863	Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. <i>Cancer</i> , 2017, 123, 3524-3531.	4.1	28
1864	Emerging drugs for urothelial (bladder) cancer. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 149-164.	2.4	9
1865	MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway. <i>Molecular Cancer</i> , 2017, 16, 96.	19.2	80
1866	Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma. <i>Oncology Letters</i> , 2017, 13, 875-880.	1.8	6
1867	Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant?. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 382-387.	1.9	9
1868	p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. <i>Histopathology</i> , 2017, 71, 296-304.	2.9	37
1869	The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769118.	1.8	8
1870	Management and Survival of Elderly and Very Elderly Patients with Endometrial Cancer: An Age-Stratified Study of 1228 Women from the FRANCOGYN Group. <i>Annals of Surgical Oncology</i> , 2017, 24, 1667-1676.	1.5	27

#	ARTICLE	IF	CITATIONS
1871	Contemporary update on neoadjuvant therapy for bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 348-358.	3.8	24
1872	A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapyâ€”A single-institution experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 38.e9-38.e15.	1.6	9
1873	A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 689-696.	1.7	9
1874	News in diagnosis, treatment, and risk group assessment. <i>Nature Reviews Urology</i> , 2017, 14, 74-76.	3.8	10
1875	Robot-assisted surgery in elderly and very elderly population: our experience in oncologic and general surgery with literature review. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 55-63.	2.9	55
1876	Genetic polymorphisms of IL-18 rs1946518 and IL-1 β rs16944 are associated with prognosis and survival of acute myeloid leukemia. <i>Inflammation Research</i> , 2017, 66, 249-258.	4.0	27
1877	Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer?. <i>Human Pathology</i> , 2017, 61, 190-198.	2.0	9
1878	Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study. <i>Nutrition and Cancer</i> , 2017, 69, 1196-1204.	2.0	10
1879	Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization. <i>Biochemical and Biophysical Research Communications</i> , 2017, 494, 165-172.	2.1	30
1880	MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelialâ€”mesenchymal transition progression in bladder cancer. <i>Cell Death and Disease</i> , 2017, 8, e3010-e3010.	6.3	53
1881	Understanding Simple Cystectomy for Benign Disease: A Unique Patient Cohort With Significant Risks. <i>Urology</i> , 2017, 110, 239-243.	1.0	7
1882	Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery. <i>Biomaterials</i> , 2017, 145, 233-241.	11.4	47
1883	Bladder Preservation Therapies in Bladder Cancer. , 2017, , 85-101.		0
1884	Comparative analysis between radical cystectomy and trimodality therapy for clinical stage II bladder cancer â€” Experience from a tertiary referral center. <i>Urological Science</i> , 2017, , .	0.6	0
1885	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 672.e1-672.e6.	1.6	4
1886	The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. <i>Cancer</i> , 2017, 123, 4574-4582.	4.1	36
1887	Curcumin inhibits bladder cancer progression via regulation of β -catenin expression. <i>Tumor Biology</i> , 2017, 39, 101042831770254.	1.8	27
1888	Systematic review of perioperative outcomes and complications after open, laparoscopic and robot-assisted radical cystectomy. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2017, 41, 416-425.	0.2	4

#	ARTICLE	IF	CITATIONS
1890	Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. <i>Pharmacogenomics</i> , 2017, 18, 1167-1178.	1.3	7
1891	Laparoscopic and robotic nephroureterectomy: does lymphadenectomy have an impact on the clinical outcome?. <i>International Urology and Nephrology</i> , 2017, 49, 1785-1792.	1.4	6
1892	Is it the End for Urologic Pelvic Laparoscopic Surgery?. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2017, 27, 139-146.	0.8	4
1893	Management of Non-muscle-Invasive and Muscle-Invasive Bladder Cancers. , 2017, , 59-74.		1
1894	Surgical robots for radical cystectomies in a medium-volume hospital. <i>Surgical Practice</i> , 2017, 21, 136-140.	0.2	0
1895	High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 191-199.	0.4	4
1896	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 272-294.	0.1	6
1897	Landmarks in the treatment of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 565-574.	3.8	122
1898	Oncologic surveillance following radical cystectomy: an individualized risk-based approach. <i>World Journal of Urology</i> , 2017, 35, 1863-1869.	2.2	8
1899	Robot-Assisted Laparoscopic Surgery for the Treatment of Urological Malignancy. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 343-347.	0.7	0
1900	Editorial comment. <i>Urology</i> , 2017, 106, 124.	1.0	0
1901	Robotic-assisted radical cystectomy versus open radical cystectomy for management of bladder cancer: review of literature and randomized trials. <i>Future Oncology</i> , 2017, 13, 1195-1204.	2.4	3
1902	The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy. <i>International Urology and Nephrology</i> , 2017, 49, 1577-1583.	1.4	25
1903	Impact of suboptimal neoadjuvant chemotherapy on perioperative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study. <i>BJU International</i> , 2017, 119, 605-611.	2.5	20
1904	Does steep Trendelenburg positioning effect the ocular hemodynamics and intraocular pressure in patients undergoing robotic cystectomy and robotic prostatectomy?. <i>International Urology and Nephrology</i> , 2017, 49, 55-60.	1.4	14
1905	90-Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study. <i>World Journal of Urology</i> , 2017, 35, 907-911.	2.2	90
1906	Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e45-e52.	1.9	12
1907	Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 224-233.	6.4	39

#	ARTICLE	IF	CITATIONS
1908	Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. World Journal of Urology, 2017, 35, 657-663.	2.2	13
1909	A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. International Journal of Cancer, 2017, 140, 381-389.	5.1	33
1910	Port-Site Metastases After Robotic Radical Cystectomy: A Systematic Review and Management Options. Clinical Genitourinary Cancer, 2017, 15, 440-444.	1.9	15
1911	Functional Outcomes Following Radical Cystectomy in Women with Bladder Cancer: A Systematic Review. European Urology Focus, 2017, 3, 136-143.	3.1	46
1912	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clinical Genitourinary Cancer, 2017, 15, 356-362.	1.9	31
1913	Facing the Fate of the Remnant Urothelium After Radical Cystectomy: There Is Room for Improvement. European Urology, 2017, 71, 558-559.	1.9	0
1914	External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 740-746.	0.8	7
1915	Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 34.e1-34.e8.	1.6	12
1916	Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nature Reviews Clinical Oncology, 2017, 14, 221-234.	27.6	89
1917	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e267-e273.	1.9	33
1918	Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection. Oncology Reports, 2017, 37, 2761-2770.	2.6	13
1919	Urothelial Carcinoma with Squamous Differentiation is Associated with High Tumor Stage and Pelvic Lymph-Node Metastasis. Cancer Control, 2017, 24, 78-82.	1.8	38
1922	Readmission Rate and Causes at 90-Day after Radical Cystectomy in Patients on Early Recovery after Surgery Protocol. Bladder Cancer, 2017, 3, 51-56.	0.4	43
1923	Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. Bladder Cancer, 2017, 3, 105-112.	0.4	9
1924	The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer, 2017, 3, 19-30.	0.4	22
1925	The Inhibitory Effect of PDIA6 Downregulation on Bladder Cancer Cell Proliferation and Invasion. Oncology Research, 2017, 25, 587-593.	1.5	30
1927	Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer. Oncotarget, 2017, 8, 61404-61414.	1.8	28
1928	Oncologic Outcomes after Radical Cystectomy: Comparison between Primary and Progressive Muscle Invasive Bladder Cancer. Journal of Cancer Science & Therapy, 2017, 09, .	1.7	0

#	ARTICLE	IF	CITATIONS
1929	Oncologic Outcomes and Predictive Factors for Recurrence Following Robot-Assisted Radical Cystectomy for Urothelial Carcinoma: Multicenter Study from Korea. Journal of Korean Medical Science, 2017, 32, 1662.	2.5	4
1930	Gender-related Outcome in Bladder Cancer Patients undergoing Radical Cystectomy. Journal of Cancer, 2017, 8, 3567-3574.	2.5	16
1931	Functional Assay of Cancer Cell Invasion Potential Based on Mechanotransduction of Focused Ultrasound. Frontiers in Oncology, 2017, 7, 161.	2.8	29
1932	Partial cystectomy for urothelial carcinoma of the bladder: Practice patterns and outcomes in the general population. Canadian Urological Association Journal, 2017, 11, 412-8.	0.6	6
1933	Evidence of Atypical Recurrences After Robot-Assisted Radical Cystectomy: A Comprehensive Review of the Literature. Bladder Cancer, 2017, 3, 231-236.	0.4	17
1934	Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. Oncotarget, 2017, 8, 95620-95631.	1.8	38
1935	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. Translational Andrology and Urology, 2017, 6, 1067-1080.	1.4	19
1936	Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study. PLoS ONE, 2017, 12, e0174978.	2.5	18
1937	Prognostic implications of preoperative anemia in urothelial carcinoma: A meta-analysis. PLoS ONE, 2017, 12, e0171701.	2.5	9
1938	IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer. BMC Cancer, 2017, 17, 636.	2.6	18
1939	Transperineal cryotherapy for unresectable muscle invasive bladder cancer: preliminary experience with 7 male patients. BMC Urology, 2017, 17, 81.	1.4	5
1940	Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget, 2017, 8, 56398-56407.	1.8	25
1941	The delivery of radical radiotherapy to the bladder and pelvis in node-positive (N1) bladder cancer: a five patient case series. BJR case Reports, 2017, 3, 20160102.	0.2	1
1942	Transitional metaplasia in intestinal epithelium of rats submitted to intestinal cystoplasty and treatment with L-lysine. Acta Cirurgica Brasileira, 2017, 32, 297-306.	0.7	1
1943	Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study. Bladder Cancer, 2017, 3, 35-44.	0.4	13
1944	Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2017, 11, 24.	0.6	8
1945	Lymphadenectomy in Muscle Invasive Bladder Cancer. , 0, , .		1
1946	The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. Molecular and Clinical Oncology, 2017, 7, 1112-1118.	1.0	6

#	ARTICLE	IF	CITATIONS
1947	Impact of CD44 expression on radiation response for bladder cancer. <i>Journal of Cancer</i> , 2017, 8, 1137-1144.	2.5	35
1948	PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. <i>Oncotarget</i> , 2017, 8, 66849-66864.	1.8	47
1949	Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis. <i>Oncotarget</i> , 2017, 8, 68996-69004.	1.8	30
1950	Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-12.	2.1	9
1951	Immune Checkpoint Blockade in Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2109-2112.	1.6	11
1952	Evolving Treatment of Advanced Urothelial Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 309-315.	2.5	18
1953	Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017. <i>Translational Andrology and Urology</i> , 2017, 6, 1049-1059.	1.4	3
1954	Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2017, 8, 81204-81214.	1.8	23
1955	The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1191-1200.	2.2	12
1957	Bladder and Upper Urinary Tract Urothelial Cancer. , 2018, , 73-104.		1
1958	Sarcopenia as a comorbidityâ€independent predictor of survival following radical cystectomy for bladder cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 505-513.	7.3	93
1959	Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1201-1207.	2.2	68
1960	Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis. <i>International Journal of Surgery</i> , 2018, 52, 214-220.	2.7	9
1961	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 423-431.	1.6	16
1962	Are There Extended Benefits with Extended Lymph Node Dissection During Radical Prostatectomy?. <i>European Urology</i> , 2018, 74, 138-139.	1.9	2
1963	Enhanced Recovery After Surgery Pathways. <i>Urologic Clinics of North America</i> , 2018, 45, 229-239.	1.8	5
1964	A Genomic-clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. <i>EBioMedicine</i> , 2018, 31, 54-65.	6.1	25
1965	SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival. <i>Oncogene</i> , 2018, 37, 3937-3952.	5.9	44

#	ARTICLE	IF	CITATIONS
1966	Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. <i>Cancer</i> , 2018, 124, 3127-3135.	4.1	37
1967	Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 434-440.	2.5	13
1968	Rates and Predictors of Conversion to Open Surgery During Minimally Invasive Radical Cystectomy. <i>Journal of Endourology</i> , 2018, 32, 488-494.	2.1	4
1969	Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. <i>BJU International</i> , 2018, 122, 89-98.	2.5	28
1970	Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. <i>Bladder Cancer</i> , 2018, 4, 31-40.	0.4	15
1971	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. <i>BJU International</i> , 2018, 122, 627-632.	2.5	24
1972	Improved surgical outcomes following radical cystectomy at high-volume centers influence overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 308.e11-308.e17.	1.6	33
1973	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e879-e892.	1.9	25
1974	Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. <i>Cell Death and Disease</i> , 2018, 9, 274.	6.3	28
1977	MiR-22 suppresses epithelial-mesenchymal transition in bladder cancer by inhibiting Snail and MAPK1/Slug/vimentin feedback loop. <i>Cell Death and Disease</i> , 2018, 9, 209.	6.3	73
1978	Flavonoid silybin improves the response to radiotherapy in invasive bladder cancer. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 5402-5412.	2.6	17
1979	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. <i>World Journal of Urology</i> , 2018, 36, 639-644.	2.2	18
1980	Kidney, Ureteral, and Bladder Cancer. <i>Medical Clinics of North America</i> , 2018, 102, 231-249.	2.5	11
1981	Contribution of bladder cancer pathology assessment in planning clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 39, 713-719.	1.6	8
1982	Impact of body mass index on the oncological outcomes of patients with upper and lower urinary tract cancers treated with radical surgery: A multi-institutional retrospective study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 310-317.	1.1	7
1983	A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. <i>Oncogene</i> , 2018, 37, 1911-1925.	5.9	102
1984	Nivolumab for the treatment of urothelial cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 215-221.	2.4	18
1985	Outcomes of Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Urology</i> , 2018, 199, 1302-1311.	0.4	154

#	ARTICLE	IF	CITATIONS
1986	Conduit Urinary Diversion. Urologic Clinics of North America, 2018, 45, 25-36.	1.8	17
1987	It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer—A competing risks analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 39-42.	1.6	2
1988	Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. BJU International, 2018, 121, 745-751.	2.5	37
1989	Automatic T1 bladder tumor detection by using wavelet analysis in cystoscopy images. Physics in Medicine and Biology, 2018, 63, 035031.	3.0	9
1990	Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis. Scientific Reports, 2018, 8, 374.	3.3	10
1991	Precision Molecular Pathology of Bladder Cancer. Molecular Pathology Library, 2018, , .	0.1	0
1994	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. Molecular Pathology Library, 2018, , 85-101.	0.1	0
1995	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 213-218.	1.9	13
1996	Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis. World Journal of Urology, 2018, 36, 331-340.	2.2	26
1997	Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. Radiotherapy and Oncology, 2018, 127, 136-142.	0.6	10
1998	Role of bowel suspension technique to prevent early intestinal obstruction after radical cystectomy with ileal orthotopic neobladder: A retrospective cohort study. International Journal of Surgery, 2018, 55, 9-14.	2.7	8
1999	Robotics in urology. Annals of the Royal College of Surgeons of England, 2018, 100, 45-54.	0.6	43
2000	Preoperative Prediction of Node Metastases in Bladder Cancer Patients Using Genomic and Clinicopathologic Data. EBioMedicine, 2018, 31, 5-6.	6.1	0
2001	Bladder-Sparing Treatments. , 2018, , 467-505.		0
2002	History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aNO M0 Bladder Cancer Patients Treated With Radical Cystectomy. Clinical Genitourinary Cancer, 2018, 16, e969-e976.	1.9	12
2003	Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. Urologic Clinics of North America, 2018, 45, 257-266.	1.8	3
2004	Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database. Journal of Urology, 2018, 200, 535-540.	0.4	4
2005	Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urologic Clinics of North America, 2018, 45, 155-167.	1.8	14

#	ARTICLE	IF	CITATIONS
2006	Quality of Life After Radical Cystectomy. <i>Urologic Clinics of North America</i> , 2018, 45, 249-256.	1.8	41
2007	Whole Versus Partial Bladder Radiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 107-114.	1.3	16
2008	Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. <i>European Urology Focus</i> , 2018, 4, 245-251.	3.1	24
2009	Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': the case for super centralisation. <i>BJU International</i> , 2018, 121, 217-224.	2.5	54
2010	Enhanced recovery after surgery for radical cystectomy with ileal urinary diversion: a multi-institutional, randomized, controlled trial from the Chinese bladder cancer consortium. <i>World Journal of Urology</i> , 2018, 36, 41-50.	2.2	47
2011	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. <i>Acta Oncologica</i> , 2018, 57, 491-497.	1.8	22
2012	Is the open cystectomy era over? An update on the available evidence. <i>International Journal of Urology</i> , 2018, 25, 187-195.	1.0	20
2013	Atezolizumab in urothelial bladder carcinoma. <i>Future Oncology</i> , 2018, 14, 331-341.	2.4	10
2014	Patient Selection and Counseling for Urinary Diversion. <i>Urologic Clinics of North America</i> , 2018, 45, 1-9.	1.8	11
2015	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 543-557.	1.9	105
2016	Cystectomy. , 2018, , 253-259.		0
2017	Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder. <i>Journal of Clinical Pathology</i> , 2018, 71, 154-160.	2.0	18
2018	Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3189-3191.	1.6	11
2019	Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer. <i>International Journal of Oncology</i> , 2019, 54, 167-176.	3.3	1
2021	Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 307-318.	3.8	35
2022	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3353-3360.	1.6	474
2023	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, 230-238.	0.6	51
2024	Atlas of PET-CT. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
2025	Detection of circulating tumor DNA for advanced bladder cancer: where are we going?. Translational Andrology and Urology, 2018, 7, S101-S103.	1.4	1
2026	Surviving travel or travelling to survive: the association of travel distance with survival in muscle invasive bladder cancer. Translational Andrology and Urology, 2018, 7, S83-S85.	1.4	5
2027	MRI Markers for Early Assessment of Bladder Cancer: A Review. , 2018, , .		4
2028	Evaluating the role of neoadjuvant chemotherapy in bladder cancer patients with occult lymph node metastases. Translational Andrology and Urology, 2018, 7, 742-744.	1.4	3
2029	Evaluation of lymph node status in patients with urothelial carcinomaâ€”still in search of the perfect imaging modality: a systematic review. Translational Andrology and Urology, 2018, 7, 783-803.	1.4	13
2030	Predictive Biomarkers for Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer: A survey. , 2018, , .		0
2032	Predictive Biomarkers for Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer: A survey. , 2018, , .		1
2033	A novel and accurate microfluidic assay of CD62L in bladder cancer serum samples. Analyst, The, 2018, 143, 5505-5511.	3.5	6
2035	A Retrospective Study Comparing Surgical and Early Oncological Outcomes between Intracorporeal and Extracorporeal Ileal Conduit after Laparoscopic Radical Cystectomy from a Single Center. Chinese Medical Journal, 2018, 131, 784-789.	2.3	7
2036	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Current Urology Reports, 2018, 19, 109.	2.2	47
2037	Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis. International Journal of Molecular Sciences, 2018, 19, 3708.	4.1	14
2038	Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. Future Science OA, 2018, 4, FSO341.	1.9	8
2039	Urologic Pathology. Surgical Pathology Clinics, 2018, 11, 893-901.	1.7	2
2040	ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk â€œBCG failureâ€”non muscle invasive bladder cancer: 3â€”years follow-up outcomes. BMC Cancer, 2018, 18, 1224.	2.6	51
2041	Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 530.e19-530.e27.	1.6	4
2042	Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population. Scientific Reports, 2018, 8, 17792.	3.3	16
2043	Laparoscopic radical cystectomy with pelvic re-peritonealization: the technique and initial clinical outcomes. BMC Urology, 2018, 18, 113.	1.4	2
2044	Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget, 2018, 9, 7961-7974.	1.8	9

#	ARTICLE	IF	CITATIONS
2045	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018, 8, 463.	2.8	27
2046	Early Complications and Mortality following Radical Cystectomy: Associations with Malnutrition and Obesity. <i>Bladder Cancer</i> , 2018, 4, 377-388.	0.4	26
2047	Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies. <i>World Journal of Surgical Oncology</i> , 2018, 16, 197.	1.9	30
2048	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. <i>Urology</i> , 2018, 122, 121-126.	1.0	5
2049	miR-203 Suppresses Bladder Cancer Cell Growth and Targets Twist1. <i>Oncology Research</i> , 2018, 26, 1155-1165.	1.5	38
2050	Semi-competing risk model to predict perioperative and oncologic outcomes after radical cystectomy. <i>Therapeutic Advances in Urology</i> , 2018, 10, 317-326.	2.0	2
2051	MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targetting ZEB2. <i>Bioscience Reports</i> , 2018, 38, .	2.4	48
2052	Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy. <i>Current Urology Reports</i> , 2018, 19, 108.	2.2	18
2053	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.4	0
2054	The Role of Lymph Node Dissection in the Treatment of Bladder Cancer. <i>Frontiers in Surgery</i> , 2018, 5, 62.	1.4	22
2055	Long-term outcomes of high-grade T1 bladder cancer treated with intravesical bacillus Calmette-Guérin: experience of a single center. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 501-508.	3.9	14
2056	National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging. <i>Cancer Medicine</i> , 2018, 7, 5370-5381.	2.8	14
2057	A patient-derived orthotopic xenograft model enabling human high-grade urothelial cell carcinoma of the bladder tumor implantation, growth, angiogenesis, and metastasis. <i>Oncotarget</i> , 2018, 9, 32718-32729.	1.8	12
2058	Management of High-grade T1 Urothelial Carcinoma. <i>Current Urology Reports</i> , 2018, 19, 103.	2.2	7
2059	Effect of variant histology presence and squamous differentiation on oncological results and patient's survival after radical cystectomy. <i>Archivio Italiano Di Urologia Andrologia</i> , 2018, 90, 172-175.	0.8	7
2060	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. <i>Surgical Pathology Clinics</i> , 2018, 11, 877-891.	1.7	0
2061	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1041-1053.	4.9	171
2062	Robotic Radical Cystectomy and Urinary Diversions: Complications and Outcomes. , 2018, , 779-790.		0

#	ARTICLE	IF	CITATIONS
2064	Laparoscopic radical cystectomy with intracorporeal ileal conduit diversion: Modified techniques and long-term outcomes. Surgical Practice, 2018, 22, 125-130.	0.2	1
2065	Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences, 2018, 19, 2568.	4.1	15
2066	The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. Cancer Treatment and Research, 2018, 175, 193-214.	0.5	3
2067	An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSH) compared to flexible cystoscopy in the diagnosis of bladder cancer. PLoS ONE, 2018, 13, e0202796.	2.5	14
2068	Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma. Current Treatment Options in Oncology, 2018, 19, 36.	3.0	22
2069	Treatment for Carcinoma In Situ. , 2018, , 213-229.		0
2070	Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. , 2018, , 337-352.		0
2071	Radical Cystectomy (RC) with Urinary Diversion. , 2018, , 353-368.		0
2072	Open Techniques and Extent (Including Pelvic Lymphadenectomy). , 2018, , 369-437.		0
2073	Adjuvant Chemotherapy. , 2018, , 451-466.		2
2074	The Surveillance for Muscle-Invasive Bladder Cancer (MIBC). , 2018, , 553-597.		1
2076	Postoperative complications and 90-day mortality in radical cystectomy in high-risk patients: A monocentric retrospective observational study. Urologia, 2018, 85, 111-117.	0.7	11
2077	Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. European Urology, 2018, 74, 465-471.	1.9	189
2078	Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images. Advances in Radiation Oncology, 2018, 3, 331-338.	1.2	14
2079	Diagnostic Accuracy of F-18 FDG PET/CT for Preoperative Lymph Node Staging in Newly Diagnosed Bladder Cancer Patients: A Systematic Review and Meta-Analysis. Oncology, 2018, 95, 31-38.	1.9	49
2080	Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. Radiotherapy and Oncology, 2018, 129, 499-506.	0.6	10
2081	Prostate sparing cystectomy for bladder cancer: A two-center study. European Journal of Surgical Oncology, 2018, 44, 1446-1452.	1.0	12
2082	Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet, The, 2018, 391, 2525-2536.	13.7	537

#	ARTICLE	IF	CITATIONS
2083	Robot-assisted versus open cystectomy. Lancet, The, 2018, 391, 2479-2480.	13.7	3
2085	The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer. Bladder Cancer, 2018, 4, 205-213.	0.4	19
2086	Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention. Molecular Nutrition and Food Research, 2018, 62, e1800079.	3.3	105
2087	Development and Validation of an MRI-Based Radiomics Signature for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. EBioMedicine, 2018, 34, 76-84.	6.1	109
2088	5 - Trattamento Chirurgico Della Malattia Muscolo-Invasiva E Localmente Avanzata (MIBC). Tumori, 2018, 104, S17-S23.	1.1	0
2089	Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treatment Reviews, 2018, 70, 88-97.	7.7	26
2090	Polymorphism in lncRNA AC008392.1 and its interaction with smoking on the risk of lung cancer in a Chinese population. Cancer Management and Research, 2018, Volume 10, 1377-1387.	1.9	13
2092	Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer. ANZ Journal of Surgery, 2018, 88, 1033-1036.	0.7	0
2093	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	1.9	61
2094	Radical treatment of muscle-invasive bladder cancer—are options equal?. Journal of Radiation Oncology, 2018, 7, 181-186.	0.7	0
2095	The prognostic significance of preoperative serum albumin in urothelial carcinoma: a systematic review and meta-analysis. Bioscience Reports, 2018, 38, .	2.4	28
2096	Computed tomography and magnetic resonance imaging evaluation of pelvic lymph node metastasis in bladder cancer. Chinese Journal of Cancer, 2018, 37, 3.	4.9	19
2097	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 19 372	1.9	372
2098	Extracellular vesicles: Toward a clinical application in urological cancer treatment. International Journal of Urology, 2018, 25, 533-543.	1.0	32
2099	CREB1, a direct target of miR-122, promotes cell proliferation and invasion in bladder cancer. Oncology Letters, 2018, 16, 3842-3848.	1.8	16
2100	Vaginal cuff recurrence after radical cystectomy: an under - studied site of bladder cancer relapse. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 491-499.	1.5	3
2101	Robot-assisted radical cystectomy with intracorporeal urinary diversion â€“ The new â€“gold standardâ€™? Evidence from a systematic review. Arab Journal of Urology Arab Association of Urology, 2018, 16, 307-313.	1.5	15
2102	Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling. Annals of Surgical Oncology, 2018, 25, 3518-3526.	1.5	27

#	ARTICLE	IF	CITATIONS
2103	AG490 reverses phenotypic alteration of dendritic cells by bladder cancer cells. <i>Oncology Letters</i> , 2018, 16, 2851-2856.	1.8	8
2104	Functionalization of single-walled carbon nanohorns for simultaneous fluorescence imaging and cisplatin delivery in vitro. <i>Carbon</i> , 2018, 138, 309-318.	10.3	26
2105	Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2018, 8, 8360.	3.3	22
2106	Beyond classic risk adjustment: Socioeconomic status and hospital performance in urologic oncology surgery. <i>Cancer</i> , 2018, 124, 3372-3380.	4.1	4
2107	Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 36-41.	1.3	41
2108	Current controversies on the role of lymphadenectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 193-200.	1.6	6
2109	Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade. <i>Asian Journal of Urology</i> , 2019, 6, 222-229.	1.2	21
2110	Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 667-690.	2.2	52
2111	Activation of type 4 metabotropic glutamate receptor promotes cell apoptosis and inhibits proliferation in bladder cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 2741-2755.	4.1	17
2112	Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). <i>Journal of Clinical Oncology</i> , 2019, 37, 2682-2688.	1.6	8
2113	Elderly patients undergoing cystectomy, comparing preoperative American Society of Anesthesiology and Eastern Cooperative Oncology Group scores and operative approaches. <i>Urologia</i> , 2019, 86, 183-188.	0.7	4
2114	Qici Sanling decoction suppresses bladder cancer growth by inhibiting the Wnt/ β -catenin pathway. <i>Pharmaceutical Biology</i> , 2019, 57, 507-513.	2.9	13
2116	Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPAR γ -mediated pathway in bladder cancer. <i>Clinical Science</i> , 2019, 133, 1745-1758.	4.3	72
2117	Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 4148-4156.	1.5	15
2118	Local Treatment, Radical Cystectomy, and Urinary Diversion. , 2019, , 351-371.		0
2119	Multimodality Treatment for Bladder Conservation. , 2019, , 373-382.		0
2120	Risk Stratification and Prognostication of Bladder Cancer. , 2019, , 423-436.		0
2121	Downregulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR-432-5p/ β -catenin feedback loop. <i>FASEB Journal</i> , 2019, 33, 10973-10985.	0.5	22

#	ARTICLE	IF	CITATIONS
2122	Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. Trends in Cancer, 2019, 5, 426-439.	7.4	52
2123	Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis. BMC Cancer, 2019, 19, 716.	2.6	35
2124	Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway. International Journal of Biological Sciences, 2019, 15, 1488-1499.	6.4	22
2125	A Qualitative Transcriptional Signature for Predicting Recurrence Risk of Stage III Bladder Cancer Patients After Surgical Resection. Frontiers in Oncology, 2019, 9, 629.	2.8	4
2126	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 573.e19-573.e29.	1.6	13
2127	Post-surgical complications in patients with bladder cancer treated with cystectomy: Differences between open and laparoscopic approach. Actas Urológicas Españolas (English Edition), 2019, 43, 305-313.	0.2	2
2128	Transvaginal mesh repair of anterior enterocoele following radical cystectomy and ileal conduit diversion. Urogynaecologia International Journal, 2019, 31, .	0.2	0
2130	Risk factors of postoperative major adverse cardiac events after radical cystectomy: implication of diastolic dysfunction. Scientific Reports, 2019, 9, 14096.	3.3	14
2131	Association between perioperative morbidity and mortality after radical cystectomy: an opportunity to understand the complication snowball effect. Translational Andrology and Urology, 2019, 8, S261-S262.	1.4	2
2132	Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3. In Vivo, 2019, 33, 2217-2224.	1.3	2
2133	The investigation of haematuria and bladder cancer. Trends in Urology & Men's Health, 2019, 10, 25-27.	0.4	2
2135	Preoperative CD4+CD25+/CD4+ and tumor diameter predict prognosis in male patients with bladder cancer. Biomarkers in Medicine, 2019, 13, 1387-1397.	1.4	2
2136	Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis. Frontiers in Oncology, 2019, 9, 1030.	2.8	51
2137	Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens. Oncoimmunology, 2019, 8, e1644108.	4.6	34
2138	The multifaceted immune regulation of bladder cancer. Nature Reviews Urology, 2019, 16, 613-630.	3.8	123
2139	Late Recurrence of Bladder Cancer following Radical Cystectomy: Characteristics and Outcomes. Urologia Internationalis, 2019, 103, 291-296.	1.3	8
2140	Cordycepin induces apoptosis in human bladder cancer T24 cells through ROS-dependent inhibition of the PI3K/Akt signaling pathway. BioScience Trends, 2019, 13, 324-333.	3.4	18
2141	How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?. European Urology Oncology, 2019, 4, 663-669.	5.4	1

#	ARTICLE	IF	CITATIONS
2142	Multicenter Analysis of Postoperative Complications in Octogenarians After Radical Cystectomy and Ureterocutaneostomy: The Role of the Frailty Index. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 402-407.	1.9	33
2143	Robot Assisted Radical Cystectomy vs Open Radical Cystectomy: Over 10 years of the Mayo Clinic Experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 862-869.	1.6	23
2144	De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study. <i>Disease Markers</i> , 2019, 2019, 1-8.	1.3	18
2145	Assessing the Impact of Time to Cystectomy for Variant Histology of Urothelial Bladder Cancer. <i>Urology</i> , 2019, 133, 157-163.	1.0	8
2146	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 826-836.	1.6	33
2147	Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder. <i>European Urology Oncology</i> , 2019, 2, 656-663.	5.4	4
2148	A new era in the detection of urothelial carcinoma by sequencing cell-free DNA. <i>Translational Andrology and Urology</i> , 2019, 8, S497-S501.	1.4	10
2149	Real-world data: towards achieving the achievable in cancer care. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 312-325.	27.6	187
2150	Intraoperative hypothermia is a significant prognostic predictor of radical cystectomy especially for stage II muscle-invasive bladder cancer. <i>Medicine (United States)</i> , 2019, 98, e13962.	1.0	5
2151	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. <i>Urologia Internationalis</i> , 2019, 102, 269-276.	1.3	9
2152	Radical Cystectomy. , 2019, , 69-113.		0
2153	The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). <i>Targeted Oncology</i> , 2019, 14, 15-32.	3.6	12
2154	A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16). <i>PLoS ONE</i> , 2019, 14, e0209998.	2.5	1
2155	Multimodality Therapy. , 2019, , 115-122.		0
2156	SIUâ€“ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 61-83.	2.2	40
2157	The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. <i>Surgical Oncology</i> , 2019, 28, 208-213.	1.6	14
2158	Reply to Siebren Dijkstra and Carl J. Wijnburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. <i>Eur Urol</i> 2018;74:465â€“71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?. <i>European Urology</i> , 2019, 75, e138-e139.	1.9	1
2159	Influence of the laparoscopic approach on cancer-specific mortality of patients with stage pt3-4 bladder cancer treated with cystectomy. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2019, 43, 71-76.	0.2	1

#	ARTICLE	IF	CITATIONS
2160	The functions of microRNA-124 on bladder cancer. OncoTargets and Therapy, 2019, Volume 12, 3429-3439.	2.0	12
2162	Adjuvant chemotherapy versus observation after radical cystectomy in patients with node-positive bladder cancer. Scientific Reports, 2019, 9, 8305.	3.3	10
2163	Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis. Journal of Visualized Experiments, 2019, , .	0.3	4
2164	Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. International Journal of Urology, 2019, 26, 820-826.	1.0	0
2165	Transcriptionally elevation of miR-494 by new ChIA-F compound via a HuR/JunB axis inhibits human bladder cancer cell invasion. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2019, 1862, 822-833.	1.9	4
2166	Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. European Urology, 2019, 76, 200-206.	1.9	41
2167	Clinical outcomes of robot-assisted radical cystectomy and continent urinary diversion. Scandinavian Journal of Urology, 2019, 53, 81-88.	1.0	11
2168	Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?. PLoS ONE, 2019, 14, e0216255.	2.5	17
2169	The long non-coding RNA LINC00460 predicts the prognosis and promotes the proliferation and migration of cells in bladder urothelial carcinoma. Oncology Letters, 2019, 17, 3874-3880.	1.8	15
2170	The prognostic value of sarcopenia in patients with surgically treated urothelial carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2019, 45, 747-754.	1.0	42
2172	PPAR γ 3 inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. Journal of Cellular and Molecular Medicine, 2019, 23, 3724-3736.	3.6	33
2173	The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. World Journal of Urology, 2019, 37, 2707-2714.	2.2	6
2174	Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. Investigative and Clinical Urology, 2019, 60, 64.	2.0	12
2175	High-precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-day Integrated Boost Technique with Image Guidance Using Lipiodol Markers. European Urology Oncology, 2019, 2, 39-46.	5.4	6
2176	Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. European Urology, 2019, 76, 126.	1.9	2
2177	Recovering from Cystectomy: Patient Perspectives. Bladder Cancer, 2019, 5, 51-61.	0.4	14
2178	Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. World Journal of Urology, 2019, 37, 1557-1570.	2.2	15
2179	Vitamin D ₃ enhances the response to cisplatin in bladder cancer through VDR and TA α 73 signaling crosstalk. Cancer Medicine, 2019, 8, 2449-2461.	2.8	11

#	ARTICLE	IF	CITATIONS
2180	The Cancer of the Bladder Risk Assessment (COBRA) score for predicting cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder: External validation in a cohort of Korean patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 470-477.	1.6	4
2181	Perioperative management of radical cystectomy in the Nordic countries. <i>Scandinavian Journal of Urology</i> , 2019, 53, 51-55.	1.0	4
2182	Four novel biomarkers for bladder cancer identified by weighted gene coexpression network analysis. <i>Journal of Cellular Physiology</i> , 2019, 234, 19073-19087.	4.1	22
2183	Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/ROG 0712â€”A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 44-51.	1.6	83
2184	Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882367.	2.0	10
2185	Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). <i>Scientific Reports</i> , 2019, 9, 2084.	3.3	57
2186	MCL1 and DEDD Promote Urothelial Carcinoma Progression. <i>Molecular Cancer Research</i> , 2019, 17, 1294-1304.	3.4	4
2187	Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts. <i>International Journal of Molecular Sciences</i> , 2019, 20, 793.	4.1	25
2188	Machine learning models for predicting post-cystectomy recurrence and survival in bladder cancer patients. <i>PLoS ONE</i> , 2019, 14, e0210976.	2.5	50
2189	Cumulative sum analysis of the robotic learning curve in the surgical management of malignant pelvic neoplasms. <i>Laparoscopic Surgery</i> , 2019, 3, 33-33.	0.9	1
2190	Cost comparison between open radical cystectomy, laparoscopic radical cystectomy, and robot-assisted radical cystectomy for patients with bladder cancer: a systematic review of segmental costs. <i>BMC Urology</i> , 2019, 19, 110.	1.4	19
2191	Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy. <i>The Cochrane Library</i> , 2019, 2019, CD013336.	2.8	10
2192	The long-term efficacy of one-shot neoadjuvant intra-arterial chemotherapy combined with radical cystectomy versus radical cystectomy alone for bladder cancer: a propensity-score matching study. <i>BMC Urology</i> , 2019, 19, 117.	1.4	3
2193	The Prognostic Value of Tumor Regression Grades Combined With TNM Classification in Patients With Muscle-Invasive Bladder Cancer Who Underwent Neoadjuvant Chemotherapy Followed by Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1203-e1211.	1.9	3
2194	TGF-Î² and microRNA Interplay in Genitourinary Cancers. <i>Cells</i> , 2019, 8, 1619.	4.1	19
2195	Nuclear Factor-Î² Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1954.	2.4	8
2196	Radical Cystectomy in Female Patients - Improving Outcomes. <i>Current Urology Reports</i> , 2019, 20, 83.	2.2	5
2197	Upper urinary tract recurrence following bladder cancer therapy. <i>Current Opinion in Urology</i> , 2019, 29, 189-197.	1.8	7

#	ARTICLE	IF	CITATIONS
2198	Prognostic nomogram for bladder cancer with brain metastases: a National Cancer Database analysis. <i>Journal of Translational Medicine</i> , 2019, 17, 411.	4.4	16
2199	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5082-5093.	7.0	82
2200	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 7-14.e3.	1.9	9
2201	SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 64-74.	2.4	16
2202	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. <i>European Urology</i> , 2019, 75, 649-658.	1.9	82
2203	Staging of bladder cancer. <i>Histopathology</i> , 2019, 74, 112-134.	2.9	117
2204	Assessing trends in urinary diversion after radical cystectomy for bladder cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 180.e1-180.e9.	1.6	14
2205	Hypermethylated in cancer 1 (HIC1) suppresses bladder cancer progression by targeting yes-associated protein (YAP) pathway. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 6471-6481.	2.6	7
2206	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e1-179.e7.	1.6	8
2207	Induction of Mitotic Catastrophe via Inhibition of Aurora B by Ionizing Radiation With Additive of Mulberry Water Extract in Human Bladder Cancer Cells. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541880858.	2.0	2
2208	The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients With Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-matched Study. <i>Urology</i> , 2019, 125, 138-145.	1.0	11
2209	Laparoscopic Radical Cystectomy With Extracorporeal Neobladder: Our Initial Experience. <i>Urology</i> , 2019, 124, 286-291.	1.0	5
2210	Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 1-11.	1.6	11
2211	Management of Urothelial Carcinoma. , 2019, , .		0
2212	Influencia del acceso laparoscópico en la mortalidad cÁncer especÁfica de los pacientes con cÁncer de vejiga en un estadio pT3-4 tratados con cistectomÁa. <i>Actas UrolÁgicas EspaÁolas</i> , 2019, 43, 71-76.	0.7	1
2213	Downregulation of microRNA-532-5p promotes the proliferation and invasion of bladder cancer cells through promotion of HMGB3/Wnt/ β 2-catenin signaling. <i>Chemico-Biological Interactions</i> , 2019, 300, 73-81.	4.0	47
2214	A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease. <i>World Journal of Urology</i> , 2019, 37, 1605-1613.	2.2	9
2215	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. <i>World Journal of Urology</i> , 2019, 37, 1773-1784.	2.2	22

#	ARTICLE	IF	CITATIONS
2216	Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. <i>European Urology</i> , 2019, 75, 604-611.	1.9	197
2217	TROY expression is associated with pathological stage and poor prognosis in patients treated with radical cystectomy. <i>Cancer Biomarkers</i> , 2019, 24, 91-96.	1.7	3
2218	A delay of 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 116-122.	1.6	24
2219	Effectiveness of hyaluronic acid/carboxymethylcellulose in preventing adhesive bowel obstruction after laparoscopic radical cystectomy. <i>Asian Journal of Surgery</i> , 2019, 42, 394-400.	0.4	7
2220	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 38-45.	1.9	29
2221	Comprehensive Imaging and Surgical Review of Urinary Diversions: What the Radiologist Needs to Know. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 161-171.	1.4	5
2222	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2019, 5, 224-241.	3.1	74
2223	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. <i>European Urology Focus</i> , 2020, 6, 1226-1232.	3.1	18
2224	Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 858-866.	1.6	14
2225	Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 330-337.	0.9	5
2226	Involving Patients in the Development and Evaluation of an Educational and Training Experiential Intervention (ETEI) to Improve Muscle Invasive Bladder Cancer Treatment Decision-making and Post-operative Self-care: a Mixed Methods Approach. <i>Journal of Cancer Education</i> , 2020, 35, 808-818.	1.3	3
2227	Robot-assisted radical cystectomy with totally intracorporeal urinary diversion: surgical and early functional outcomes through the learning curve in a single high-volume center. <i>Journal of Robotic Surgery</i> , 2020, 14, 261-269.	1.8	22
2228	The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy. <i>World Journal of Urology</i> , 2020, 38, 397-406.	2.2	8
2229	Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?. <i>European Urology Focus</i> , 2020, 6, 617-619.	3.1	3
2230	Prognostic impact of tumor-associated immune cell infiltrates at radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 4.e7-4.e15.	1.6	2
2231	Lymph Node Dissection for Advanced Bladder Cancer: Is There a Role?. <i>European Urology Focus</i> , 2020, 6, 615-616.	3.1	2
2232	PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: <i>In Situ</i> and Abscopal Effects. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 211-220.	4.1	32
2233	Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 73-79.	1.3	8

#	ARTICLE	IF	CITATIONS
2234	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020, 78, 43-59.	1.9	34
2235	The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study. <i>Clinical Oncology</i> , 2020, 32, 93-100.	1.4	13
2236	Carcinoma of the Bladder. , 2020, , 1382-1400.e4.		2
2237	Transurethral-Assisted Transumbilical Laparoendoscopic Single-Site Radical Cystectomy: Initial Short-Term Experience. <i>Urologia Internationalis</i> , 2020, 104, 22-27.	1.3	1
2238	The Impact of Lymphovascular Invasion on Risk of Upstaging and Lymph Node Metastasis at the Time of Radical Cystectomy. <i>European Urology Focus</i> , 2020, 6, 292-297.	3.1	15
2239	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020, 38, 1959-1968.	2.2	22
2240	An EMTâ€related gene signature for the prognosis of human bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 605-617.	3.6	132
2241	Granulocytic myeloid-derived suppressor cells correlate with outcomes undergoing neoadjuvant chemotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 5.e17-5.e23.	1.6	2
2242	Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). <i>European Urology</i> , 2020, 77, 110-118.	1.9	82
2243	Apaziquone for Nonmuscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 73-82.	1.8	5
2244	Bacillus Calmetteâ€GuÃ©rinâ€unresponsive nonâ€muscleâ€invasive bladder cancer: Its definition and future therapeutic strategies. <i>International Journal of Urology</i> , 2020, 27, 108-116.	1.0	22
2245	Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2020, 38, 2207-2213.	2.2	4
2246	Risk factors and reasons for reoperation after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 269-277.	1.6	13
2247	Lnc<sc>RNA MBNL</sc>1 represses cell proliferation and enhances cell apoptosis via targeting miRâ€135aâ€5p<sc>PHLPP</sc>2<sc>FOXO</sc>1 axis in bladder cancer. <i>Cancer Medicine</i> , 2020, 9, 724-736.	2.8	31
2248	The Feasibility and Impact of a Presurgical Exercise Intervention Program (Prehabilitation) for Patients Undergoing Cystectomy for Bladder Cancer. <i>Urology</i> , 2020, 145, 106-112.	1.0	23
2250	Impact of second transurethral resection on recurrence in patients with highâ€grade Ta bladder cancer. <i>International Journal of Urology</i> , 2020, 27, 1130-1135.	1.0	8
2251	Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models. <i>Scientific Reports</i> , 2020, 10, 17464.	3.3	11
2252	Quality of life and functional outcomes after radical cystectomy with ileal orthotopic neobladder replacement for bladder cancer: a multicentre observational study. <i>World Journal of Urology</i> , 2021, 39, 2525-2530.	2.2	13

#	ARTICLE	IF	CITATIONS
2253	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. <i>Nature Medicine</i> , 2020, 26, 1839-1844.	30.7	245
2254	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768.	2.2	20
2255	Radiomics nomogram for preoperative prediction of progression-free survival using diffusion-weighted imaging in patients with muscle-invasive bladder cancer. <i>European Journal of Radiology</i> , 2020, 131, 109219.	2.6	17
2256	Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. <i>BMC Urology</i> , 2020, 20, 97.	1.4	20
2257	The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e478-e483.	1.9	3
2258	Survival Outcomes of Early versus Deferred Cystectomy for High-Grade Non-Muscle-Invasive Bladder Cancer: A Systematic Review. <i>Current Urology</i> , 2020, 14, 66-73.	0.6	15
2259	Marital Status and Prognostic Nomogram for Bladder Cancer With Distant Metastasis: A SEER-Based Study. <i>Frontiers in Oncology</i> , 2020, 10, 586458.	2.8	26
2260	ADNP Upregulation Promotes Bladder Cancer Cell Proliferation via the AKT Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 491129.	2.8	8
2261	Radical cystectomy—what is the optimal surgical approach?. <i>Translational Andrology and Urology</i> , 2020, 9, 2308-2312.	1.4	4
2262	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2021, 7, 1092-1099.	3.1	4
2263	Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1980.	7.4	817
2264	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 404-423.	329.8	507
2265	Preoperative Risk Factors Predicting Postoperative Complications in Radical Cystectomy for Bladder Cancer. <i>Bladder Cancer</i> , 2020, 6, 151-159.	0.4	2
2266	Outcomes of Urinary Diversion for Late Adverse Effects of Gynecologic Radiotherapy. <i>Urology</i> , 2020, 144, 214-219.	1.0	5
2267	Diagnostic Accuracy of Multiparametric MRI for Local Staging of Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Urology</i> , 2020, 145, 22-29.	1.0	16
2268	Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. <i>Journal of Sexual Medicine</i> , 2020, 17, 1995-2004.	0.6	12
2269	<p>Plasma Fibrinogen Predicts the Prognosis of Bladder Cancer Patients After Radical Cystectomy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9303-9314.	1.9	8
2270	Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. <i>Bladder Cancer</i> , 2020, 6, 265-276.	0.4	5

#	ARTICLE	IF	CITATIONS
2271	Optimum Management Of The T1 High Grade Bladder Cancer. Bangladesh Journal of Urology, 2020, 16, 26-32.	0.0	0
2272	FROGG patterns of practice survey and consensus recommendations on radiation therapy for MIBC. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 882-893.	1.8	4
2273	Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database. Urology, 2020, 146, 168-176.	1.0	8
2274	<p>Risk Factors for Urethral Recurrence in Men After Radical Cystectomy with Orthotopic Urinary Diversion for Urothelial Carcinoma: A Retrospective Cohort Study</p>. Cancer Management and Research, 2020, Volume 12, 6739-6746.	1.9	2
2275	Is It Safe to Offer Radical Cystectomy to Patients above 85 Years of Age? A Long-Term Follow-Up in a Single-Center Institution. Urologia Internationalis, 2020, 104, 975-981.	1.3	8
2276	Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma. BioMed Research International, 2020, 2020, 1-13.	1.9	2
2277	The relationship between type of urinary diversion and quality of life after radical cystectomy: Ileal conduit versus orthotopic bladder. BJUI Compass, 2020, 1, 133-138.	1.3	5
2278	Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. Frontiers in Immunology, 2020, 11, 1900.	4.8	7
2279	Enhanced recovery after surgery (ERAS) following radical cystectomy: is it worth implementing for all patients?. World Journal of Urology, 2021, 39, 1927-1933.	2.2	19
2280	Enhanced Sensitivity to NVP-BEZ235 by Inhibition of p62/SQSTM1 in Human Bladder Cancer KoTCC-1 Cells Both In Vitro and In Vivo. In Vivo, 2020, 34, 1001-1008.	1.3	3
2281	Bladder preservation therapy in muscle-invasive bladder cancer: Current evidence and future perspectives. AME Medical Journal, 0, 5, 16-16.	0.4	5
2282	Role of tyrosine kinases in bladder cancer progression: an overview. Cell Communication and Signaling, 2020, 18, 127.	6.5	19
2283	Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 288.	8.6	11
2284	Adjuvant Treatment of Residual Disease Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer. Bladder Cancer, 2020, 6, 525-535.	0.4	0
2285	Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy. Scientific Reports, 2020, 10, 21562.	3.3	6
2286	Clinical outcomes of a cohort of patients with bulky, clinically node-positive bladder cancer undergoing radical cystectomy in the contemporary era. Canadian Urological Association Journal, 2020, 15, E286-E289.	0.6	0
2287	Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, , .	1.6	0
2288	Bladder Cancer Following Medicaid Expansion: No Changes in the Diagnosis of Muscle-Invasive Disease and Time to Treatment. Bladder Cancer, 2020, 6, 143-150.	0.4	1

#	ARTICLE	IF	CITATIONS
2289	Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx1. <i>Bladder Cancer</i> , 2020, 6, 453-460.	0.4	0
2290	<p>Clinical Characteristics and Prognosis of Rare Histological Variants of Bladder Cancer: A Single-Center Retrospective Study from China</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9635-9641.	1.9	2
2291	Perioperative complications and oncological outcomes following radical cystectomy among different racial groups: A long-term, single-center study. <i>Canadian Urological Association Journal</i> , 2020, 14, E493-E498.	0.6	2
2292	Laparoscopic and Robotic Surgery in Urology. , 2020, , .		0
2293	Robotâ€assisted intracorporeal orthotopic bladder substitution after radical cystectomy: perioperative morbidity and oncological outcomes â€a singleâ€institution experience. <i>BJU International</i> , 2020, 126, 464-471.	2.5	15
2294	Bioinformatics Analysis Identifying Key Biomarkers in Bladder Cancer. <i>Data</i> , 2020, 5, 38.	2.3	3
2295	The Usefulness of the Modified Frailty Index for Muscle-Invasive Bladder Cancer Patients Treated with Radical Cystectomy. <i>Current Urology</i> , 2020, 14, 32-37.	0.6	7
2296	Sarcopenia predicts prognosis of bladder cancer patients after radical cystectomy: A study based on the Chinese population. <i>Clinical and Translational Medicine</i> , 2020, 10, e105.	4.0	13
2297	Evaluation of laparoscopic approach in radical cystectomy from implementation to consolidation: Internal validation. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2020, 44, 62-70.	0.2	1
2298	Prognostic significance of previous tonsillectomy after radical cystectomy for bladder cancer. <i>Scandinavian Journal of Urology</i> , 2020, 54, 297-303.	1.0	0
2299	Neoadjuvant therapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 603-614.	2.4	11
2300	<p>LncRNA NCK1-AS1 Promotes Cancer Cell Proliferation and Increase Cell Stemness in Urinary Bladder Cancer Patients by Downregulating miR-143</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1661-1668.	1.9	19
2301	Bladder-sparing treatment options in localized muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 179-188.	2.4	8
2302	Factors Associated with Patient-Reported Penile Length Loss After Radical Cystoprostatectomy in Male Patients with Bladder Cancer. <i>Journal of Sexual Medicine</i> , 2020, 17, 957-963.	0.6	5
2303	Molecular lymph node staging for bladder cancer patients undergoing radical cystectomy with pelvic lymph node dissection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e11-639.e19.	1.6	5
2304	Perioperative outcomes after open radical cystectomy for muscle invasive bladder cancer. <i>Journal of Patan Academy of Health Sciences</i> , 2020, 6, 23-30.	0.2	0
2305	Surgical outcomes and learning curve of totally intracorporeal ileal conduit urinary diversion following laparoscopic radical cystectomy at a single institution. <i>Asian Journal of Endoscopic Surgery</i> , 2020, 13, 532-538.	0.9	2
2306	Commentary on â€œThe top 100 most cited manuscripts in bladder cancer: A bibliometric analysisâ€ International <i>Journal of Surgery</i> , 2020, 76, 47.	2.7	0

#	ARTICLE	IF	CITATIONS
2307	Quantitative Analysis of Enhanced Computed Tomography in Differentiating Cystitis Glandularis and Bladder Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-7.	1.9	3
2308	The Role of Exenterative Surgery in Advanced Urological Neoplasms. <i>Current Urology</i> , 2020, 14, 57-65.	0.6	3
2309	The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. <i>European Urology Focus</i> , 2020, 7, 554-565.	3.1	7
2310	Novel Potential Biomarkers Associated With Epithelial to Mesenchymal Transition and Bladder Cancer Prognosis Identified by Integrated Bioinformatic Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 931.	2.8	12
2311	Benefits of robotic cystectomy compared with open cystectomy in an Enhanced Recovery After Surgery program: A propensity-matched analysis. <i>International Journal of Urology</i> , 2020, 27, 783-788.	1.0	12
2312	Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data. <i>Cancer Management and Research</i> , 2020, Volume 12, 5077-5084.	1.9	2
2313	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large institutional cohort. <i>BJU International</i> , 2020, 126, 704-714.	2.5	7
2314	Mortality prediction model for patients with bladder urothelial tumor after radical cystectomy. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 215-223.	0.2	1
2315	Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100536.	1.1	13
2316	Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 346-351.	1.0	40
2317	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e473-e477.	1.9	1
2318	Loss of GATA6 expression promotes lymphatic metastasis in bladder cancer. <i>FASEB Journal</i> , 2020, 34, 5754-5766.	0.5	17
2319	Robot-assisted orthotopic ileal neobladder in male patients: step-by-step video-illustrated technique and preliminary outcomes. <i>Journal of Robotic Surgery</i> , 2020, 14, 739-744.	1.8	6
2320	The applicability and utility of immunohistochemical biomarkers in bladder pathology. <i>Human Pathology</i> , 2020, 98, 32-55.	2.0	21
2321	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1043-1053.	1.0	46
2322	Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. <i>Scandinavian Journal of Urology</i> , 2020, 54, 46-51.	1.0	3
2323	Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. <i>European Urology Focus</i> , 2020, 6, 632-638.	3.1	30
2324	Robot-assisted radical cystectomy: Review of surgical technique, and perioperative, oncological and functional outcomes. <i>International Journal of Urology</i> , 2020, 27, 194-205.	1.0	14

#	ARTICLE	IF	CITATIONS
2325	Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review. <i>Diagnostics</i> , 2020, 10, 39.	2.6	74
2326	Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort. <i>International Journal of Urology</i> , 2020, 27, 250-256.	1.0	10
2327	The top 100 most cited manuscripts in bladder cancer: A bibliometric analysis (review article). <i>International Journal of Surgery</i> , 2020, 75, 130-138.	2.7	37
2328	The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 609-616.	1.3	3
2329	Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e557-e562.	1.9	9
2330	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 387-394.	1.9	32
2332	Utility of lymphadenectomy in bladder cancer: where do we stand?. <i>Current Opinion in Urology</i> , 2020, 30, 407-414.	1.8	4
2333	Bladder cancer therapy without toxicity—A dose-escalation study of alpha1-antitrypsin. <i>International Journal of Cancer</i> , 2020, 147, 2479-2492.	5.1	11
2334	Atypical oncologic failure after laparoscopic and robot-assisted radical cystectomy at a single institution. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1385-1392.	2.2	2
2335	Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1377-1384.	2.2	4
2336	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e651-e659.	1.9	7
2337	Tumor-infiltrating IL-17A ⁺ cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer. <i>Oncotarget</i> , 2020, 9, 17473-17482.	4.6	6
2338	Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity. <i>BMC Urology</i> , 2020, 20, 39.	1.4	30
2339	Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 94-102.	0.2	1
2340	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	1.9	1,152
2341	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. <i>World Journal of Urology</i> , 2021, 39, 443-451.	2.2	13
2342	Pelvic Floor Organ Prolapse After Radical Cystectomy in Patients With Uroepithelial Carcinoma. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2021, 27, e501-e504.	1.1	5
2343	Lymph node dissection for bladder cancer: Current standards and the latest evidence. <i>International Journal of Urology</i> , 2021, 28, 7-15.	1.0	16

#	ARTICLE	IF	CITATIONS
2344	Tryptophanâ€“kynurenine ratio as a biomarker of bladder cancer. BJU International, 2021, 127, 445-453.	2.5	19
2345	â€œReal-worldâ€•outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 76.e15-76.e22.	1.6	8
2346	Surgical Pathology Findings in Patients Who Have Undergone Radical Cystectomy/Cystoprostatectomy With Extended Versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder: A Contemporary Analysis. International Journal of Surgical Pathology, 2021, 29, 150-154.	0.8	0
2347	Higher nodal yield with robot-assisted pelvic lymph node dissection for bladder cancer compared to laparoscopic dissection: implications for more accurate staging. Arab Journal of Urology Arab Association of Urology, 2021, 19, 92-97.	1.5	3
2348	Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy. Clinical Oncology, 2021, 33, 46-49.	1.4	6
2349	Robtic-assisted radical cystectomy: Literature review. Asian Journal of Urology, 2021, 8, 14-19.	1.2	4
2350	Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. European Urology, 2021, 79, 214-221.	1.9	130
2351	Can anesthetics affect bladder cancer recurrence? Total intravenous versus volatile anesthesia in patients undergoing robot-assisted radical cystectomy: A single institution retrospective analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 233.e1-233.e8.	1.6	10
2352	The effect of body mass index on oncological and surgical outcomes in patients undergoing radical cystectomy for bladder cancer: A multicentre study of the association of urooncology, Turkey. International Journal of Clinical Practice, 2021, 75, e13750.	1.7	3
2353	The comprehensive complication index is associated with a significant increase in complication severity between 30 and 90 days after radical cystectomy for bladder cancer. European Journal of Surgical Oncology, 2021, 47, 1163-1171.	1.0	11
2354	Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer?. Lancet Oncology, The, 2021, 22, 8-9.	10.7	8
2355	Radical cystectomy for locally advanced urothelial carcinoma of the urinary bladder: Health-related quality of life, oncological outcomes and predictors for survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 299.e15-299.e21.	1.6	3
2356	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Current Treatment Options in Oncology, 2021, 22, 7.	3.0	6
2357	Our laparoscopic cystectomy experiences. Urologia, 2021, 88, 30-33.	0.7	0
2358	Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. Clinical and Translational Radiation Oncology, 2021, 26, 30-34.	1.7	8
2359	Guar bean in urinary cytology: a morphologic pitfall. Journal of the American Society of Cytopathology, 2021, 10, 41-46.	0.5	4
2360	The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer, 2021, 127, 1387-1394.	4.1	10
2361	High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 196.e1-196.e7.	1.6	5

#	ARTICLE	IF	CITATIONS
2362	Prognostic impact of perioperative blood transfusions on oncological outcomes of patients with bladder cancer undergoing radical cystectomy: A systematic review. Arab Journal of Urology Arab Association of Urology, 2021, 19, 24-30.	1.5	5
2363	A perioperative management to reduce rate of urinary tract infection for patient underwent radical cystectomy with ileal conduit diversion. International Urology and Nephrology, 2021, 53, 401-407.	1.4	4
2364	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 953-963.	0.8	6
2365	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e15-235.e21.	1.6	10
2366	Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: Radiologic variables can predict response. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 133.e1-133.e8.	1.6	6
2367	Quantitation of bladder cancer for the prediction of muscle layer invasion as a complement to the vesical imaging-reporting and data system. European Radiology, 2021, 31, 1656-1666.	4.5	28
2368	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	4.7	67
2369	Sulforaphane Inhibits ICAM-1 Expression and Monocyte Adhesion in Human Bladder Cancer T24 Cells. Anatomy & Biological Anthropology, 2021, 34, 21.	0.3	0
2370	Postoperative C-reactive protein to albumin ratio predicts poor prognosis in patients with bladder cancer undergoing radical cystectomy. Molecular and Clinical Oncology, 2021, 14, 54.	1.0	3
2371	Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. Translational Andrology and Urology, 2021, 10, 4036-4050.	1.4	11
2372	Is ERCC1 a prognostic biomarker for urothelial cancer following radical cystectomy? A long-term analysis. Central European Journal of Urology, 2021, 74, 348-354.	0.3	0
2374	RLC score (R status, lymphovascular invasion, C-reactive protein) predicts survival following radical cystectomy for muscle-invasive bladder cancer. Aktuelle Urologie, 2022, 53, 545-551.	0.3	2
2375	Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. Investigative and Clinical Urology, 2021, 62, 361.	2.0	14
2376	Micropapillary Bladder Cancer Metastatic to the Breast: A Case Report and Brief Literature Review. In Vivo, 2021, 35, 453-459.	1.3	2
2377	Emerging role of RNF2 in cancer: From bench to bedside. Journal of Cellular Physiology, 2021, 236, 5453-5465.	4.1	11
2378	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. OncoTargets and Therapy, 2021, Volume 14, 315-324.	2.0	5
2379	Adjuvant Chemotherapy in Bladder Cancer. , 2021, , 251-256.		0
2380	Risk Stratification of Patients: Risk Tables and Assessment of NMIBC and MIBC. , 2021, , 41-52.		1

#	ARTICLE	IF	CITATIONS
2381	Clinical Trials in Localized Muscle-Invasive Bladder Cancer. , 2021, , 355-363.		0
2382	Contemporary Outcomes of Open Radical Cystectomy: a 5-Year Experience from a Tertiary Care Center. Indian Journal of Surgical Oncology, 2021, 12, 86-93.	0.7	2
2383	The efficacy of enhanced recovery protocol from anesthesia in diabetic patients undergoing radical cystectomy. Alexandria Journal of Medicine, 2021, 57, 38-43.	0.6	0
2384	Radical Cystectomy. , 2021, , 139-175.		0
2386	Recurrent ZNF83-E293V Mutation Promotes Bladder Cancer Progression through the NF- κ B Pathway via Transcriptional Dysregulation of S100A8. Molecular Therapy, 2021, 29, 275-290.	8.2	8
2387	Pembrolizumab<i>Versus</i>Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer. In Vivo, 2021, 35, 1889-1894.	1.3	4
2388	Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium â€” an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Investigational New Drugs, 2021, 39, 812-820.	2.6	12
2389	Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. Current Oncology Reports, 2021, 23, 24.	4.0	5
2390	Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy. International Journal of Urology, 2021, 28, 593-597.	1.0	9
2391	Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study. OncoTargets and Therapy, 2021, Volume 14, 845-855.	2.0	5
2392	The role of extended lymph node dissection in patients undergoing radical cystectomy. Turkish Journal of Urology, 2021, 47, S27-S32.	1.3	0
2393	A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer. Frontiers in Oncology, 2021, 11, 614927.	2.8	5
2394	Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. Cancer Treatment Reviews, 2021, 93, 102142.	7.7	27
2395	Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer. Current Urology, 2021, 15, 11-15.	0.6	3
2396	Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer. Translational Andrology and Urology, 2021, 10, 1192-1201.	1.4	0
2397	Imaging and Management of Bladder Cancer. Cancers, 2021, 13, 1396.	3.7	30
2398	Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matchedâ€”pair analysis in a multicenter cohort. International Journal of Urology, 2021, 28, 656-664.	1.0	8
2399	A Serum Metabolomic Signature for the Detection and Grading of Bladder Cancer. Applied Sciences (Switzerland), 2021, 11, 2835.	2.5	9

#	ARTICLE	IF	CITATIONS
2401	Predictive biomarkers in bladder cancer. <i>Biomarkers in Medicine</i> , 2021, 15, 241-246.	1.4	2
2403	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. <i>Urology</i> , 2021, 149, 154-160.	1.0	4
2404	Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 15-20.	0.8	11
2405	BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?. <i>World Journal of Urology</i> , 2021, 39, 4037-4046.	2.2	14
2406	Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy. <i>Advances in Radiation Oncology</i> , 2021, 6, 100646.	1.2	1
2407	RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4188.	4.1	6
2408	The Usefulness of Lymphadenectomy in Bladder Cancer—Current Status. <i>Medicina (Lithuania)</i> , 2021, 57, 415.	2.0	8
2409	Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?. <i>Immunotherapy</i> , 2021, 13, 459-463.	2.0	2
2410	Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4102.	4.1	5
2411	Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, E424-E460.	0.6	7
2412	Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4326-4339.	3.6	19
2413	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	10.7	225
2414	Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1865-1877.	1.4	7
2415	Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. <i>Advances in Therapy</i> , 2021, 38, 2759-2778.	2.9	11
2416	Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. <i>BJU International</i> , 2021, 128, 607-614.	2.5	10
2417	Trimodality treatment for muscle-invasive bladder cancer: an institutional experience. <i>Advances in Radiation Oncology</i> , 2021, 6, 100718.	1.2	0
2418	Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2022, 8, 718-727.	3.1	0
2419	Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 2496.	3.7	8

#	ARTICLE	IF	CITATIONS
2420	Down-regulation LncRNA-SNHG15 contributes to proliferation and invasion of bladder cancer cells. BMC Urology, 2021, 21, 83.	1.4	11
2421	La infección del tracto urinario como causa principal de ingreso en pacientes cistectomizados. Actas Urológicas Españolas, 2021, 45, 247-256.	0.7	2
2422	Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder. Cancers, 2021, 13, 2377.	3.7	4
2423	Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. Minerva Urology and Nephrology, 2021, 73, 215-224.	2.5	4
2424	Guideline adherence for radical cystectomy significantly affects survival outcomes in non-muscle-invasive bladder cancer patients. Japanese Journal of Clinical Oncology, 2021, 51, 1303-1312.	1.3	2
2425	Urinary tract infection as the main cause of admission in cystectomized patients. Actas Urológicas Españolas (English Edition), 2021, 45, 247-256.	0.2	1
2426	KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Journal of Personalized Medicine, 2021, 11, 473.	2.5	5
2427	Intra-corporeal robot-assisted versus open radical cystectomy: a propensity score-matched analysis comparing perioperative and long-term survival outcomes and recurrence patterns. International Journal of Clinical Oncology, 2021, 26, 1514-1523.	2.2	8
2428	Oncologic Outcomes of Intracorporeal vs Extracorporeal Urinary Diversion After Robot-Assisted Radical Cystectomy: A Multi-Institutional Korean Study. Journal of Endourology, 2021, 35, 1490-1497.	2.1	7
2429	Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 2770.	3.7	7
2430	Predictive Nomogram and Risk Factors for Lymph Node Metastasis in Bladder Cancer. Frontiers in Oncology, 2021, 11, 690324.	2.8	13
2431	Perioperative Outcomes of Robot-Assisted Radical Cystectomy with Intracorporeal Versus Extracorporeal Urinary Diversion. Annals of Surgical Oncology, 2021, 28, 9209-9215.	1.5	9
2432	Robot-assisted radical cystectomy with intracorporeal Mainz rectosigmoid pouch for muscle-invasive bladder cancer. International Journal of Medical Robotics and Computer Assisted Surgery, 2021, 17, e2284.	2.3	1
2433	Surgery for Bladder and Upper Tract Urothelial Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 543-566.	2.2	4
2434	The Epidemiology of Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 445-455.	2.2	28
2435	Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial. Journal of Urology, 2021, 205, 1605-1611.	0.4	11
2436	The impact of robotic surgery in bladder cancer patients. AME Medical Journal, 2021, 6, 14-14.	0.4	2
2437	Concomitant Systemic Therapy: Current and Future Perspectives. Clinical Oncology, 2021, 33, e257-e263.	1.4	3

#	ARTICLE	IF	CITATIONS
2438	Sexual-Sparing Robot Assisted Radical Cystectomy in Female: A Step-By-Step Guide. <i>Urology</i> , 2021, 156, 322-323.	1.0	9
2439	What is the Optimal Dose, Fractionation and Volume for Bladder Radiotherapy?. <i>Clinical Oncology</i> , 2021, 33, e245-e250.	1.4	3
2440	Comparison of intracorporeal versus extracorporeal urinary diversion after robot-assisted radical cystectomy at a medium-sized facility. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1714-1721.	2.2	3
2441	A Novel Nomogram Based on Machine Learning-Pathomics Signature and Neutrophil to Lymphocyte Ratio for Survival Prediction of Bladder Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 703033.	2.8	8
2442	RAZOR trial: analysis of 3-year follow-up: an era of robotic radical cystectomy: is it a new beginning?. <i>African Journal of Urology</i> , 2021, 27, .	0.4	0
2443	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114.	27.0	427
2444	ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. <i>Nature</i> , 2021, 595, 432-437.	27.8	293
2445	A comparative study of perioperative and survival outcomes of robot-assisted radical cystectomy in patients over 80 and under 80 years old. <i>World Journal of Surgical Oncology</i> , 2021, 19, 202.	1.9	11
2446	Neoadjuvant Chemotherapy Followed by Cystectomy: a Single-Center Experience. <i>Indian Journal of Surgical Oncology</i> , 0, , 1.	0.7	0
2447	Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7201.	4.1	8
2448	Single Incision Robotic Cystectomy and Hybrid Orthotopic Neobladder Reconstruction: A Step by Step Description. <i>Urology</i> , 2021, 156, 285-288.	1.0	3
2449	PROGNOSTIC FACTORS TOWARD BLADDER CANCER PATIENT RECOVERY AFTER RADICAL CYSTECTOMY SURGERY. <i>Jurnal Urologi Indonesia</i> , 2021, 28, 135-141.	0.0	0
2450	Factors affecting recurrence after transurethral treatment of muscle-invasive bladder cancer. <i>African Journal of Urology</i> , 2021, 27, .	0.4	1
2451	Shorter Leukocyte Telomere Length Is Associated with Worse Survival of Patients with Bladder Cancer and Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3774.	3.7	3
2452	Comparison of clips and electrosurgical instruments in sealing of lymphatic vessels during pelvic lymph node dissection at the time of radical cystectomy. <i>Onkourologiya</i> , 2021, 17, 93-102.	0.3	0
2453	A gravity-assisted approach to the management of urinary diversion: 99mTc-MAG3 diuresis renography with F-18 NaF PET/CT method. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1127-1135.	2.2	2
2454	Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer. <i>Anticancer Research</i> , 2021, 41, 3741-3746.	1.1	4
2455	Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 3903.	3.7	5

#	ARTICLE	IF	CITATIONS
2456	Identification of Biomarkers Related to Prognosis of Bladder Transitional Cell Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 682237.	2.3	3
2457	Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e9-496.e15.	1.6	8
2458	Young age increases the risk of lymph node positivity but improves prognosis in patients with bladder cancer treated via cystectomy: a population-based study. <i>Translational Andrology and Urology</i> , 2021, 10, 3375-3385.	1.4	1
2459	Extranodal Extension Predicts Poor Survival Outcomes among Patients with Bladder Cancer. <i>Cancers</i> , 2021, 13, 4108.	3.7	1
2460	Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence. <i>Urology</i> , 2021, 154, 8-15.	1.0	4
2461	Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy. <i>Biomedicines</i> , 2021, 9, 1125.	3.2	1
2462	Contemporary outcomes of bladder carcinoma <i>in situ</i> treated with an adequate bacille Calmette-Guérin immunotherapy. <i>BJU International</i> , 2022, 129, 542-550.	2.5	4
2463	Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. <i>Radiotherapy and Oncology</i> , 2021, 161, 95-114.	0.6	19
2464	Psoas Muscle Mass can Predict Postsurgical Outcomes in Patients Who Undergo Radical Cystectomy and Urinary Diversion Reconstruction. <i>Urology</i> , 2021, 158, 142-149.	1.0	7
2466	Complication Rate after Radical Cystectomy Depends on the Surgical Technique and Patient's Clinical Status. <i>Urologia Internationalis</i> , 2021, , 1-8.	1.3	3
2467	Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers. <i>Scandinavian Journal of Urology</i> , 2021, 55, 448-454.	1.0	2
2468	¿Puede la cirugía mínimamente invasiva resultar en sitios inusuales de metástasis?. <i>Actas Urológicas Españolas</i> , 2021, 45, 512-519.	0.7	0
2469	Does minimally invasive surgery for bladder cancer result in unusual sites of metastasis?. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 512-519.	0.2	1
2470	Single-session laparoscopic cystectomy and nephroureterectomy: is it real and useful choice of treatment or fiction?. <i>Journal of Surgical Case Reports</i> , 2021, 2021, rjab409.	0.4	1
2471	Impact of preoperative chemotherapy on pathologic nodal status in muscle-invasive bladder cancer: optimal lymphadenectomy in the preoperative chemotherapy era. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	2.5	0
2472	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 734963.	2.8	4
2473	Setting standards for cystectomy using the British Association of Urological Surgeons Complex Operations Reports, 2016-2018. <i>Journal of Clinical Urology</i> , 0, , 205141582110334.	0.1	0
2474	Prediction of Metastatic Patterns in Bladder Cancer: Spatiotemporal Progression and Development of a Novel, Web-based Platform for Clinical Utility. <i>European Urology Open Science</i> , 2021, 32, 8-18.	0.4	8

#	ARTICLE	IF	CITATIONS
2475	Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 732.e9-732.e16.	1.6	6
2476	PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 734.e1-734.e10.	1.6	4
2477	Robotic-Assisted Radical Cystectomy Outcomes. , 2021, , 1149-1157.		0
2479	Role of immunotherapy in bladder cancer. Cancer Treatment and Research Communications, 2021, 26, 100296.	1.7	41
2481	Orthotopic MAINZ pouch bladder substitution â€“ long-term follow-up. Central European Journal of Urology, 2021, 74, 235-240.	0.3	2
2483	Imaging of Urinary Tract Tumors. Cancer Treatment and Research, 2008, 143, 299-317.	0.5	5
2484	Radical Cystectomy in Muscle-Infiltrative Bladder Cancer and Conservative Treatment in Localized Disease. , 2013, , 247-263.		3
2485	Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers. , 2015, , 1-30.		3
2486	Chemotherapy for Metastatic Bladder Cancer. , 2011, , 409-431.		2
2487	Economics of Bladder Cancer Diagnosis and Surveillance. , 2011, , 121-137.		1
2489	Patient Selection and Perioperative Management. , 2007, , 47-53.		2
2490	Robot-Assisted Radical Cystectomy in Male: Technique of Spaces. , 2011, , 503-510.		1
2491	Simultaneous Segmentation of Multiple Regions in 3D Bladder MRI by Efficient Convex Optimization of Coupled Surfaces. Lecture Notes in Computer Science, 2017, , 528-542.	1.3	10
2492	Acute Postoperative Complications. , 2007, , 364-429.		2
2493	Harnableitung. , 2009, , 91-116.		1
2494	Harnblasenkarzinom. , 2014, , 415-502.		3
2495	Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. International Urology and Nephrology, 2019, 51, 435-441.	1.4	8
2496	Nonâ€“Muscle-Invasive Bladder Cancer (Ta, T1, and CIS). , 2012, , 2335-2354.e8.		17

#	ARTICLE	IF	CITATIONS
2497	Surgery for Bladder Cancer. , 2012, , 2375-2385.e1.		8
2498	Orthotopic Urinary Diversion. , 2012, , 2479-2506.e5.		12
2500	Adult Genitourinary Cancer—Prostate and Bladder. , 2007, , 523-569.		3
2501	Efecto de la quimioterapia adyuvante en el carcinoma urotelial de vejiga localmente avanzado tratado con cistectomía. Actas Urológicas Españolas, 2020, 44, 94-102.	0.7	1
2502	Long-term Health-related Quality of Life Outcomes Following Radical Cystectomy. Urology, 2017, 106, 82-86.	1.0	21
2503	Genitourinary malignancies. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 547-564.	0.5	2
2504	Significance of age and comorbidity as prognostic indicators for patients with bladder cancer. Asian Journal of Andrology, 2010, 12, 766-774.	1.6	7
2505	CircRNA circPDSS1 promotes bladder cancer by down-regulating miR-16. Bioscience Reports, 2020, 40, .	2.4	17
2506	IMPACT OF SEPARATE VERSUS EN BLOC PELVIC LYMPH NODE DISSECTION ON THE NUMBER OF LYMPH NODES RETRIEVED IN CYSTECTOMY SPECIMENS. Journal of Urology, 2001, , 2295-2296.	0.4	9
2507	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2002, , 1295-1298.	0.4	8
2508	A MULTICENTER STUDY OF THE MORBIDITY OF RADICAL CYSTECTOMY IN SELECT ELDERLY PATIENTS WITH BLADDER CANCER. Journal of Urology, 2002, , 1325-1328.	0.4	6
2509	Long-Term Voiding Pattern of Patients With Ileal Orthotopic Bladder Substitutes. Journal of Urology, 2002, , 2052-2057.	0.4	7
2510	Distressful Symptoms and Well-being After Radical Cystectomy and Orthotopic Bladder Substitution Compared With a Matched Control Population. Journal of Urology, 2002, , 168-175.	0.4	6
2511	Preservation of the Anterior Vaginal Wall During Female Radical Cystectomy With Orthotopic Urinary Diversion: Technique and Results. Journal of Urology, 2002, , 1442-1445.	0.4	2
2512	An Interval Longer than 12 Weeks Between the Diagnosis of Muscle Invasion and Cystectomy is Associated with Worse Outcome in Bladder Carcinoma. Journal of Urology, 2003, , 110-115.	0.4	6
2513	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. Journal of Urology, 2003, , 177-181.	0.4	4
2514	A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. Journal of Urology, 2003, 169, 96-100; discussion 100.	0.4	82
2515	Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. Journal of Urology, 2020, 203, 522-529.	0.4	75

#	ARTICLE	IF	CITATIONS
2516	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. <i>Journal of Urology</i> , 2020, 204, 460-465.	0.4	2
2517	Metastatic transitional cell carcinoma of the tibia radiologically mimicking osteosarcoma. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200626-bcr2013200626.	0.5	1
2518	The prognostic value of De Ritis (AST/ALT) ratio in patients after surgery for urothelial carcinoma: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2020, 20, 39.	4.1	13
2519	Urinary schistosomiasis and the associated bladder cancer: update. <i>Journal of the Egyptian National Cancer Institute</i> , 2020, 32, 44.	1.5	28
2520	A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. <i>PLOS Currents</i> , 2011, 3, RRN1248.	1.4	11
2521	Functional Promoter -94 ins/del ATG Polymorphism in NFKB1 Gene Is Associated with Bladder Cancer Risk in a Chinese Population. <i>PLoS ONE</i> , 2013, 8, e71604.	2.5	30
2522	A Retrospective Analysis of Incidence and Its Associated Risk Factors of Upper Urinary Tract Recurrence following Radical Cystectomy for Bladder Cancer with Transitional Cell Carcinoma: The Significance of Local Pelvic Recurrence and Positive Lymph Node. <i>PLoS ONE</i> , 2014, 9, e96467.	2.5	15
2523	The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder. <i>PLoS ONE</i> , 2014, 9, e105326.	2.5	26
2524	Protein Profiling of Bladder Urothelial Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0161922.	2.5	9
2525	Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. <i>PLoS ONE</i> , 2017, 12, e0187975.	2.5	4
2526	Bladder preservation in the treatment of muscle-invasive bladder cancer. <i>Bladder</i> , 2014, 1, 5.	0.2	2
2527	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. <i>Bladder</i> , 2018, 5, e34.	0.2	2
2528	MiR-381-3p/RAB2A axis activates cell proliferation and inhibits cell apoptosis in bladder cancer. <i>Cellular and Molecular Biology</i> , 2020, 66, 117-120.	0.9	7
2529	Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 300-306.	1.2	12
2530	Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? Opinion: Yes. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 184-187.	1.5	10
2531	Long noncoding RNA NNT-AS1 enhances the malignant phenotype of bladder cancer by acting as a competing endogenous RNA on microRNA-496 thereby increasing HMGB1 expression. <i>Aging</i> , 2019, 11, 12624-12640.	3.1	12
2532	A greater number of dissected lymph nodes is associated with more favorable outcomes in bladder cancer treated by radical cystectomy: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 61284-61294.	1.8	31
2533	Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. <i>Oncotarget</i> , 2017, 8, 38378-38388.	1.8	83

#	ARTICLE	IF	CITATIONS
2534	Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma. <i>Oncotarget</i> , 2017, 8, 71117-71127.	1.8	4
2535	FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. <i>Oncotarget</i> , 2017, 8, 47595-47606.	1.8	16
2536	The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. <i>Oncotarget</i> , 2017, 8, 58642-58653.	1.8	58
2537	Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer. <i>Oncotarget</i> , 2017, 8, 65492-65505.	1.8	9
2538	Overexpression of COL3A1 confers a poor prognosis in human bladder cancer identified by co-expression analysis. <i>Oncotarget</i> , 2017, 8, 70508-70520.	1.8	77
2539	Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium. <i>Oncotarget</i> , 2018, 9, 8765-8771.	1.8	5
2540	DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer. <i>Oncotarget</i> , 2015, 6, 24119-24131.	1.8	42
2541	Adenovirus-mediated downregulation of the ubiquitin ligase RNF8 sensitizes bladder cancer to radiotherapy. <i>Oncotarget</i> , 2016, 7, 8956-8967.	1.8	14
2542	Metastasectomy of oligometastatic urothelial cancer: a single-center experience. <i>Translational Andrology and Urology</i> , 2020, 9, 1296-1305.	1.4	10
2543	Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2920-2937.	1.4	14
2544	Radical cystectomy: a review of techniques, developments and controversies. <i>Translational Andrology and Urology</i> , 2020, 9, 3073-3081.	1.4	16
2545	Perioperative immunotherapy in muscle-invasive bladder cancer. <i>Translational Cancer Research</i> , 2020, 9, 6546-6553.	1.0	8
2546	Bladder Cancer: Innovative Approaches Beyond the Diagnosis. <i>Current Medicinal Chemistry</i> , 2014, 21, 2219-2236.	2.4	9
2547	Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis. <i>Current Molecular Pharmacology</i> , 2020, 13, 150-172.	1.5	9
2548	Bladder-sparing treatment in MIBC: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 101-112.	3.9	17
2549	A systematic review and meta-analysis comparing the outcomes of open and robotic assisted radical cystectomy. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 553-568.	3.9	32
2550	Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. <i>Health Technology Assessment</i> , 2010, 14, 1-331, iii-iv.	2.8	236
2551	Optimal timing of chemotherapy and cystectomy. <i>F1000 Medicine Reports</i> , 2010, 2, .	2.9	1

#	ARTICLE	IF	CITATIONS
2552	Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Translational Andrology and Urology, 2015, 4, 273-82.	1.4	4
2553	Robotic radical cystectomy and intracorporeal urinary diversion: The USC technique. Indian Journal of Urology, 2014, 30, 300.	0.6	30
2554	Is frozen section analysis of the urethra at the time of radical cystectomy and orthotopic neobladder urinary diversion mandatory?. Indian Journal of Urology, 2015, 31, 349.	0.6	7
2555	Treatment options in non-muscle-invasive bladder cancer after BCG failure. Indian Journal of Urology, 2015, 31, 312.	0.6	16
2556	An audit of early complications of radical cystectomy using Clavien-Dindo classification. Indian Journal of Urology, 2016, 32, 282.	0.6	12
2557	Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer. Indian Journal of Urology, 2008, 24, 77.	0.6	2
2558	Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder. Indian Journal of Urology, 2008, 24, 48.	0.6	4
2559	Radical cystectomy for bladder cancer: A single center experience. Indian Journal of Urology, 2008, 24, 54.	0.6	16
2560	Treatment of locally advanced and metastatic bladder cancer. Indian Journal of Urology, 2008, 24, 84.	0.6	5
2561	Technical steps of open radical cystectomy and orthotopic neobladder to achieve the goals of "minimally invasive surgery". Indian Journal of Urology, 2010, 26, 457.	0.6	4
2562	Does preoperative neutrophil/lymphocyte rate have an effect on survival of the bladder cancer patients who received radical cystectomy?. Journal of Cancer Research and Therapeutics, 2018, 14, 432-436.	0.9	2
2563	CA 19-9 as a serum marker in urothelial carcinoma. Urology Annals, 2012, 4, 98.	0.6	14
2564	Role of laparoscopy in the era of robotic surgery in urology in developing countries. Indian Journal of Urology, 2021, 37, 32.	0.6	11
2565	Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?. Indian Journal of Urology, 2017, 33, 111.	0.6	7
2566	New therapies in nonmuscle invasive bladder cancer treatment. Indian Journal of Urology, 2018, 34, 11.	0.6	35
2567	The current status of robot-assisted cystectomy. Indian Journal of Urology, 2018, 34, 101.	0.6	17
2568	The Feasibility of Robot-Assisted Laparoscopic Radical Cystectomy with Pelvic Lymphadenectomy: from the Viewpoint of Extended Pelvic Lymphadenectomy. Korean Journal of Urology, 2009, 50, 870.	1.2	7
2569	Clinical Prognostic Factors for Radical Cystectomy in Bladder Cancer. Cancer Research and Treatment, 2005, 37, 48.	3.0	4

#	ARTICLE	IF	CITATIONS
2570	Detecting Metastatic Bladder Cancer Using ^{18}F -Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography. <i>Cancer Research and Treatment</i> , 2015, 47, 834-843.	3.0	17
2571	PET/CT and MRI in Bladder Cancer. <i>Journal of Cancer Science & Therapy</i> , 2012, s14, .	1.7	30
2572	Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2009, 1, 62.	2.0	6
2574	Cistectomía radical laparoscópica: ¿Dónde estamos?. <i>Archivos Espanoles De Urologia</i> , 2010, 63, .	0.2	5
2575	Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy. <i>World Journal of Radiology</i> , 2014, 6, 344.	1.1	34
2576	Is survival after radical cystectomy for bladder cancer in Saudi patients different from that of Western patients?. <i>Annals of Saudi Medicine</i> , 2017, 37, 194-200.	1.1	2
2577	Prognostic significance of tumor budding in muscle invasive urothelial carcinomas of the bladder. <i>Turkish Journal of Urology</i> , 2019, 45, 273-278.	1.3	8
2578	The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres – results of CysTiming Poland study. <i>Central European Journal of Urology</i> , 2014, 67, 329-32.	0.3	10
2579	Clinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder. <i>Central European Journal of Urology</i> , 2015, 68, 30-6.	0.3	15
2580	Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience. <i>Central European Journal of Urology</i> , 2015, 68, 278-83.	0.3	14
2581	Current role of lymphadenectomy in the upper tract urothelial carcinoma. <i>Central European Journal of Urology</i> , 2016, 69, 384-390.	0.3	7
2582	Factors affecting one-year survival after radical cystectomy: a prospective study. <i>Central European Journal of Urology</i> , 2017, 70, 238-244.	0.3	2
2583	Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer. <i>Central European Journal of Urology</i> , 2020, 73, 26-32.	0.3	5
2584	Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract. <i>World Journal of Clinical Oncology</i> , 2015, 6, 237.	2.3	18
2585	Identification of lymphatic pathway involved in the spread of bladder cancer: Evidence obtained from fluorescence navigation with intraoperatively injected indocyanine green. <i>Canadian Urological Association Journal</i> , 2013, 7, E322-8.	0.6	13
2586	In-vitro cytotoxic effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomy. <i>Canadian Urological Association Journal</i> , 2015, 9, 109.	0.6	7
2587	Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. <i>Canadian Urological Association Journal</i> , 2015, 9, 207.	0.6	13
2588	Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta. <i>Canadian Urological Association Journal</i> , 2016, 10, 33.	0.6	12

#	ARTICLE	IF	CITATIONS
2589	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Canadian Urological Association Journal, 2016, 10, 90.	0.6	6
2590	Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients. Chinese Journal of Cancer, 2014, 33, 165-171.	4.9	11
2591	Molecular Diagnostics in Urologic Malignancies: A Work in Progress. Archives of Pathology and Laboratory Medicine, 2011, 135, 610-621.	2.5	24
2592	Comorbidity Relationship to Outcome of Radical Cystectomy in Chinese: a Single Institution Study with the ACE-27 Comorbidity Index. Asian Pacific Journal of Cancer Prevention, 2012, 13, 827-831.	1.2	3
2593	Comparison of Radical Cystectomy and Chemoradiotherapy in Patients with Locally Advanced Bladder Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6519-6524.	1.2	9
2594	Increased expression of POLR3G predicts poor prognosis in transitional cell carcinoma. PeerJ, 2020, 8, e10281.	2.0	10
2596	Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer. Cancer Management and Research, 2021, Volume 13, 7833-7839.	1.9	4
2597	Comparing Prognosis Associated with Partial Cystectomy and Trimodal Therapy for Muscle-Invasive Bladder Cancer Patients. Urologia Internationalis, 2023, 107, 46-57.	1.3	1
2598	Emerging roles of autophagy in the development and treatment of urothelial carcinoma of the bladder. Expert Opinion on Therapeutic Targets, 2021, 25, 787-797.	3.4	6
2599	Expression of proto-oncogene c-Myc in patients with urinary bladder transitional cell carcinoma. Current Urology, 2021, Publish Ahead of Print, 231-233.	0.6	3
2600	Genitourinary Malignancies: Bladder/Penis/Urethral Cancers. , 2003, , 521-530.		0
2603	Selected Disorders of the Genitourinary System. , 2003, , 852-858.		0
2604	Intensity-Modulated Radiation Therapy for Lymph Node Metastases in Bladder Cancer. Medical Radiology, 2004, , 157-169.	0.1	0
2605	Orthotopic bladder replacement in women. , 2004, , 189-195.		0
2606	Indications et résultats actuels de l'entéroplastie de substitution après cystectomie radicale. Bulletin De L'Academie Nationale De Medecine, 2005, 189, 123-134.	0.0	0
2607	Ureter, Bladder, Penis, and Urethra. , 2006, , 813-832.		0
2611	Urologic Oncology. , 2007, , 387-401.		0
2613	Regional Therapy of Bladder Tumors. , 2007, , 343-353.		0

#	ARTICLE	IF	CITATIONS
2614	Combined Chemoradiotherapy Advances. Cancer Treatment and Research, 2008, , 277-301.	0.5	1
2616	Multidisciplinary Care of Invasive Bladder Cancer: Emerging Roles of Chemotherapy. , 2008, , 361-376.		0
2619	Robotic-Assisted Radical Cystectomy. , 2008, , 113-132.		0
2621	Neoadjuvant Chemotherapy: The New Standard. , 2009, , 231-237.		0
2622	Presence and Significance of Micrometastases. , 2009, , 79-88.		0
2623	Reoperation for Bladder Cancer. , 2009, , 61-79.		0
2624	Detection of Extravesical Disease: A Lack of Bladder Cancer Markers. , 2009, , 55-65.		1
2625	Adjuvant Chemotherapy in Bladder Cancer: A Good Concept But Whereâ€™s the Proof?. , 2009, , 239-245.		1
2626	Continent Diversion: QOL of Orthotopic Diversion vs. Ileal Conduit. , 2009, , 190-199.		0
2627	Identification of Nodal Metastases: The role of Iron Oxide Enhanced MRI. , 2009, , 67-77.		0
2628	Nerve Sparing Radical Cystectomy. , 2009, , 169-175.		0
2630	Nodal Staging of Cancer Using Diagnostic Optical Imaging Techniques. , 2010, , 185-207.		1
2631	Robotic-Assisted Radical Cystectomy. , 2010, , 11-18.		0
2632	Cancer of the Genitourinary Tract. , 2010, , 233-277.		0
2633	Cancer of the Bladder. , 2010, , 901-924.		0
2635	Laparoscopic Cystectomy and Urinary Diversion. , 2010, , 277-289.		0
2637	Laparoscopic Cystectomy and Robotic-Assisted Cystectomy. , 2011, , 365-376.		0
2638	Cystectomy for Nonmuscle-Invasive Bladder Cancer. , 2011, , 297-310.		0

#	ARTICLE	IF	CITATIONS
2639	Prognostic Markers for Bladder Cancer. , 2011, , 139-163.		6
2640	Radical Surgery for Muscle-Invasive Bladder Cancer. , 2011, , 311-330.		0
2641	Molecular Signatures of Bladder Cancer. , 2011, , 91-119.		0
2642	Robotic Radical Cystectomy and Use of Intestinal Segments for Reconstruction in the Adult Patient. , 2011, , 153-165.		0
2643	Treatment of Low-Grade Bladder Tumors. , 2011, , 237-252.		0
2644	Molecular Nomograms for Predicting Prognosis and Treatment Response. , 2011, , 165-191.		0
2645	Robotic-Assisted Urologic Applications. , 2011, , 679-700.		0
2646	Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Bladder Cancer. , 2011, , 523-532.		0
2647	Robotic-Assisted Radical Cystectomy. , 2011, , 397-407.		0
2648	Intra-arterial Combination Chemotherapy with Maximum Transurethral Resection of Bladder Tumour for T1 Grade 3 and T2-3NOM0 Bladder Cancers. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	0
2649	Genitourinary Cancer. , 2011, , 459-479.		4
2651	Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder. Indian Journal of Urology, 2011, 27, 262.	0.6	0
2653	Urothelial Carcinoma: Role of Perioperative Systemic Chemotherapy. , 2012, , 283-292.		0
2654	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
2655	Bladder Cancer Overview and Staging. , 2012, , 83-112.		0
2657	Management of Metastatic and Invasive Bladder Cancer. , 2012, , 2355-2374.e6.		4
2658	Microwave-induced hyperthermia and microwave tissue coagulation for bladder cancer patients. Journal of Microwave Surgery, 2012, 30, 231-237.	0.3	0
2659	Molecular Pathogenesis of Bladder Cancer. , 2012, , 323-343.		0

#	ARTICLE	IF	CITATIONS
2661	Robot-Assisted Radical Cystectomy as a Treatment Modality for Patients with Muscle-Invasive Bladder Cancer. , 0, , .		0
2662	UHRF1 is a Potential Molecular Marker for Diagnosis and Prognosis of Bladder Cancer. , 0, , .		0
2663	A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Chemoradiation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 200-206.	3.8	0
2665	Oncologic Outcomes. , 2014, , 137-144.		0
2666	Questions and Concerns of Robotic Approaches to Bladder Cancer Surgery. , 2014, , 177-195.		0
2667	Perioperative Outcomes and Complications of Robot-Assisted Cystectomy. , 2014, , 145-158.		0
2668	Perioperative Care: The Radical Cystectomy Pathway. , 2014, , 127-136.		0
2669	Robot-Assisted Pelvic Lymphadenectomy. , 2014, , 93-101.		0
2670	Principles of Bladder Cancer Surgery. , 2014, , 5-25.		1
2671	History of Minimally Invasive Techniques for Radical Cystectomy with Urinary Diversion. , 2014, , 1-4.		0
2672	Age, tumour stage, and preoperative serum albumin level are independent predictors of mortality after radical cystectomy for treatment of bladder cancer in Hong Kong Chinese. Hong Kong Medical Journal, 2013, 19, 400-6.	0.1	11
2673	Radical Cystectomy in Elderly Patients, Single Center, 25 Years Experience. Clinical Medicine Research, 2014, 3, 206.	0.1	0
2674	Knochenmetastasen bei urologischen Malignomen. , 2014, , 177-192.		0
2676	Inkontinente Harnableitungen. , 2014, , 1-17.		0
2678	Urothelkarzinom der Harnblase: Chirurgische Therapie. , 2014, , 1-22.		0
2679	New Imaging Techniques in the Staging of Urothelial Carcinoma of the Bladder. , 2015, , 73-83.		0
2684	The Role of Chemotherapy and Radiotherapy in the Surgical Management of Muscle Invasive Bladder Cancer. International Journal of Medical Students, 2014, 2, 125-131.	0.5	0
2686	Quality of Life Measures. , 2015, , 95-110.		0

#	ARTICLE	IF	CITATIONS
2688	Prognostication and Risk Assessment. , 2015, , 111-143.		0
2689	Invasive Bladder Cancer: Combined Modality Treatment. , 2015, , 591-608.		0
2690	MANAGEMENT OF CARCINOMA BLADDER: A REVIEW LITERATURE. Journal of Evolution of Medical and Dental Sciences, 2014, 4, 95-111.	0.1	0
2691	Pelvic Lymphadenectomy for Prostate and Bladder Cancer. , 2015, , 69-78.		0
2692	Gasless Single-Port RoboSurgeon Partial Cystectomy: A Hybrid Technique Combining an Intravesical and Extravesical Approach. , 2015, , 143-158.		0
2693	Management of Pelvic Retroperitoneal Tumors. , 2015, , 209-216.		0
2694	History of the Robotic Surgical System. , 2015, , 3-17.		0
2695	Comparative Effectiveness Research in Urologic Cancers. Cancer Treatment and Research, 2015, 164, 221-235.	0.5	0
2696	Retrospective analysis of hospital data. Journal of Clinical Neonatology, 2015, 4, 218.	0.2	0
2697	Radical Cystectomy: Robotic, Laparoscopic, Open and Partial. , 2015, , 155-164.		0
2698	The Importance of Lymphovascular Invasion at Radical Cystectomy. Clinical Medicine Research, 2015, 4, 34.	0.1	0
2699	Gasless Single-Port RoboSurgeon Total Cystectomy with Urinary Diversion. , 2015, , 127-141.		1
2700	Predictors of Oncologic Outcomes After Treatment of Urothelial Cancer. , 2015, , 577-591.		1
2701	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
2702	Positron Emission Tomography/Computed Tomography in Bladder Carcinoma. Åœroonkoloji BÃ¼lteni, 2015, 14, 13-17.	0.1	1
2715	Inkontinente Harnableitungen. , 2016, , 797-809.		0
2716	Urothelkarzinom der Harnblase: Chirurgische Therapie. , 2016, , 735-749.		0
2717	Alternative Verfahren bei Urothelkarzinom. , 2016, , 99-127.		0

#	ARTICLE	IF	CITATIONS
2718	Synchronous dual primary malignancy of urinary bladder and hypopharynx: An extremely rare phenomenon. The Journal of Clinical and Scientific Research, 2016, 5, 136.	0.1	0
2719	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2016, , 1-43.		0
2720	Selecting Patients for Continent or Incontinent, Heterotopic or Orthotopic Diversion. , 2016, , 39-57.		0
2721	Ileal Orthotopic Bladder Replacement without Stenting of the Ureterointestinal Anastomosis-10 Years Observation. Urology & Nephrology Open Access Journal, 2016, 2, .	0.1	0
2722	Early Experiences with Studerâ€™s Orthotopic Neobladder. Medical Journal of Shree Birendra Hospital, 2016, 14, 9-15.	0.0	0
2723	RNAi-Mediated Knockdown of Skp2 Inhibits Human Bladder Cancer Proliferation and Invasion in T24 Cells. Iranian Red Crescent Medical Journal, 2016, 19, .	0.5	0
2724	Age Adjusted Charlson Comorbidity Index: Predictor of 90-Day Mortality after Radical Cystectomy. Journal of Surgery Operative Care, 2016, 1, .	0.0	0
2725	Dynamics of indicators of early and late results of radical cystectomy depending on the time of the surgery from 2005 to 2016. Health of Man, 2016, .	0.0	1
2726	Patient Selection for Urinary Diversion. , 2017, , 1-10.		0
2727	Laparoscopic Radical Cystectomy with Intracorporeal Ileal Conduit. , 2017, , 483-492.		0
2728	Harnblasenkarzinom beim alten und geriatrischen Patienten. , 2017, , 1-12.		0
2729	Target Volume Delineation Target Volume Delineation for bladder cancer Guidelines in Bladder Cancer. , 2017, , 75-84.		0
2730	Systemic Therapy for Bladder Cancer. , 2017, , 103-109.		0
2731	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2017, , 839-881.		0
2732	Matrix metalloproteinases in urinary system tumors. Part II - Matrix metalloproteinases in urinary bladder carcinoma. Progress in Health Sciences, 2017, 7, 0-0.	0.1	0
2733	Radical cystectomy: a comparative evaluation of perioperative outcomes in patients with a complicated and uncomplicated postoperative period. Health of Man, 2017, .	0.0	1
2734	Impact of preoperative diagnostic TURBT on progression-free survival in patients with pathological high-grade, stage T3/T4 bladder urothelial carcinoma. Oncotarget, 2017, 8, 89228-89235.	1.8	1
2736	Risk Stratification and Prognostication of Bladder Cancer. , 2018, , 1-14.		0

#	ARTICLE	IF	CITATIONS
2737	Impact of Histologic Variants of Bladder Cancer on Oncology Outcome After Radical Cystectomy. The Korean Journal of Urological Oncology, 2017, 15, 121-130.	0.1	0
2738	Multimodality Treatment for Bladder Conservation. , 2018, , 1-10.		0
2739	Local Treatment, Radical Cystectomy, and Urinary Diversion. , 2018, , 1-21.		0
2740	Bladder Cancer in Older Adults. , 2018, , 1-18.		0
2741	Radical robot-assisted cystectomy: experience of the first 20 operations. Endoscopic Surgery, 2018, 24, 3.	0.2	0
2742	Systemic Chemotherapy for Upper Tract Urothelial Cancer. , 2018, , 315-321.		0
2743	Metastatic Nodal Pattern: Is There a Role for Paraaortic Lymph Node Dissection. , 2018, , 255-266.		0
2744	Minimally Invasive Radical Cystectomy and Its Role and Future in Treatment of Bladder Cancer Patients. Myth or Reality?. , 2018, , 65-74.		0
2745	Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Bladder Cancer. , 2018, , 743-754.		0
2746	Postoperative rehabilitation after radical cystectomy with urinary reservoir plasty. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 14.	0.2	0
2747	Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer. Journal of Cancer Research and Therapeutics, 2018, 14, 1260-1265.	0.9	24
2748	Radiotherapy for the Treatment of Muscle-Invasive Bladder Cancer. , 2018, , 83-89.		0
2749	Robotically-Assisted Laparoscopic Radical Cystoprostatectomy and Anterior Exenteration. , 2018, , 131-157.		0
2750	Is There Still a Role for Radical Cystectomy?. , 2018, , 55-64.		0
2751	Developments in the area of bladder cancer genomics and its importance in the treatment selection. , 2018, 02, .		2
2752	Harnblasenkarzinom beim alten und geriatrischen Patienten. , 2018, , 461-472.		0
2753	The activity lactate dehydrogenase in the artificial bladder (experimental study). Urology, 2018, 22, .	0.1	0
2754	Robotic radical cystectomy for the management of bladder cancer: Analysis of operative and pathological outcomes of eighteen patient. Turkish Journal of Urology, 2018, 44, 311-315.	1.3	2

#	ARTICLE	IF	CITATIONS
2755	Prediction of early postoperative complications of radical cystectomy with different method of urinary derivation through methods of mathematical modeling. Urology, 2018, 22, .	0.1	1
2756	Preoperative AST/ALT (De Ritis) Ratio as a Prognostic Factor in a Cohort of Patients who underwent radical cystectomy. Cumhuriyet Medical Journal, 0, , .	0.1	0
2757	Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. Indian Journal of Cancer, 2019, 56, 54.	0.2	10
2758	Kontinente Harnableitung. Springer Reference Medizin, 2019, , 1-8.	0.0	0
2759	Is robotic approach useful to palliate advanced bladder cancer? A monocentric single surgeon experience. Central European Journal of Urology, 2019, 72, 113-120.	0.3	3
2760	Predictors of Oncologic Outcomes After Treatment of Urothelial Cancer. , 2019, , 659-673.		0
2761	Modified U-Shaped ileal neobladder designed for facilitating neobladder-urethral anastomosis in extracorporeal reconstruction after robotic-assisted radical cystectomy. Journal of Cancer Research and Therapeutics, 2019, 15, S51-S55.	0.9	2
2762	Survival and metastasis in muscle-invasive bladder cancer patients who present with indeterminate pulmonary nodules before treatment. Annals of Saudi Medicine, 2019, 39, 42-47.	1.1	0
2763	Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer: Mansoura Experience. Cancer Research Journal, 2019, 7, 1.	0.0	3
2764	Implementation of neoadjuvant chemotherapy in muscle invasive bladder cancer treatment in Poland: a single institution retrospective study. Central European Journal of Urology, 2019, 72, 100-105.	0.3	2
2766	Role of pelvic lymph node dissection in bladder cancer: is it better to do more?. Translational Cancer Research, 2019, 8, S180-S182.	1.0	0
2767	Lymphoepithelial “Like Carcinoma with Papillary Transitional Cell Carcinoma of the Urinary Bladder Associated with Carcinoma in situ Changes of the Urothelium; A Case Report and Review of Literature. , 2019, 14, 156-164.		1
2768	Oncologic, Perioperative Outcomes of Female Radical Cystectomy: Results from a Multicenter Study in Korea. Cancer Research and Treatment, 2019, 51, 1064-1072.	3.0	2
2769	Complicaciones posquirúrgicas en los pacientes con cáncer de vejiga tratados con cistectomía: Diferencias entre el abordaje abierto y laparoscópico. Actas Urológicas Españolas, 2019, 43, 305-313.	0.7	9
2770	Urinary undiversion from a sigma-rectum pouch to a cutaneous urinary stoma as a treatment for severe metabolic disorders post-radical cystectomy: A case report. Experimental and Therapeutic Medicine, 2019, 18, 4881-4887.	1.8	1
2771	Bladder Cancer in Older Adults. , 2020, , 671-688.		0
2772	Long Non-Coding RNAs to Predict Postoperative Recurrence in Muscle-Invasive Bladder Cancer and to Develop a New Molecular Classification System. SSRN Electronic Journal, 0, , .	0.4	0
2773	Evaluación del abordaje laparoscópico en la cistectomía radical desde la implantación hasta su consolidación: validación interna. Actas Urológicas Españolas, 2020, 44, 62-70.	0.7	3

#	ARTICLE	IF	CITATIONS
2774	Robot-Assisted and Open Radical Cystectomy: Comparative Analysis of Results. Urology Herald, 2020, 8, 59-68.	0.4	2
2775	Modelo predictivo de mortalidad en pacientes con tumor urotelial de vejiga tras cistectom�a radical. Actas Urol�gicas Espa�olas, 2020, 44, 215-223.	0.7	3
2776	Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy. Translational Andrology and Urology, 2020, 9, 1270-1277.	1.4	1
2777	Quality of surgical care can impact survival in patients with bladder cancer after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. African Journal of Urology, 2020, 26, .	0.4	0
2778	The significance of preoperative estimated glomerular filtration rate on survival outcomes in patients who underwent radical cystectomy and non-continent urinary diversion. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 566-574.	1.5	2
2779	miR-19a-3p Promotes Tumor-Relevant Behaviors in Bladder Urothelial Carcinoma via Targeting THBS1. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-11.	1.3	7
2780	Consensus statements from the EAU-ESMO collaboration for advanced and variant bladder cancer: can we move the needle to improve survival?. Translational Andrology and Urology, 2020, 9, 2488-2492.	1.4	1
2781	Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy Followed by Radical Cystectomy: A Single-Center Retrospective Study. The Korean Journal of Urological Oncology, 2020, 18, 194-200.	0.1	1
2782	The Significance of Neutrophil-to-Lymphocyte Ratio and Combined Chemoradiotherapy in Patients Undergoing Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer. Cancer Management and Research, 2020, Volume 12, 13125-13135.	1.9	2
2783	Surgical treatment of urinary bladder cancer. Onkologie (Czech Republic), 2019, 13, 195-200.	0.1	0
2785	Renal function outcomes in the early and intermediate phases after radical cystectomy by ileal conduit. Journal of Rural Medicine: JRM, 2020, 15, 178-182.	0.5	2
2786	Chemotherapeutic Agents for Urologic Oncology: Basic Principles. , 2020, , 611-637.		0
2787	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
2789	Malignant Tissue Optical Properties. , 2020, , 3-106.		2
2790	Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer. European Urology, 2022, 81, 62-63.	1.9	0
2791	Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience. South Asian Journal of Cancer, 2020, 09, 121-125.	0.6	1
2792	Harnblasenkarzinom. , 2014, , 415-502.		0
2793	Treatment Options in Superficial (pTA/pT1/CIS) Bladder Cancer. , 2005, , 131-144.		0

#	ARTICLE	IF	CITATIONS
2795	Molekulare Prognosemarker des Harnblasenkarzinoms. , 2005, , 27-65.		0
2796	Therapie des muskelinvasiven und des lokal fortgeschrittenen Blasenkarzinoms im Jahr 2004. , 2005, , 81-90.		0
2798	Komplikationen bei der transurethralen und offen-operativen Blasentumorchirurgie. , 2005, , 65-69.		0
2799	Wie verhindere ich Komplikationen nach orthotoper Harnableitung?. , 2005, , 159-164.		0
2801	Treatment Options in Superficial (pTa/pT1/CIS) Bladder Cancer. , 2007, , 75-101.		0
2802	Cross-Sectional Imaging of the Lower Urinary Tract. , 2009, , 185-199.		0
2803	Harnableitung. , 2007, , 151-175.		0
2805	Harnableitungsmethoden. , 2014, , 193-221.		0
2806	Urothelkarzinom der Harnblase. , 2014, , 175-195.		0
2807	Islam and urostoma: a modern view through the prism of a religiously traditional legal system. Onkourologiya, 2020, 16, 205-208.	0.3	0
2808	Determining the optimal treatment for advanced bladder cancer. Reviews in Urology, 2001, 3, 159-62.	0.9	0
2809	Selecting patients for immediate cystectomy. Reviews in Urology, 2007, 9, 239-41.	0.9	2
2810	Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Reviews in Urology, 2008, 10, 281-9.	0.9	21
2811	Urinary bladder carcinoma associated with Paget's disease of skull: Imaging findings on Tc99m-MDP bone scintigraphy, F18-Fluoride PET/CT and F18-FDG PET/CT. Indian Journal of Nuclear Medicine, 2011, 26, 42-3.	0.3	5
2812	Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. Canadian Urological Association Journal, 2012, 6, E217-23.	0.6	9
2813	Emerging intravesical therapies for management of nonmuscle invasive bladder cancer. Open Access Journal of Urology, 2010, 2, 67-84.	0.3	4
2814	Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder. International Journal of Clinical and Experimental Pathology, 2014, 7, 340-7.	0.5	19
2815	Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder. International Journal of Clinical and Experimental Pathology, 2014, 7, 4231-8.	0.5	10

#	ARTICLE	IF	CITATIONS
2816	B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 6768-75.	0.5	14
2817	Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application. American Journal of Cancer Research, 2015, 5, 854-68.	1.4	14
2818	Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 1954-60.	0.5	52
2819	Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer. Bladder, 2016, 3, .	0.2	1
2820	Emodin inhibits the proliferation and invasion of bladder cancer cells via down-regulating Notch1. International Journal of Clinical and Experimental Pathology, 2017, 10, 9452-9459.	0.5	3
2821	The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator. American Journal of Translational Research (discontinued), 2020, 12, 3033-3045.	0.0	4
2822	The down-regulation of SNCG inhibits the proliferation and invasiveness of human bladder cancer cell line 5637 and suppresses the expression of MMP-2/9. International Journal of Clinical and Experimental Pathology, 2020, 13, 1873-1879.	0.5	1
2824	Identification and validation of an immune-related gene-based prognostic index for bladder cancer. American Journal of Translational Research (discontinued), 2020, 12, 5188-5204.	0.0	6
2825	Prognostic significance of tumor-infiltrating immune cells in muscle-invasive bladder cancer. American Journal of Translational Research (discontinued), 2020, 12, 6524-6536.	0.0	3
2826	Laparoscopic radical cystectomy and nephroureterectomy resection with lomboarctic and pelvic lymph node dissection. Medicine and Pharmacy Reports, 2020, 93, 390-395.	0.4	0
2827	Comparative Analysis between Radical Cystectomy and Trimodality Therapy for Clinical Stage II Bladder Cancer. Urological Science, 2018, 29, 25-32.	0.6	0
2828	Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion. Urological Science, 2019, 30, 157-163.	0.6	0
2829	Advantages of an Intracorporeal W-shaped Neobladder. European Urology Open Science, 2022, 35, 14-15.	0.4	1
2830	Lip metastasis after radical cystectomy. Urology, 2021, , .	1.0	0
2831	Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions. International Journal of Molecular Sciences, 2021, 22, 12864.	4.1	9
2832	Long noncoding RNAs to predict postoperative recurrence in bladder cancer and to develop a new molecular classification system. Cancer Medicine, 2021, , .	2.8	2
2833	Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients. International Urology and Nephrology, 2022, 54, 71-79.	1.4	1
2834	Feasibility and Safety of Stentless Uretero-Intestinal Anastomosis in Radical Cystectomy with Ileal Orthotopic Neobladder. Journal of Clinical Medicine, 2021, 10, 5372.	2.4	1

#	ARTICLE	IF	CITATIONS
2835	Long-Term Renal Function Following Radical Cystectomy for Bladder Cancer. <i>Urology</i> , 2022, 160, 147-153.	1.0	11
2836	Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 37-37.	1.6	2
2837	The impact of 18F-fluorodeoxyglucose PET/computed tomography on clinical staging in bladder cancer. <i>Nuclear Medicine Communications</i> , 2022, 43, 172-176.	1.1	0
2838	Prognostic Effect of Preoperative Psoas Muscle Hounsfield Unit at Radical Cystectomy for Bladder Cancer. <i>Cancers</i> , 2021, 13, 5629.	3.7	3
2839	Imaging and quantifying analysis the binding behavior of PD-L1 at molecular resolution by atomic force microscopy. <i>Analytica Chimica Acta</i> , 2022, 1191, 339281.	5.4	5
2840	High-Grade Non-Muscle Invasive Bladder Cancer: When to Move to Early Radical Cystectomy?. <i>Cureus</i> , 2021, 13, e19399.	0.5	0
2841	Neoadjuvant chemotherapy for bladder cancer. <i>Journal of Cancer Research and Practice</i> , 2020, 7, 149.	0.2	1
2842	Gender-related outcomes in robot-assisted radical cystectomy: A multi-institutional study. <i>Investigative and Clinical Urology</i> , 2022, 63, 53.	2.0	0
2843	Avelumab in locally advanced or metastatic urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	2.4	1
2845	Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. <i>Journal of Urology</i> , 2022, 207, 302-313.	0.4	31
2846	Laparoscopic radical cystectomy and nephroureterectomy en bloc resection with lomboarctic and pelvic lymph node dissection. <i>Medicine and Pharmacy Reports</i> , 2020, 93, 390-395.	0.4	1
2847	Surgical management of urinary diversion and stomas in adults: multidisciplinary Italian panel guidelines. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	2
2848	An Investigation of the Pathology Report of Bladder Cancer Patients with Radical Cystectomy in Southern Iran, 2013-2018: A Cross-Sectional Study. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	1
2849	Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 497.	2.4	3
2850	Development and validation of pyroptosis-related lncRNAs prediction model for bladder cancer. <i>Bioscience Reports</i> , 2022, 42, .	2.4	2
2851	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	1.6	42
2852	Risk of recurrence and long-term mortality following radical cystectomy for bladder cancer. <i>Scandinavian Journal of Urology</i> , 2022, 56, 149-154.	1.0	3
2853	PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma. <i>Medicine (United States)</i> , 2022, 101, e28591.	1.0	0

#	ARTICLE	IF	CITATIONS
2854	Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors. Investigative and Clinical Urology, 2022, 63, 14.	2.0	0
2856	PET/CT in Bladder Cancer: An Update. Seminars in Nuclear Medicine, 2022, 52, 475-485.	4.6	14
2863	Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer. Central European Journal of Urology, 2022, 75, 41-46.	0.3	3
2864	Apparent Diffusion Coefficient Value as a Biomarker for Detecting Muscle-Invasive and High-Grade Bladder Cancer: A Systematic Review. Applied Sciences (Switzerland), 2022, 12, 1278.	2.5	2
2865	PET imaging in renal and bladder cancers. , 2022, , .		0
2866	Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer. Cancers, 2022, 14, 758.	3.7	10
2867	Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. Molecular Therapy - Oncolytics, 2022, 24, 507-521.	4.4	7
2868	Role of radiotherapy in the management of bladder cancer: Recommendations of the French society for radiation oncology. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 315-322.	1.4	2
2869	Is adjuvant immunotherapy effective in patients with urothelial cancer?. Minerva Urology and Nephrology, 2022, , .	2.5	0
2870	Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder. Expert Review of Anticancer Therapy, 2022, 22, 259-267.	2.4	1
2872	Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group. Cancers, 2022, 14, 1130.	3.7	4
2873	ERAS vs. Traditional Protocol in Patients Who Had Radical Cystectomy with Ileal Conduit: A Retrospective Comparative Analysis of 182 Cases. Advances in Urology, 2022, 2022, 1-5.	1.3	3
2874	The Predictive and Prognostic Value of Precystectomy Serum Gamma-Glutamyltransferase Levels in Patients With Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2022, , .	1.9	0
2875	New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2022, 20, 12-24.	0.1	0
2876	The role of single-nucleotide polymorphisms of the 8q24 chromosome region in patients with concomitant bladder and prostate cancer. Scandinavian Journal of Urology, 2022, 56, 126-130.	1.0	1
2877	MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma. Scientific Reports, 2022, 12, 4141.	3.3	10
2878	Long-term Health-related Quality of Life (HRQOL) After Radical Cystectomy and Urinary Diversion - A Propensity Score-matched Analysis. Clinical Genitourinary Cancer, 2022, 20, e283-e290.	1.9	5
2879	Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. Journal of Clinical Oncology, 2022, 40, 2013-2022.	1.6	75

#	ARTICLE	IF	CITATIONS
2880	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	1.6	22
2881	Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor (TURBT)-Dependent Practice. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e291-e295.	1.9	5
2882	The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Cancers</i> , 2022, 14, 1640.	3.7	3
2884	New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors. <i>Cancers</i> , 2022, 14, 1416.	3.7	7
2885	Detection of bladder cancer with feature fusion, transfer learning and CapsNets. <i>Artificial Intelligence in Medicine</i> , 2022, 126, 102275.	6.5	6
2887	Current standards and practice changing studies in genitourinary (GU) cancers—a review of studies in localized/early GU cancers. <i>ESMO Open</i> , 2022, 7, 100432.	4.5	0
2888	Preoperative Metabolic Syndrome and HDL-C Level Predict the Prognosis of Patients Following Radical Cystectomy: A Propensity Score Matching Study. <i>Frontiers in Oncology</i> , 2022, 12, 833305.	2.8	2
2889	Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?. <i>Translational Oncology</i> , 2022, 19, 101387.	3.7	2
2890	Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. <i>European Urology Open Science</i> , 2022, 39, 14-21.	0.4	7
2891	Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 38, 102838.	2.6	11
2892	Reduction of Perioperative Antibiotic Prophylaxis in Open Radical Cystectomy with Ileal Conduit Is Feasible: Results of a Prospective Clinical Trial. <i>Urologia Internationalis</i> , 2021, , 1-7.	1.3	1
2894	Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: technique and results. <i>Journal of Urology</i> , 2002, 168, 1442-5.	0.4	34
2897	Effectiveness of adjuvant radiotherapy for high recurrence risk patients with upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	1
2898	The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 198.e1-198.e8.	1.6	2
2899	Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature. <i>Frontiers in Oncology</i> , 2022, 12, 816444.	2.8	7
2900	The urinary bladder, urachal remnants, urethra, renal pelves, and ureters. , 2015, , 2322-2412.		0
2913	Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients. <i>International Urology and Nephrology</i> , 2022, 54, 1505-1512.	1.4	5
2914	Relapses Rates and Patterns for Pathological T0 after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Urology</i> , 2022, , .	1.0	1

#	ARTICLE	IF	CITATIONS
2915	Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer. <i>Bladder</i> , 2016, 3, e26.	0.2	2
2919	Autoimmune pancreatitis accompanied with recurrence of bladder cancer: difficulty in diagnosis and management of systemic lesions in a case with autoimmune pancreatitis. <i>JOP: Journal of the Pancreas</i> , 2012, 13, 446-50.	1.5	2
2920	The absence of urinary diversion in radical cystectomy avoids early complications in hemodialysis patients. <i>Formosan Journal of Surgery</i> , 2022, 55, 44.	0.2	0
2921	Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. <i>World Journal of Urology</i> , 2022, 40, 1715-1721.	2.2	12
2922	A Systematic Review and Meta-Analysis of the role of immune checkpoint inhibitors (ICI) as adjuvant treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC). <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
2923	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 908-917.	1.0	2
2924	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. <i>Journal of Personalized Medicine</i> , 2022, 12, 726.	2.5	2
2925	Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma. <i>Bladder Cancer</i> , 2022, 8, 315-327.	0.4	1
2926	Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. <i>Advances in Oncology</i> , 2022, 2, 213-225.	0.2	0
2927	Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions. <i>European Journal of Pharmacology</i> , 2022, 926, 175024.	3.5	5
2928	MR imaging in the evaluation of bladder cancer. , 0, , 8-17.		1
2929	Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study. , 2022, 10, e004427.		15
2931	Update of the Diagnostic and Therapeutic Role of the Pelvic Lymph Node Dissection Boundaries During Radical Cystectomy in Muscle Invasive Bladder Cancer. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 71-81.	0.1	0
2932	SMARCC1 Enters the Nucleus via KPNA2 and Plays an Oncogenic Role in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	3.5	3
2933	Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases Residual Cancer and Improves Recurrence-Free Survival in Patients with Non-Muscle-Invasive Bladder Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2934	Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer—A Retrospective Digital Pathology Study. <i>Diagnostics</i> , 2022, 12, 1360.	2.6	3
2937	Radiologic Diagnosis and Staging of Bladder Cancer: An Update. <i>Journal of Computer Assisted Tomography</i> , 2022, 46, 530-544.	0.9	2
2938	Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration. <i>Bladder Cancer</i> , 2022, , 1-12.	0.4	0

#	ARTICLE	IF	CITATIONS
2939	CK5/6 and GATA3 Defined Phenotypes of Muscle-Invasive Bladder Cancer: Impact in Adjuvant Chemotherapy and Molecular Subtyping of Negative Cases. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	8
2940	Mass cytometry reveals immune atlas of urothelial carcinoma. <i>BMC Cancer</i> , 2022, 22, .	2.6	5
2942	Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
2943	Imaging Tips and Tricks in Management of Renal and Urothelial Malignancies. <i>Indian Journal of Radiology and Imaging</i> , 0, , .	0.8	0
2944	Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	3
2945	A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 491.e1-491.e9.	1.6	2
2946	Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy. <i>European Urology Open Science</i> , 2022, 43, 14-21.	0.4	2
2947	Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy. <i>International Journal of Urology</i> , 2022, 29, 1264-1270.	1.0	5
2948	Concepts for Banking Tissue in Urologic Oncology—The International Bladder Cancer Bank. <i>Clinical Cancer Research</i> , 2005, 11, 413-415.	7.0	11
2949	Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade. <i>Journal of Immunology Research</i> , 2022, 2022, 1-21.	2.2	1
2950	Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
2951	Antitumor Activities of Aqueous Cinnamon Extract on 5637 Cell Line of Bladder Cancer through Glycolytic Pathway. <i>International Journal of Inflammation</i> , 2022, 2022, 1-9.	1.5	2
2952	First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. <i>Annals of Oncology</i> , 2022, 33, 1179-1185.	1.2	4
2953	Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021). <i>Onkourologiya</i> , 2022, 18, 142-163.	0.3	0
2954	The prognostic role of pre-cystectomy thrombocytosis in invasive bladder cancer. <i>International Urology and Nephrology</i> , 2022, 54, 3153-3161.	1.4	3
2955	Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder. <i>Cancers</i> , 2022, 14, 3999.	3.7	2
2956	<sc>TUXEDO</sc>: a phase I<sc>II</sc> trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer. <i>BJU International</i> , 2023, 131, 63-72.	2.5	2
2957	<i>N</i>-â€(3,4â€dimethoxyphenethyl)-â€6â€methylâ€2,3,4, <sc>9â€tetrahydroâ€1</sc> <i>H</i>-â€carbazolâ€1â€amine inhibits bladder cancer progression by suppressing <sc>YAP1</sc> / <sc>TAZ</sc>. <i>Genes To Cells</i> , 0, , .	1.2	2

#	ARTICLE	IF	CITATIONS
2958	Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer. <i>Cancers</i> , 2022, 14, 3797.	3.7	5
2959	Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 178, 103795.	4.4	5
2960	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. , 2022, , 975-1022.		0
2961	Urothelkarzinom der Harnblase: Chirurgische Therapie. <i>Springer Reference Medizin</i> , 2022, , 1-16.	0.0	0
2962	Using Sankey diagrams to explore the trend of article citations in the field of bladder cancer: Research achievements in China higher than those in the United States. <i>Medicine (United States)</i> , 2022, 101, e30217.	1.0	18
2963	The impact of non-modifiable sociodemographic factors on bladder cancer survival outcomes after radical cystectomy: A systematic review and cumulative analysis of population cohort studies. <i>Frontiers in Urology</i> , 0, 2, .	0.5	0
2964	Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
2965	Clabridin inhibits urothelial bladder carcinoma cell growth <i>in vitro</i> and <i>in vivo</i> by inducing cell apoptosis and cell cycle arrest. <i>Chemical Biology and Drug Design</i> , 2023, 101, 581-592.	3.2	3
2966	Outcomes of radical cystectomy in pT4 bladder cancer frail patients: ↑ high-volume single center study. <i>Journal of Frailty, Sarcopenia and Falls</i> , 2022, 07, 147-150.	1.2	1
2967	Analysis of the Relationship between Bladder Cancer Gene Mutation and Clinical Prognosis by High-Throughput Sequencing. <i>Laboratory Medicine</i> , 2023, 54, 142-152.	1.2	1
2968	Adjuvant chemotherapy plus radiotherapy versus chemotherapy alone for locally advanced bladder cancer after radical cystectomy. <i>Bladder Cancer</i> , 2022, , 1-13.	0.4	0
2969	A Prognostic Nomogram Based on Log Odds of Positive Lymph Nodes to Predict Overall Survival for Non-Metastatic Bladder Cancer Patients after Radical Cystectomy. <i>Current Oncology</i> , 2022, 29, 6834-6846.	2.2	1
2970	HOXA1 promotes proliferation and metastasis of bladder cancer by enhancing SMAD3 transcription. <i>Pathology Research and Practice</i> , 2022, 239, 154141.	2.3	7
2971	Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	2
2972	Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single-center experience. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	1.8	2
2974	Multiomics analysis of ferroptosis-related molecular subtypes in muscle-invasive bladder cancer immunotherapy. <i>Translational Cancer Research</i> , 2022, 11, 4089-4104.	1.0	1
2975	Re. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. <i>European Urology</i> , 2023, 83, 90-91.	1.9	1
2976	Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12659.	4.1	8

#	ARTICLE	IF	CITATIONS
2977	Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). <i>Cancers</i> , 2022, 14, 5286.	3.7	0
2978	Porcine Bladder Replacement with a Bilayer Silk Fibroin Enhanced Prosthetic Reservoir: A Feasibility Study. <i>Journal of Endourology</i> , 0, , .	2.1	0
2979	Urothelial Carcinoma. <i>Surgical Pathology Clinics</i> , 2022, 15, 661-679.	1.7	1
2982	Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial. <i>Japanese Journal of Clinical Oncology</i> , 2023, 53, 16-25.	1.3	1
2983	Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3/4 or cN+ bladder cancer. <i>World Journal of Urology</i> , 2023, 41, 101-107.	2.2	2
2984	Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13206.	4.1	8
2985	Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology. <i>Clinical Epidemiology</i> , 0, Volume 14, 1375-1386.	3.0	4
2986	Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review. <i>Medicine (United States)</i> , 2022, 101, e31635.	1.0	4
2987	Robotic-assisted versus standard laparoscopic radical cystectomy in bladder cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
2988	Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 290-295.	1.1	2
2989	Importance and implications of exosomes in nephrology and urology. <i>Pflugers Archiv European Journal of Physiology</i> , 0, , .	2.8	1
2990	Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer. <i>Seminars in Radiation Oncology</i> , 2023, 33, 35-50.	2.2	0
2991	Frontiers in Non-metastatic, Muscle-invasive Bladder Cancer. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 113.	0.2	0
2992	Which lymph node dissection template is optimal for radical cystectomy? A systematic review and Bayesian network meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
2993	TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14319.	4.1	5
2994	Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: A 20-year experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	2
2995	Comparison of Laparoscopic and Open Radical Cystectomy for Muscle-Invasive Bladder Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 15995.	2.6	3
2996	Neoadjuvant immunochemotherapy in the treatment of nonmetastatic muscle-invasive bladder cancer: a systematic review. <i>Immunotherapy</i> , 2022, 14, 1407-1417.	2.0	0

#	ARTICLE	IF	CITATIONS
2997	Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	0
2998	Prognostic nomogram based on the lymph node metastasis indicators for patients with bladder cancer: A <sc>SEER</sc> population-based study and external validation. <i>Cancer Medicine</i> , 2023, 12, 6853-6866.	2.8	2
2999	A tumor microenvironment preoperative nomogram for prediction of lymph node metastasis in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
3000	Log Odds of Positive Lymph Nodes (LODDS) as an Independent Predictor of Overall Survival Following Radical Cystectomy in Urothelial Bladder Cancer: Time to Rethink Conventional Node Staging. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e175-e181.	1.9	0
3001	Clinical efficacy and prognostic analysis of radical cystectomy plus modified ureterosigmoidostomy (Mainz II) in bladder cancer. <i>Asian Journal of Surgery</i> , 2022, , .	0.4	0
3002	Predictive nomograms for early death in metastatic bladder cancer. <i>Frontiers in Surgery</i> , 0, 9, .	1.4	1
3003	Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
3005	Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer. <i>In Vivo</i> , 2023, 37, 143-148.	1.3	0
3006	Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2023, 15, 566.	3.7	1
3007	Health-related quality of life after curative treatment for muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2023, 20, 279-293.	3.8	6
3008	Comment on "Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis" on behalf of the Young Academic Urologists - Urothelial Cancer Working Group. <i>Minerva Urology and Nephrology</i> , 2023, 74, .	2.5	0
3009	Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?. <i>Medicina (Lithuania)</i> , 2023, 59, 50.	2.0	1
3010	Short-Term and Long-Term Morbidity after Radical Cystectomy in Patients with NMIBC and Comparison with MIBC: Identifying Risk Factors for Severe Short-Term Complications. <i>Urologia Internationalis</i> , 2023, 107, 246-256.	1.3	1
3011	Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2023, 12, 176-186.	1.4	1
3012	Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 325.e15-325.e23.	1.6	1
3013	Mendelian randomization investigation identified the causal relationship between body fat indexes and the risk of bladder cancer. <i>PeerJ</i> , 0, 11, e14739.	2.0	1
3014	Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis. <i>Cancers</i> , 2023, 15, 1161.	3.7	3
3015	Current status of immunotherapy in the adjuvant treatment of invasive urothelial carcinoma. <i>Onkologie (Czech Republic)</i> , 2023, 17, 26-30.	0.1	0

#	ARTICLE	IF	CITATIONS
3016	Insurance type and area deprivation are associated with worse overall mortality for patients with muscle-invasive bladder cancer. <i>Urology</i> , 2023, , .	1.0	0
3017	Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
3018	Floating poly(lactic-co-glycolic acid)-based controlled-release drug delivery system for intravesical instillation. <i>Journal of International Medical Research</i> , 2023, 51, 030006052311620.	1.0	0
3019	Carboplatin Induction Chemotherapy in Clinically Lymph Node-“positive Bladder Cancer. <i>European Urology Open Science</i> , 2023, 51, 39-46.	0.4	1
3020	Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 1884.	0.9	4
3021	Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal. <i>Acta Medica Portuguesa</i> , 2023, 36, 145-146.	0.4	0
3022	Patient Preferences for Treatment of Bacillus Calmette-Guérin-“unresponsive Non-“muscle-invasive Bladder Cancer: A Cross-country Choice Experiment. <i>European Urology Open Science</i> , 2023, 49, 92-99.	0.4	2
3024	Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1560.	2.4	2
3025	A giant neobladder stone with insignificant symptoms: A case report and literature review. <i>Frontiers in Surgery</i> , 0, 10, .	1.4	0
3026	Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations. <i>Cancers</i> , 2023, 15, 1323.	3.7	1
3027	Predictive Value of Inflammatory and Nutritional Indexes in the Pathology of Bladder Cancer Patients Treated with Radical Cystectomy. <i>Current Oncology</i> , 2023, 30, 2582-2597.	2.2	2
3028	Added Clinical Value of 18F-FDG-PET/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2023, , .	1.9	1
3029	Prognostic nomogram for estimating survival in patients with resected muscle-invasive bladder cancer receiving chemotherapy. <i>Frontiers in Surgery</i> , 0, 10, .	1.4	1
3030	Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER database. <i>Translational Andrology and Urology</i> , 2023, 12, 330-346.	1.4	1
3031	Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>European Medical Journal Urology</i> , 0, , 111-117.	0.0	0
3032	Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities. <i>European Urology Oncology</i> , 2023, 6, 366-375.	5.4	7
3033	Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2023, 28, 17-26.	2.4	0
3034	In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer. , 2023, 40, .		0

#	ARTICLE	IF	CITATIONS
3035	Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study. <i>Diagnostics</i> , 2023, 13, 1032.	2.6	0
3036	A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2023, 6, 251-262.	5.4	1
3037	Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension. <i>Current Oncology</i> , 2023, 30, 3223-3231.	2.2	0
3038	Optimizing surgical outcomes in bladder cancer patients undergoing radical cystectomy. <i>Frontiers in Surgery</i> , 0, 9, .	1.4	2
3039	Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. <i>Cancers</i> , 2023, 15, 1742.	3.7	4
3040	Body Composition of Patients Undergoing Radical Cystectomy for Bladder Cancer: Sarcopenia, Low Psoas Muscle Index, and Myosteatosis Are Independent Risk Factors for Mortality. <i>Cancers</i> , 2023, 15, 1778.	3.7	5
3041	New Approaches to Targeting Epigenetic Regulation in Bladder Cancer. <i>Cancers</i> , 2023, 15, 1856.	3.7	1
3042	Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5846.	4.1	4
3043	Screening ANLN and ASPM as bladder urothelial carcinoma-related biomarkers based on weighted gene co-expression network analysis. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	1
3044	Trimodal organâ€‘preserving treatment of muscleâ€‘invasive bladder cancer. <i>Issledovaniã I Praktika V Medicine</i> , 2023, 10, 111-125.	0.5	0
3045	Singe intraoperative instillation of chemotherapy during radical cystectomy for bladder cancer: Oncological outcome and survival predictors. <i>Cancer Medicine</i> , 0, , .	2.8	0
3046	PET Imaging in Bladder Cancer: An Update and Future Direction. <i>Pharmaceuticals</i> , 2023, 16, 606.	3.8	0
3047	P2X1 and P2X7 Receptor Overexpression Is a Negative Predictor of Survival in Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2023, 15, 2321.	3.7	3
3048	THE USEFULNESS OF POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF METASTASIS IN PATIENTS WITH UROTHELIAL CARCINOMA. <i>Japanese Journal of Urology</i> , 2022, 113, 51-55.	0.1	1
3049	IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. <i>Future Oncology</i> , 2023, 19, 509-515.	2.4	6
3050	Impact of Minimally Invasive Approach to Radical Cystectomy in Bladder Cancer Patients with Malnutrition. <i>Nutrition and Cancer</i> , 0, , 1-6.	2.0	0
3051	Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7859.	4.1	2
3052	Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies. <i>Investigative and Clinical Urology</i> , 2023, 64, 202.	2.0	2

#	ARTICLE	IF	CITATIONS
3053	Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer. <i>Clinical Oncology</i> , 2023, , .	1.4	1
3054	Perivesical Fat Invasive Pattern as Prognostic Factor and Predictor of Response to Adjuvant Chemotherapy in T3 Stage Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, , .	1.9	0
3055	Camrelizumab as adjuvant therapy in urothelial carcinomas after radical surgery in people living with HIV. <i>International Journal of STD and AIDS</i> , 0, , 095646242311731.	1.1	1
3057	Predicting Lymph Node Metastasis Status from Primary Muscle-Invasive Bladder Cancer Histology Slides Using Deep Learning: A Retrospective Multicenter Study. <i>Cancers</i> , 2023, 15, 3000.	3.7	1
3058	Perioperative mortality for radical cystectomy in the modern Era: experience from a tertiary referral center. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2023, 49, 351-358.	1.5	3
3059	Should Patients with Renal Cell Carcinoma and Pathological Nodal Invasion Be Classified As Having Stage IV Disease?. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	0
3061	Experience in using the VI-RADS system in assessing the depth of invasion of bladder tumors. <i>Medical Visualization</i> , 2023, 27, 118-129.	0.4	0
3062	Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis. <i>International Journal of Surgery</i> , 2023, 109, 2742-2750.	2.7	1
3063	Effect of decreased renal function on poor oncological outcome after radical cystectomy. <i>Investigative and Clinical Urology</i> , 0, 64, .	2.0	0
3064	Exposure to Agent Orange and Risk of Bladder Cancer Among US Veterans. <i>JAMA Network Open</i> , 2023, 6, e2320593.	5.9	1
3065	Impact of Chart-Derived Frailty Index on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2023, 30, 5295-5303.	1.5	3
3066	The Implementation of FDG PET/CT for Staging Bladder Cancer: Changes in the Detection and Characteristics of Occult Nodal Metastases at Upfront Radical Cystectomy?. <i>Journal of Clinical Medicine</i> , 2023, 12, 3367.	2.4	1
3067	Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 356.e19-356.e30.	1.6	0
3068	A randomized controlled trial investigating rectus sheath catheters following radical cystectomy. <i>BJU International</i> , 0, , .	2.5	1
3069	Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland. <i>Acta Oncol</i> , 2023, 62, 829-835.	1.8	0
3070	The Role of Lymph Node Dissection in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy Following Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 1-9.	1.9	0
3071	Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series. <i>BJU International</i> , 2023, 132, 428-434.	2.5	0
3072	Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 0, , .	1.8	2

#	ARTICLE	IF	CITATIONS
3073	Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer. <i>Methods in Molecular Biology</i> , 2023, , 229-247.	0.9	0
3074	Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following Radical Cystectomy: Two Systematic Reviews and Meta-analyses of Interplay Between Radical Cystectomy and Renal Function. <i>European Urology Focus</i> , 2024, 10, 169-181.	3.1	0
3076	Key Molecules in Bladder Cancer Affect Patient Prognosis and Immunotherapy Efficacy: Further Exploration for <i>CNTN1</i> and <i>EMP1</i> . <i>JCO Precision Oncology</i> , 2023, , .	3.0	0
3077	Management of surgically inoperable muscle-invasive bladder cancer in a resource constraint setting at a tertiary care center by bladder preservation protocol: Case series. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 725.	0.9	0
3078	Inkontinente Harnableitungen. <i>Springer Reference Medizin</i> , 2023, , 867-880.	0.0	0
3079	Urothelkarzinom der Harnblase: Chirurgische Therapie. <i>Springer Reference Medizin</i> , 2023, , 803-818.	0.0	0
3080	Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. <i>European Urology</i> , 2024, 85, 114-122.	1.9	3
3081	Conditional survival following radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 432.e11-432.e20.	1.6	0
3082	Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 3769-3770.	1.6	0
3084	Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profilingâ€“informed personalized monitoring assay. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
3085	Renal function change after radical cystectomy for urothelial carcinoma patients with a solitary kidney may be independent of urinary diversion type. <i>Investigative and Clinical Urology</i> , 2023, 64, 457.	2.0	0
3086	Adequate Pelvic Lymph Node Dissection in Radical Cystectomy in the Era of Neoadjuvant Chemotherapy: A Meta-Analysis and Systematic Review. <i>Cancers</i> , 2023, 15, 4040.	3.7	1
3087	Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-centerâ€™s real-world study. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	7
3088	Surveillance for Nonmuscle Invasive Bladder Cancer: Identifying the Point of Diminishing Returns. <i>Urology</i> , 2023, 181, 84-91.	1.0	0
3089	Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 433.e9-433.e18.	1.6	1
3090	Adult genitourinary cancer: Prostate and bladder. , 2024, , 581-634.e3.		0
3092	Outcome of small versus big capacity Hautmann neobladder reconstruction: A prospective randomized study â€™ a 5-year follow up. <i>Technology and Health Care</i> , 2023, , 1-12.	1.2	0
3093	Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
3094	The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
3095	Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	0
3096	Survival Prediction of Patients with Bladder Cancer after Cystectomy Based on Clinical, Radiomics, and Deep-Learning Descriptors. <i>Cancers</i> , 2023, 15, 4372.	3.7	0
3097	The Impact of Variant Histology in Patients with Urothelial Carcinoma Treated with Radical Cystectomy: Can We Predict the Presence of Variant Histology?. <i>Current Oncology</i> , 2023, 30, 8841-8852.	2.2	0
3098	Turning up the heat: CTLA4 blockade in urothelial cancer. <i>Nature Reviews Urology</i> , 0, , .	3.8	1
3099	Nadofaragene firadenovec: a breakthrough in the field of bladder oncology. <i>Frontiers in Urology</i> , 0, 3, .	0.5	1
3100	ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/ β^2 -catenin pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	3
3101	MRI radiomics for predicting poor disease-free survival in muscle invasive bladder cancer: the results of the retrospective cohort study. <i>Abdominal Radiology</i> , 2024, 49, 151-162.	2.1	2
3102	Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 4406-4415.	1.6	12
3103	Immunotherapy in the Treatment of Localized Genitourinary Cancers. <i>JAMA Oncology</i> , 2023, 9, 1447.	7.1	2
3104	Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	0
3106	Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, , .	1.6	1
3107	Contemporary outcomes of patients undergoing robotic-assisted radical cystectomy: A comparative analysis between intracorporeal ileal conduit and neobladder urinary diversions. <i>Asian Journal of Urology</i> , 2023, , .	1.2	0
3108	Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy. <i>International Urology and Nephrology</i> , 0, , .	1.4	0
3109	Location of Retroperitoneal Lymph Node Metastases in Upper Tract Urothelial Carcinoma: Results from a Prospective Lymph Node Mapping Study. <i>European Urology Open Science</i> , 2023, 57, 37-44.	0.4	0
3110	Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer. <i>International Urology and Nephrology</i> , 2024, 56, 509-518.	1.4	3
3111	Metastatic Carcinoma Urinary Bladder, Adjuvant Treatment and Follow-Up. , 2023, , 169-183.		0
3112	Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	0

#	ARTICLE	IF	CITATIONS
3113	Lymphadenectomy before and after radical cystectomy: does this affect the radicality? A prospective randomized comparative study. International Urology and Nephrology, 2024, 56, 965-972.	1.4	0
3114	Does neo-adjuvant chemotherapy improve the negative effect of lymphovascular invasion in survival after radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2024, 42, 30.e1-30.e7.	1.6	0
3115	Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2023, , .	1.6	0
3116	Diagnostic and prognostic impact of preoperative thrombocytosis in muscle invasive bladder cancer: Any role in clinical practice?. Journal of Clinical Ultrasound, 2023, 51, 1607-1614.	0.8	0
3117	Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer. Annals of Surgical Oncology, 0, , .	1.5	0
3118	Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients. Clinical Genitourinary Cancer, 2024, 22, 193-200.e1.	1.9	0
3119	Prognostic value of preoperative De Ritis ratio on oncological outcomes in patients with muscle-invasive bladder cancer. Journal of Surgical Oncology, 2024, 129, 641-648.	1.7	0
3120	A machine learning model based on MRI for the preoperative prediction of bladder cancer invasion depth. European Radiology, 2023, 33, 8821-8832.	4.5	2
3121	Radiotherapy combined with deep regional hyperthermia in elderly and frail patients with muscle-invasive bladder cancer: quality analysis of hyperthermia and impact on clinical results. International Journal of Hyperthermia, 2023, 40, .	2.5	0
3122	Identifying Optimal Candidates for Trimodality Therapy among Nonmetastatic Muscle-Invasive Bladder Cancer Patients. Current Oncology, 2023, 30, 10166-10178.	2.2	0
3123	The value of <sc>ATAD3A</sc> as a potential biomarker for bladder cancer. Cancer Medicine, 0, , .	2.8	0
3124	Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response. Bioengineering and Translational Medicine, 2024, 9, .	7.1	0
3125	Clinical variables associated with major adverse cardiac events following radical cystectomy. BJUI Compass, 2024, 5, 480-488.	1.3	0
3126	The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study. World Journal of Men's Health, 0, 42, .	3.3	0
3127	MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences, 2024, 25, 88.	4.1	0
3128	The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy. Current Oncology, 2023, 30, 10550-10555.	2.2	0
3129	Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial-Mesenchymal Transition and Stemness Properties. International Journal of Molecular Sciences, 2023, 24, 17610.	4.1	0
3130	Prognostic Significance of Lymph Node Density in Pathological Node Positive Urothelial Carcinoma of the Bladder -Upfront Surgery and Post Neoadjuvant Chemotherapy Cohorts. Clinical Genitourinary Cancer, 2024, 22, 385-393.	1.9	0

#	ARTICLE	IF	CITATIONS
3131	Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2024, 25, 255-264.	10.7	2
3132	Qualification of the Microsatellite Instability Analysis (MSA) for Bladder Cancer Detection: The Technical Challenges of Concordance Analysis. <i>International Journal of Molecular Sciences</i> , 2024, 25, 209.	4.1	1
3133	Laparoscopic vs. open surgical access radical cystectomy with subsequent orthotopic reconstruction in the treatment of invasive urothelial carcinoma of the bladder. <i>Folia Medica</i> , 2023, 65, 894-901.	0.5	0
3134	Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy. <i>European Urology Focus</i> , 2023, , .	3.1	0
3135	Radiomics nomogram for predicting disease-free survival after partial resection or radical cystectomy in patients with bladder cancer. <i>British Journal of Radiology</i> , 2024, 97, 201-209.	2.2	0
3137	GW4064 inhibits migration and invasion through cathepsin B and MMP2 downregulation in human bladder cancer. <i>Chemico-Biological Interactions</i> , 2024, 389, 110869.	4.0	0
3138	RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03). <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
3139	Efficacy of radical cystectomy plus adjuvant intraarterial chemotherapy with gemcitabine and cisplatin on locally advanced bladder cancer. <i>Chinese Medical Journal</i> , 2014, 127, 1249-1254.	2.3	0
3141	Successful bladder-sparing partial cystectomy for muscle-invasive domal urothelial carcinoma with sarcomatoid differentiation: a case report. <i>Therapeutic Advances in Urology</i> , 2024, 16, .	2.0	0
3142	Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases. <i>Nature Reviews Urology</i> , 0, , .	3.8	0
3143	Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
3144	Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy. <i>Cancers</i> , 2024, 16, 651.	3.7	0
3145	Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy. <i>BMC Cancer</i> , 2024, 24, .	2.6	0
3146	Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?. <i>International Journal of Urology</i> , 0, , .	1.0	0
3147	Impacts of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy: A Single High-Volume Center Experience. <i>Journal of Personalized Medicine</i> , 2024, 14, 212.	2.5	0
3149	Targeting histone modifiers in bladder cancer therapy “ preclinical and clinical evidence. <i>Nature Reviews Urology</i> , 0, , .	3.8	0
3150	CACA guidelines for holistic integrative management of urothelial carcinoma. , 2024, 3, .		0
3151	Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0

#	ARTICLE	IF	CITATIONS
3153	Successful pre-surgical treatment with carboplatin and gemcitabine chemotherapy for a patient with muscle-invasive bladder cancer and severe renal dysfunction. International Cancer Conference Journal, 0, , .	0.5	0
3154	Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine. BJU International, 0, , .	2.5	0
3155	Establishment and validation of nomograms to predict the overall survival and cancer-specific survival for non-metastatic bladder cancer patients: A large population-based cohort study and external validation. Medicine (United States), 2024, 103, e37492.	1.0	0
3156	Assessing Trifecta and Pentafecta Success Rates between Robot-Assisted vs. Open Radical Cystectomy: A Propensity Score-Matched Analysis. Cancers, 2024, 16, 1270.	3.7	0
3157	Surgical proficiency in laparoscopic radical cystectomy with extracorporeal urinary diversion and its adequacy for the execution of robotâ€assisted radical cystectomy with intracorporeal urinary diversion. Asian Journal of Endoscopic Surgery, 2024, 17, .	0.9	0